PROSPECTUS SUPPLEMENT
|
Filed Pursuant to Rule 424(b)(5)
|
To prospectus dated July 5, 2018
|
Registration No. 333-226024
|
184,800
Shares
of Series B Preferred Stock (Including Shares of Series B Preferred Stock Underlying the Series F-1 Preferred Stock Purchase Warrants,
Series F-2 Preferred Stock Purchase Warrants and Placement Agent Warrants);
Series F-1 Preferred Stock Purchase
Warrants to Purchase 59,760 Shares of Series B Preferred Stock;
Series F-2 Preferred Stock Purchase
Warrants to Purchase 60,240 Shares of Series B Preferred Stock;
Placement Agent
Warrants to Purchase 4,800 Shares of Series B Preferred Stock;
3,080,061,600
Shares of Common Stock Underlying the Series B Preferred Stock (Including Shares of Series B Preferred Stock Issuable Upon
Exercise of the Series F-1 Preferred Stock Purchase Warrants, Series F-2 Preferred Stock Purchase Warrants and Placement Agent
Warrants)
We are offering on a “best-efforts”
basis 60,000 shares of our Series B Preferred Stock, par value $0.01 per share (“Series B Preferred Stock”),
together with Series F-1 Preferred Stock Purchase Warrants (the “Series F-1 Warrants”) to purchase an aggregate of
59,760 shares of our Series B Preferred Stock and Series F-2 Preferred Stock Purchase Warrants (the “Series F-2 Warrants”,
and together with the Series F-1 Warrants, the “Series F Warrants”) to purchase an aggregate of 60,240 shares of our
Series B Preferred Stock, at a combined offering purchase price of $100.00 per fixed combination of (i) one share of Series B
Preferred Stock, (ii) one Series F-1 Warrant to purchase 0.996 shares of our Series B Preferred Stock, (iii) one Series F-2 Warrant
to purchase 1.004 shares of our Series B Preferred Stock. The shares of Series B Preferred Stock, the Series F-1 Warrants and
the Series F-2 Warrants will be issued separately but can only be purchased together in this offering.
Each share of Series B Preferred Stock
will be convertible by the holder into 16,667 shares of our common stock, subject to adjustment. Each share of Series B Preferred
Stock is convertible at any time at the option of the holder, provided that the holder will be prohibited from converting Series
B Preferred Stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates,
would beneficially own more than 9.99% of the total number of shares of our common stock then issued and outstanding after giving
effect to such conversion.
Subject to the applicable law and the rights
of the holders of any outstanding series of our preferred stock, our Series B Preferred Stock will rank pari passu on an as-converted
to common stock basis with all of our common stock as to dividends, distributions of proceeds upon certain asset sales, mergers
or consolidations and distributions of assets upon our liquidation, dissolution or winding up. Shares of our Series B Preferred
Stock will be entitled to vote on an as-converted to common stock basis on all matters on which stockholders are generally entitled
to vote (provided that no holder of Series B Preferred Stock will be entitled to such number of votes in excess of such holder’s
beneficial ownership limitation). Additionally, the vote or written consent of holders of a majority of the outstanding shares
of our Series B Preferred Stock, voting separately as a single class, will be required for certain amendments to our certificate
of incorporation.
The Series F-1 Warrants will entitle the holders
thereof to purchase 59,760 shares of our Series B Preferred Stock in the aggregate, and the Series F-2 Warrants will entitle the
holders thereof to purchase 60,240 shares of our Series B Preferred Stock in the aggregate (we refer to shares of our Series B
Preferred Stock issuable upon exercise of the Series F Warrants and Placement Agent Warrants, as “Warrant Preferred Shares”),
in each case, at an exercise price of $100.00 per share of Series B Preferred Stock. The Series F-1 Warrants will be exercisable
at any time on or after the issuance date until the five-year anniversary of such initial exercise date. The Series F-2 Warrants
will be exercisable at any time on or after the date on which we obtain stockholder approval for a reverse stock split or to increase
our authorized common stock to allow for the reservation in full of all shares of common stock issuable upon conversion of the
Warrant Preferred Shares issuable upon exercise of the Series F-2 Warrants until the five-year anniversary of such initial exercise
date.
Pursuant to this prospectus supplement
and the accompanying prospectus, we will also issue the Placement Agent Warrants described below, as part of the compensation
payable to the placement agent in connection with this offering. This prospectus supplement also relates to the offering of the
shares of common stock issuable from time to time upon conversion of the Series B Preferred Stock (including the Warrant Preferred
Shares).
For a more detailed description of our
common stock, the Series B Preferred Stock, the Series F Warrants and the Placement Agent Warrants, see the section entitled “Description
of the Securities We are Offering” beginning on page S-29 of this prospectus supplement.
Our common stock is quoted on the OTC
Pink Market operated by OTC Markets Group Inc. under the symbol “HMNY”. The closing sales price of our common stock
on March 22, 2019, was $0.012 per share. There is no public trading market for the Series B Preferred Stock, Series F Warrants
or Placement Agent Warrants, we do not expect a market to develop, and holders may not be able to resell the Series B Preferred
Stock, Series F Warrants or Placement Agent Warrants or the shares of common stock underlying the Series B Preferred Stock (including
those underlying the Warrant Preferred Shares) purchased under this prospectus supplement. In addition, we do not intend to apply
for a listing of the Series B Preferred Stock, Series F Warrants or Placement Agent Warrants or the shares of common stock underlying
the Series B Preferred Stock (including those underlying the Warrant Preferred Shares) on the Nasdaq Capital Market, any other
national securities exchange, or any nationally recognized trading system. This may affect the pricing of the Series B Preferred
Stock, Series F Warrants or Placement Agent Warrants and the shares of common stock underlying the Series B Preferred Stock (including
those underlying the Warrant Preferred Shares) in the secondary market, the transparency and availability of trading prices, and
the liquidity of the Series B Preferred Stock, Series F Warrants or Placement Agent Warrants and the shares of common stock underlying
the Series B Preferred Stock (including those underlying the Warrant Preferred Shares).
We have retained H.C. Wainwright & Co.,
LLC as our exclusive placement agent in connection with the securities offered by this prospectus supplement and the accompanying
prospectus. The placement agent has agreed to use its reasonable best efforts to solicit offers to purchase the securities offered
by this prospectus supplement and the accompanying prospectus. The placement agent has no obligation to buy any of the securities
from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. We have agreed to pay
the placement agent the placement agent fees set forth in the table below, which assumes that we sell all of the securities we
are offering. Because there is no minimum offering amount required as a condition to closing in this offering, the actual offering
amount, placement agent’s fees, and proceeds to us, if any, are not presently determinable and may be substantially less
than the total maximum offering amounts set forth below.
Investing in our securities involves
a high degree of risk. See “Risk Factors” beginning on page S-9 of this prospectus supplement and page 2 of the accompanying
prospectus.
|
|
Combined
Price per
Share
of Series B Preferred Stock
and Series F Warrants
|
|
|
Total
(2)
|
|
Offering price
|
|
$
|
100.00
|
|
|
$
|
6,000,000.00
|
|
Placement
agent fees
(1)
|
|
$
|
7.33
|
|
|
$
|
440,000.00
|
|
Proceeds to us before expenses
|
|
$
|
92.67
|
|
|
$
|
5,560,000.00
|
|
(1)
|
In addition, we have
agreed to reimburse the placement agent for certain of its expenses and to issue warrants to purchase shares of our Series
B Preferred Stock to the placement agent as described under the “Plan of Distribution” section (the “Placement
Agent Warrants”).
|
|
(2)
|
Total proceeds does not give effect to the sale or exercise,
if any, of the Series F Warrants or the Placement Agent Warrants.
|
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed on the adequacy or accuracy of this
prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
Delivery of the securities to the purchaser
is expected to be made on or about March 25, 2019, subject to the satisfaction of certain closing conditions.
H.C. Wainwright & Co.
The date of this prospectus supplement
is March 25, 2019.
TABLE OF CONTENTS
Prospectus Supplement
Prospectus
ABOUT THIS PROSPECTUS SUPPLEMENT
In this prospectus supplement, unless the
context otherwise requires, references to “we,” “us,” “our,” “our company,” the
“Company” or “Helios” refer to Helios and Matheson Analytics Inc. and its subsidiaries. On July 24, 2018,
we effected a reverse stock-split of our issued and outstanding common stock at a ratio of one-for-250 (“Reverse Stock Split”).
This prospectus supplement gives retroactive effect to the Reverse Stock Split for all periods presented.
This prospectus supplement and the accompanying
prospectus relate to the offering of shares of our Series B Preferred Stock, Series F Warrants, Placement Agent Warrants and the
shares of common stock issuable from time to time upon conversion of such Series B Preferred Stock (including upon conversion
of the Warrant Preferred Shares). Before buying any of the shares of our Series B Preferred Stock and Series F Warrants offered
hereby, we urge you to carefully read this prospectus supplement and the accompanying prospectus, together with the information
incorporated herein by reference as described under the headings “Where You Can Find More Information” and “Information
Incorporated by Reference”. These documents contain important information that you should consider when making your investment
decision. This prospectus supplement contains information about the Series B Preferred Stock and Series F Warrants offered hereby
and may add, update or change information in the accompanying prospectus.
You should rely only on the information
that we have provided or incorporated by reference in this prospectus supplement and the accompanying prospectus. Neither we nor
the placement agent (nor any of the placement agent’s affiliates) have authorized any other person to provide you with different
information. If anyone provides you with different or inconsistent information, you should not rely on it.
We and the placement agent are not making
offers to sell or solicitations to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or
in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an
offer or solicitation. You should assume that the information in this prospectus supplement and the accompanying prospectus or
any related free writing prospectus is accurate only as of the date on the front of the document and that any information that
we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the
time of delivery of this prospectus supplement, the accompanying prospectus or any related free writing prospectus, or any sale
of a security.
This document is in two parts. The first
part is this prospectus supplement, which adds to and updates information contained in the accompanying prospectus. The second
part is the accompanying prospectus which provides more general information, some of which may not apply to this offering. Generally,
when we refer to this prospectus supplement, we are referring to both parts of this document combined. To the extent there is a
conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus,
you should rely on the information in this prospectus supplement.
This prospectus supplement and the accompanying
prospectus contain summaries of certain provisions contained in some of the documents described herein, but reference is made to
the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies
of some of the documents referred to herein have been or will be filed as exhibits to the registration statement of which this
prospectus supplement is a part or as exhibits to documents incorporated by reference herein, and you may obtain copies of those
documents as described below under the headings “Where You Can Find More Information” and “Information Incorporated
by Reference”.
The industry and market data and other statistical
information contained in this prospectus supplement, the accompanying prospectus and the documents we incorporate by reference
are based on management’s estimates, independent publications, government publications, reports by market research firms
or other published independent sources, and, in each case, are believed by management to be reasonable estimates. Although we believe
these sources are reliable, we have not independently verified the information. None of the independent industry publications used
in this prospectus supplement, the accompanying prospectus or the documents we incorporate by reference were prepared on our or
our affiliates’ behalf and none of the sources cited by us consented to the inclusion of any data from its reports, nor have
we sought their consent.
DISCLOSURE REGARDING FORWARD-LOOKING
STATEMENTS
This prospectus supplement and the accompanying
prospectus, including the documents that we incorporate by reference, may contain forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”).
Forward-looking statements in this
prospectus supplement and the accompanying prospectus include, without limitation, statements related to our financial and operating
performance, our plans, strategies, objectives, expectations, intentions and adequacy of resources. Certain important risks, including
those discussed in the risk factors set forth under “Risk Factors” of this prospectus supplement, could cause results
to differ materially from those anticipated by some of the forward-looking statements. Some, but not all, of these risks include,
among other things:
|
●
|
the impact of the delisting of our common stock from the Nasdaq Capital Market;
|
|
●
|
our ability to successfully develop the business model of MoviePass Inc. (“MoviePass”), Moviefone, MoviePass Films
LLC (“MoviePass Films”) and MoviePass Ventures, LLC (“MoviePass Ventures”);
|
|
●
|
our ability to integrate
the operations of MoviePass, Moviefone, MoviePass Films and MoviePass Ventures;
|
|
●
|
our capital requirements and whether or not we will
be able to raise capital when we need it;
|
|
●
|
consumer acceptance
of the new MoviePass Uncapped subscription plan;
|
|
●
|
our ability to fulfill our payment obligations to MoviePass’ merchant processors in a timely manner to prevent MoviePass
service interruptions;
|
|
●
|
audience acceptance of the films and acquired content of MoviePass Films;
|
|
●
|
delays, cost overruns, cancellation or abandonment of the completion or release of MoviePass Films’ films; failure of
third party distributors to distribute MoviePass Films’ films and their failure to perform or promote such films;
|
|
●
|
changes in consumer discretionary spending;
|
|
●
|
the inability of MoviePass, MoviePass Films and Moviefone to compete effectively;
|
|
●
|
the risk that increased monthly usage by MoviePass’ subscribers may cause MoviePass to incur losses and negative cash
flow;
|
|
●
|
risk of attempts at unauthorized or improper use of MoviePass’ services;
|
|
●
|
the inability to maintain or rebuild the value of the MoviePass brand;
|
|
●
|
the inability to successfully respond to rapid technological changes and alternative forms of delivery or storage to remain
competitive;
|
|
●
|
the inability to maintain relationships with program suppliers and vendors;
|
|
●
|
the ability of Moviefone to obtain advertising revenues; consumer acceptance of Moviefone services; the ability of Moviefone
to develop and offer compelling content, products and services and attract new users or maintain existing users;
|
|
●
|
breaches of network and data security measures;
|
|
●
|
a disruption or failure of networks and information systems;
|
|
●
|
changes in local, state or federal regulations that will adversely affect our business;
|
|
●
|
our ability to retain our existing clients and subscribers and market and sell our services to new clients and subscribers;
|
|
●
|
the success of our cost-reduction and subscription revenue increase measures;
|
|
●
|
the impact of legal proceedings or governmental action against us;
|
|
●
|
our ability to attract brokers and investors who do not trade in lower priced stock;
|
|
●
|
the risk that the conditions to the completion of the creation of MoviePass Entertainment Holdings Inc. are not satisfied,
including the inability of MoviePass Entertainment Holdings Inc. to complete the necessary audited financial statements and to
file and have its registration statement on Form S-1 declared effective by the Securities and Exchange Commission, and the risk
that we may not have the required surplus or cash flow solvency under Delaware law to effect a distribution of shares of MoviePass
Entertainment Holdings Inc. to our security holders;
|
|
●
|
whether we will continue to receive the services of certain officers and directors;
|
|
●
|
our ability to protect our intellectual property and operate our business without infringing upon the intellectual property
rights of others;
|
|
●
|
our ability to effectively react to other risks and uncertainties described from time to time in our filings with the Securities
and Exchange Commission, such as fluctuation of quarterly financial results, reliance on third party consultants, litigation or
other proceedings and stock price volatility;
|
|
●
|
other uncertainties, all of which are difficult to predict and many of which are beyond our control; and
|
|
●
|
the risk factors described in this prospectus supplement under “Risk Factors”.
|
In some cases, you can identify forward-looking
statements by terminology such as “may,” “will,” “should,” “could,” “expects,”
“plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,”
“potential,” or “continue” or the negative of such terms or other comparable terminology. Although we believe
that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of
activity, performance or achievements. Readers are cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. We do not undertake any obligation to publicly update or review any forward-looking statement.
PROSPECTUS SUPPLEMENT SUMMARY
OUR BUSINESS
This is only a summary and may not contain
all the information that is important to you. You should carefully read both this prospectus supplement and the accompanying prospectus
and any other offering materials, together with the additional information described under the heading “Where You Can Find
More Information”.
About Helios and Matheson Analytics Inc.
Overview
On December 11, 2017, we acquired a
majority interest in MoviePass, whose primary product offering is the MoviePass™ movie theater subscription service. MoviePass
now allows its subscribers to see an uncapped number of 2D movies in MoviePass’ theater network, subject to managing network
demand and availability as set forth in its new terms of use, at most theaters nationwide for a fixed price, which varies depending
on whether the subscriber chooses to pay monthly or annually. Since December 2017, we have acquired additional shares of MoviePass
common stock and as of the date of this prospectus supplement, we own approximately 92% of MoviePass’ outstanding common
stock (excluding shares underlying MoviePass options and warrants).
We formed MoviePass Ventures in January
2018 to collaborate with film distributors to share in film revenues while using the data analytics MoviePass offers for marketing
and targeting services for MoviePass’ paying subscribers using the platform. In March 2018, MoviePass Ventures acquired a
stake in the now award-winning film
American Animals
by Bart Layton. In April 2018, MoviePass Ventures acquired a stake
in the movie
Gotti
. In May 2018, we formed MoviePass Films and subsequently, Emmett Furla Oasis Films LLC, or EFO Films,
acquired a 49% membership interest in MoviePass Films. MoviePass Films focuses on studio-driven content and new film production
for theatrical release and other distribution channels. Following this acquisition of interests in MoviePass Films by EFO
Films, we are conducting our film business, including that of MoviePass Ventures, through MoviePass Films. We plan to capitalize
on the capabilities of MoviePass to market future MoviePass Films productions to MoviePass subscribers.
We believe that by utilizing the MoviePass
subscriber base to drive a positive impact at the box office, MoviePass Films can then leverage the higher box office to obtain
additional downstream revenues, such as international distribution rights, streaming rights, DVD rights, transactional rights (iTunes),
on demand and foreign movie rights.
On April 4, 2018, we acquired the Moviefone
TM
brand and related assets from Oath Inc. (formerly, AOL Inc.), an entertainment service owned by Oath Inc., a wholly-owned
subsidiary of Verizon Communications Inc. Moviefone provides over 6 million monthly unique visitors full access to the entertainment
ecosystem, from movie theaters to streaming content. Moviefone delivers movie show times and tickets, trailers, TV schedules,
streaming information, cast and crew interviews, photo galleries and more. Moviefone’s editorial coverage includes up-to-date
entertainment news, trailers and clips, red-carpet coverage and celebrity features. We believe Moviefone will help MoviePass continue
to grow its subscriber base and expand its marketing and advertising platform for its studio and brand partners. We also believe
Moviefone will allow MoviePass to provide relevant and appealing content to moviegoers while simultaneously increasing the value
of the Moviefone brand.
On March 6, 2019, we announced a new
business strategy that prioritizes self-generated revenues without dependence on studios or exhibitors, to build more reliable
revenue streams. We plan to focus on technological innovation and high-quality content production through our three key channels:
MoviePass; MoviePass Films and Moviefone. We believe the MoviePass subscription service will enhance box office results of MoviePass
Films’ productions, and that revenues from our MoviePass Films’ productions will help contribute to an expansion of
our MoviePass subscription service, with the Moviefone multimedia information and advertising service supporting the entire group
of companies. By seeking to generate new revenues and profit centers within our own ecosystem, we believe we can accelerate our
overall growth in the U.S. market. MoviePass, MoviePass Films, and Moviefone plan to work together in a more interconnected fashion
and share resources across each company. MoviePass Films will seek to optimize its platform to accelerate content production for
theatrical release as well as expand distribution deals for in-home video, and retail, transactional and international sales.
On March 19, 2019, MoviePass announced a new version of its uncapped subscription
plan, called MoviePass Uncapped. Under the new MoviePass Uncapped subscription plan, subscribers can see an uncapped number of
2D movies in MoviePass’ theater network, subject to managing network demand and availability as set forth in its new terms
of use, at most theaters nationwide for a fixed price, which varies depending on whether the subscriber chooses to pay monthly
or annually. Under its new terms of use, MoviePass may limit the availability of movies for an individual subscriber if such subscriber’s
use adversely impacts MoviePass’ system-wide capacity or availability for other subscribers, and a subscriber cannot see
a particular movie more than once. MoviePass will allow subscribers under its previous “Select”, “All Access”
and “Red Carpet” plans, which allow subscribers to see up to three movies a month, at most theaters nationwide for
a fixed price, which varies depending on the subscription plan selected by the subscriber, and additional movies at a discounted
price, to remain on such plans. However, the “Select”, “All Access” and “Red Carpet” plans
will no longer be available for purchase.
Financial Update
As of March 21, 2019, we had cash on
hand of approximately $2.8 million and approximately $13.1 million on deposit with our merchant and fulfillment processors related
to subscription revenues. The funds held by these processors represent a portion of the payments received for annual and other
extended term MoviePass subscription plans and future ticket fulfillment, which we classify as current assets on our balance sheet
and which we expect to be disbursed to us or utilized during 2019.
Corporate Information
Our executive offices are located at The
Empire State Building, 350 Fifth Avenue, New York, New York 10118, and our telephone number is (212) 979-8228. Additional information
about us is available on our website at
www.hmny.com
. The information contained on or that may be obtained from our website
is not, and shall not be deemed to be, a part of this prospectus supplement. Our common stock, par value $0.01 per share, currently
is quoted on the OTC Pink Market operated by OTC Markets Group Inc. under the symbol “HMNY”.
For a description of our business, financial
condition, results of operations and other important information regarding us, we refer you to our filings with the SEC incorporated
by reference in this prospectus supplement. For instructions on how to find copies of these documents, see “Where You Can
Find More Information.”
THE OFFERING
Series B Preferred Stock offered by us
|
60,000 shares of Series B Preferred Stock will be offered
in this offering.
This prospectus also relates to the issuance of
Warrant Preferred Shares issuable upon exercise of the Series F Warrants and the Placement Agent Warrants and shares of our common
stock issuable upon conversion of our Series B Preferred Stock (including upon conversion of the Warrant Preferred Shares).
See “Description of the Securities We are Offering”
for additional information.
|
|
|
Conversion
|
Each share of our
Series B Preferred Stock is convertible into 16,667 shares of our common stock, subject to adjustment (the “Conversion
Rate”); provided, that the holder will be prohibited from converting Series B Preferred Stock into shares of our common
stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99%
of the total number of shares of our common stock then issued and outstanding after giving effect to such conversion.
|
|
|
Ranking; Liquidation preference
|
Subject to the applicable law and the rights of the holders of any outstanding series of our preferred stock, our Series B Preferred Stock will rank pari passu on an as-converted to common stock basis with all of our common stock as to distributions of assets upon our liquidation, dissolution or winding up.
|
|
|
Voting rights
|
Shares of our Series B Preferred Stock will be entitled to vote
on an as-converted to common stock basis on all matters on which stockholders are generally entitled to vote (provided that no
holder of Series B Preferred Stock will be entitled to such number of votes in excess of such holder’s beneficial ownership
limitation as set forth in the Certificate of Designation). Additionally, the vote or written consent of holders of a majority
of the outstanding shares of our Series B Preferred Stock, voting separately as a single class, will be required to:
●
amend,
alter or repeal any provision of our certificate of incorporation if such amendment, alteration or repeal would increase or decrease
the aggregate number of authorized shares of the Series B Preferred Stock;
●
amend,
alter or repeal any provision of our certificate of incorporation if such amendment, alteration or repeal would increase or decrease
the par value of the shares of the Series B Preferred Stock; or
●
amend,
alter or repeal any provision of our certificate of incorporation, whether by merger, consolidation or otherwise, if such amendment,
alteration or repeal would alter or change the powers, preferences or special rights of the holders of shares of Series B Preferred
Stock so as to affect them adversely.
|
Dividends
|
Subject to the applicable law and the rights of the holders of any outstanding series of our preferred stock, shares of Series B Preferred Stock will be entitled to receive dividends equal, on an as-converted to common stock basis, to and in the same form as dividends actually paid on shares of common stock when, as and if such dividends are paid on shares of common stock.
|
|
|
Rights in connection with certain fundamental transactions
|
In the event of any merger or consolidation which
results in 50% or more of the surviving entity being held by persons other than persons that, immediately prior to such merger
or consolidation, owned 50% or more of our capital stock, subject to the rights of the holders of any outstanding series of our
preferred stock, shares of Series B Preferred Stock will be entitled to receive consideration from such merger or consolidation
equal, on an as-converted to common stock basis, to and in the same form as consideration actually paid on shares of common stock.
In the event of any sale, lease or exchange of all
or substantially all of our property and assets, subject to the rights of the holders of any outstanding series of our preferred
stock, shares of Series B Preferred Stock will be entitled to receive cash consideration from such sale, lease or exchange equal,
on an as-converted to common stock basis, to the consideration actually paid on shares of common stock. Following payment of the
foregoing amounts in connection with such a sale, lease or exchange, we may, at our election, repurchase each outstanding shares
of Series B Preferred Stock for a repurchase price of $0.0001 per share.
|
Warrants offered by us
|
Series F-1 Warrants to purchase up to an aggregate of 59,760 shares
of our Series B Preferred Stock at an exercise price of $100.00 per share of Series B Preferred Stock, subject to adjustment. The
Series F-1 Warrants will be exercisable at any time on or after the issuance date until the five-year anniversary of such initial
exercise date.
Series F-2 Warrants to purchase up to an aggregate of 60,240
shares of our Series B Preferred Stock at an exercise price of $100.00 per share of Series B Preferred Stock, subject to adjustment. The
Series F-2 Warrants will be exercisable at any time on or after the date on which we obtain stockholder approval for a reverse
stock split or to increase our authorized common stock to allow for the reservation in full of all shares of common stock issuable
upon conversion of the Warrant Preferred Shares issuable upon exercise of the Series F-2 Warrants until the five-year anniversary
of such initial exercise date.
Pursuant to this prospectus supplement and the accompanying
prospectus, we will also issue the Placement Agent Warrants described under “Plan of Distribution,” as part of the
compensation payable to the placement agent in connection with this offering.
This prospectus supplement also relates to the offering
of shares of our common stock issuable upon conversion of the Warrant Preferred Shares.
See “Description of the Securities We are Offering––Warrants.”
|
Offering price
|
$ 100.00 per
fixed combination of one share of Series B Preferred Stock, one Series F-1 Warrant and one Series F-2 Warrant.
|
|
|
Series B Preferred Stock outstanding after the offering
|
60,000 shares
of Series B Preferred Stock (excluding Warrant Preferred Shares).
|
|
|
Common stock outstanding after the offering
|
2,001,541,260 shares of common stock (excluding shares of common stock issuable upon
conversion of shares of Series B Preferred Stock (including Warrant Preferred Shares)).
(1)
|
|
|
Best efforts
|
We have retained H.C. Wainwright & Co., LLC as our exclusive placement
agent in connection with the securities offered by this prospectus supplement and the accompanying
prospectus. The placement agent has agreed to use its reasonable best efforts to solicit offers to
purchase the securities offered by this prospectus supplement and the accompanying prospectus. The
placement agent has no obligation to buy any of the securities from us or to arrange for the purchase
or sale of any specific number or dollar amount of the securities. See “Plan of Distribution”
on page S-33.
|
|
|
Dividend policy
|
We have not declared or paid any cash dividends on our common stock since February 18, 2014. We do not anticipate paying any cash dividends in the foreseeable future.
|
|
|
Amendments to certain outstanding warrants
|
In connection with the offering, we will enter into amendments with holders of certain of
our outstanding warrants to purchase an aggregate of 666,666,668 shares of common stock, to reduce the exercise price
of each such warrants from $0.0163 to $0.01 per share of common stock.
|
|
|
Risk factors
|
Investing in our securities involves a high degree of risk. See “Risk Factors”
beginning on page S-9, as well as the other information included in or incorporated by reference in this prospectus supplement
and the accompanying prospectus, for a discussion of risks you should carefully consider before investing in our securities.
|
|
|
Use of proceeds
|
We will use approximately $870,000 of the net proceeds from the sale
of the Series B Preferred Stock and the Series F Warrants offered by us under this prospectus supplement to redeem a portion
of our outstanding indebtedness and the remaining proceeds for general corporate purposes of the Company and its subsidiaries
and transaction expenses. See “Use of Proceeds” on page S-25.
|
|
|
OTC Pink Market Symbol
|
“HMNY”
|
|
|
No public trading market for the Series B Preferred Stock or Warrants
|
There is no public trading market for the
Series B Preferred Stock, Series F Warrants or Placement Agent Warrants, we do not expect a market to develop, and holders
may not be able to resell the Series B Preferred Stock, Series F Warrants or Placement Agent Warrants or the shares of common
stock underlying the Series B Preferred Stock (including those underlying the Warrant Preferred Shares) purchased under this
prospectus supplement. In addition, we do not intend to apply for a listing of the Series B Preferred Stock, Series F Warrants
or Placement Agent Warrants or the shares of common stock underlying the Series B Preferred Stock (including those underlying
the Warrant Preferred Shares) on the Nasdaq Capital Market, any other national securities exchange, or any nationally recognized
trading system. This may affect the pricing of the Series B Preferred Stock, Series F Warrants or Placement Agent Warrants
and the shares of common stock underlying the Series B Preferred Stock (including those underlying the Warrant Preferred Shares)
in the secondary market, the transparency and availability of trading prices, and the liquidity of the Series B Preferred
Stock, Series F Warrants or Placement Agent Warrants and the shares of common stock underlying the Series B Preferred Stock
(including those underlying the Warrant Preferred Shares).
|
(1)
|
The number of shares of common stock to be outstanding after this offering is based on 2,001,541,260
shares of common stock outstanding as of March 20, 2019, and excludes, in each case as of March 20, 2019:
|
|
●
|
10,440 shares of common stock available and reserved for issuance pursuant to the Helios and Matheson Analytics Inc. 2014 Equity Incentive Plan;
|
|
●
|
29,364 shares of common stock that may be issued upon the exercise of warrants by Palladium Capital Advisors LLC;
|
|
●
|
18,545 shares of common stock reserved for issuance to various officers, directors, employees and consultants;
|
|
●
|
16,000 shares of common stock issuable to MoviePass upon receipt of stockholder approval and unrestricted conversion of the convertible promissory note in the principal amount of $12 million that we issued to MoviePass upon the closing of the Securities Purchase Agreement, dated August 15, 2017, between the Company and MoviePass;
|
|
●
|
50,886 shares of common stock issuable upon the exercise of warrants issued in public offerings in December 2017, February 2018 and April 2018;
|
|
●
|
10,201 shares of common stock issuable upon the exercise of warrants, issued to Oath Inc. upon the closing of the acquisition of the Moviefone assets;
|
|
●
|
2,000 shares of common stock reserved for issuance to Helios and Matheson Information Technology
Ltd. in exchange for entering into prior lockup agreements;
|
|
|
|
|
●
|
1,026,666,669 shares of common stock that may be issued upon the exercise of warrants issued
to certain institutional investors and affiliates of H.C. Wainwright & Co., LLC on January 16, 2019 (the “January
2019 Offering”). In connection with this offering, the exercise price of warrants to purchase 666,666,668
shares of common stock issued to institutional investors in the January 2019 Offering will be reduced from $0.0163 to
$0.01 per share of common stock; and
|
|
|
|
|
●
|
3,080,061,600 shares
of common stock issuable upon the conversion of the Series B Preferred Stock (including the Warrant Preferred Shares).
|
RISK FACTORS
Investing in our securities involves
a high degree of risk. Please see the risk factors set forth in Part I, Item 1A of our most recent Annual Report on Form 10-K and
in Part II, Item 1A of our Quarterly Reports on Form 10-Q and other filings we make with the SEC, which are incorporated by reference
into this prospectus supplement, as well as the other risk factors listed in this prospectus supplement and underlying prospectus.
Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate
by reference in this prospectus supplement. The risks and uncertainties we have described are not the only ones we face. Additional
risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business operations.
These risks could materially affect our business, results of operations or financial condition and cause the value of our securities
to decline.
Risks Related to our MoviePass Business
We have a limited operating history and our businesses
have a history of net losses, and it is likely that we will experience net losses for the foreseeable future.
We have experienced significant net losses
since inception and our businesses have a history of net losses. Given the significant operating and capital expenditures associated
with our business plans, we anticipate continuing to incur net losses and significant negative cash flows for the foreseeable future.
If we ever do achieve profitability, of which no assurances can be given, we may be unable to sustain or increase such profitability.
To achieve and sustain profitability, we
will need to accomplish numerous objectives, including substantially increasing the number of paying subscribers to MoviePass’
service and securing additional sources of revenue and economies of scale. There is a significant risk that we will be unable to
achieve these objectives, which would damage our business.
MoviePass currently spends more to retain a subscriber
than the revenue derived from that subscriber, and there is no assurance that we or MoviePass will be able to increase other sources
of revenue to offset the losses or achieve a positive gross profit margin.
MoviePass currently spends more to retain
a subscriber than the revenue derived from that subscriber, and other sources of revenue are currently inadequate to offset or
exceed the costs of subscriber retention. This results in a negative gross profit margin. We expect MoviePass’ negative gross
profit margin to remain significant until it can sufficiently increase our other sources of revenues to offset the losses or achieve
substantial economies of scale. There is no assurance that MoviePass or we will be able to sufficiently increase our other sources
of revenue or be able to achieve economies of scale that would reduce the cost of revenue sufficiently to generate a positive gross
profit margin. Failure to achieve positive gross profit margin in the foreseeable future could materially and adversely impact
our results of operations.
Due to recent changes to MoviePass’ subscription
plans, the number of its subscribers has decreased, and it may continue to lose subscribers or fail to attract new subscribers.
In an effort to reduce its monthly deficit
and improve profitability, MoviePass changed its monthly subscription plan to a three-movies-per-month plan, at a price of $9.95
per month and limited the available movies to those listed on a schedule. In August 2018, MoviePass began to convert subscribers
on an annual subscription plan to a three-movies-per-month subscription plan, by giving annual subscribers the option to either
cancel their annual subscription plan and receive a pro-rated refund or continue on the new three-movies-per-month subscription
plan. As a result of these changes, MoviePass has experienced subscriber losses. MoviePass may continue to lose subscribers, or
fail to attract new subscribers, and our business and operating results could be adversely affected.
In January 2019, MoviePass made available
updated pricing plans, featuring a three-tier pricing structure. Under the “Select” plan, subscribers will be able
to see up to three movies a month at some point during their theatrical run, other than opening weekends, based on a programming
schedule; under the “All Access” plan, subscribers will be able to see up to three movies of their choice per month
at any time during their theatrical run in standard 2D format; and under the “Red Carpet” plan, subscribers will be
able to see up to three movies of their choice per month at any time during their theatrical run, and may choose to use one of
their allotted three movies for IMAX 2D, IMAX 3D or supported Premium Large Format screenings, including RealD 3D. Prices for each
plan vary based on geographic areas designed to reflect the difference in average ticket prices in different areas of the country.
Subscribers may purchase plans for three-, six- and twelve-month terms, and receive discounts for buying multiple subscription
plans. In December 2018, MoviePass also announced two limited-time holiday offers to offer the “All Access” and “Red
Carpet” plans at a reduced rate for twelve months.
On March 19, 2019, MoviePass announced
a new version of its uncapped subscription plan, called MoviePass Uncapped. Under the new MoviePass Uncapped subscription plan,
subscribers can see an uncapped number of 2D movies in MoviePass’ theater network, subject to managing network demand and
availability as set forth in its new terms of use, at most theaters nationwide for a fixed price, which varies depending on whether
the subscriber chooses to pay monthly or annually. Under its new terms of use, MoviePass may limit the availability of movies
for an individual subscriber if such subscriber’s use adversely impacts MoviePass’ system-wide capacity or availability
for other subscribers, and a subscriber cannot see a particular movie more than once. MoviePass will allow subscribers under its
previous “Select”, “All Access” and “Red Carpet” plans, which allow subscribers to see up
to three movies a month, at most theaters nationwide for a fixed price, which varies depending on the subscription plan selected
by the subscriber, and additional movies at a discounted price, to remain on such plans. However, the “Select”, “All
Access” and “Red Carpet” plans will no longer be available for purchase.
These changes and future changes to MoviePass’ subscription plan
may not be favorably received by customers and MoviePass may not be able to attract or retain subscribers, and as a result, our
revenue and results of operations may be affected adversely. The number of recent changes to MoviePass’ subscription plans
may also make competitors’ subscription plans more attractive to customers, and MoviePass may be unable to successfully compete
with current and new competitors.
Increased monthly usage by MoviePass’ subscribers
may cause MoviePass to incur losses and negative cash flow.
MoviePass’ new MoviePass Uncapped
subscription plan allows subscribers to see an uncapped number of 2D movies in MoviePass’ theater network, subject to managing
network demand and availability, at most theaters nationwide for a fixed price, which varies depending on whether the subscriber
chooses to pay monthly or annually. MoviePass’ will also continue to allow subscribers on its previous “Select”,
“All Access” and “Red Carpet”, which allow subscribers to see up to three movies per month for a fixed
price, which varies depending on the subscription plan selected by the subscriber, and additional movies at a discounted price,
to remain on such plans. In most cases, MoviePass pays, and expects to continue to pay, the theaters the full cost for each movie
ticket that a subscriber uses. Accordingly, even though MoviePass’ new terms of use contains features that allow MoviePass
to manage network demand and availability and prevent abuse of its service, including the ability to limit the availability of
movies for an individual subscriber if such subscriber’s use adversely impacts MoviePass’ system-wide capacity or
availability for other subscribers, increased movie viewing by subscribers may result in significant and increasing losses per
subscriber and negative cash flow and adversely affects our financial condition and results of operations.
If MoviePass is not able to manage its growth, its business
could be affected adversely.
On March 19, 2019, MoviePass announced
a new version of its uncapped subscription plan, called MoviePass Uncapped. Under the new MoviePass Uncapped subscription plan,
subscribers can see an uncapped number of 2D movies in MoviePass’ theater network, subject to managing network demand and
availability as set forth in its new terms of use, at most theaters nationwide for a fixed price, which varies depending on whether
the subscriber chooses to pay monthly or annually. When MoviePass announced a similar uncapped plan in August 2017, MoviePass’
subscriber base expanded rapidly, which placed significant demands on its managerial, operational, administrative and financial
resources.
MoviePass may not be able, for many reasons,
including lack of financing or adequate personnel resources, to meet the demand to timely deliver MoviePass cards to its subscribers
or otherwise service its business in the event of another rapid expansion of its subscriber base. As such, MoviePass could experience
a significant slowdown or stoppage as it attempts to serve the expanding subscriber base.
MoviePass anticipates that further expansion
of its operations will be required to address any significant growth in its subscriber base and to take advantage of favorable
market opportunities. Any future expansion will likely place significant demands on its managerial, operational, administrative
and financial resources. If it is not able to respond effectively to new or increased demands that arise because of MoviePass’
growth, or, if in responding, MoviePass’ management is materially distracted from current operations, MoviePass’ business
may be affected adversely.
Any reduction in anticipated spending
by advertisers could harm our business.
Future advertising revenues are critical
to MoviePass’ business model and if advertisers’ spending on online or mobile advertising is significantly reduced
due to any political, economic, social or technological change or any other reason, our financial condition could be adversely
affected.
The MoviePass business depends on mobile technology and
continued, unimpeded access to internet and wireless services. Adverse changes to that access could harm our business.
A few large companies provide wireless
services to consumers. If MoviePass’ users’ access to Internet and wireless services is interfered with or limited
due to any political, economic, social or technological reason, MoviePass may not be able to make the MoviePass application readily
available to its users or may not be able to do so in an effective manner, including ensuring that the MoviePass application will
remain accessible within an acceptable load time. Failure to provide the MoviePass subscription service in a timely manner without
interruption could generate consumer complaints and adversely affect our business.
MoviePass’ failure or inability to protect its intellectual
property rights could diminish the value of its brand and weaken its competitive position.
MoviePass relies on a combination of trademark,
trade secret and unfair competition laws, as well as confidentiality agreements and procedures and licensing arrangements, and
where appropriate, patents and copyright to establish and protect its intellectual property rights. There is a risk that the steps
taken by MoviePass to protect its intellectual property rights will be inadequate to prevent infringement of such rights by others,
including imitation of its services and misappropriation of its brand. Additionally, the process of obtaining patent or trademark
protection is expensive and time-consuming, and we and MoviePass may not be able to prosecute all necessary or desirable patent
applications or apply for all necessary or desirable trademark applications at a reasonable cost or in a timely manner.
Moreover, costly and time-consuming litigation
could be necessary to enforce and determine the scope of MoviePass’ proprietary rights, and the failure or inability to obtain
or maintain trade secret protection or otherwise protect our proprietary rights could adversely affect our business. MoviePass
may be subject to intellectual property-related lawsuits in various jurisdictions, and there is a risk that its products or activities
violate the patents, trademarks, or other intellectual property rights of third-party claimants. We or MoviePass may also need
to institute litigation to protect MoviePass’ intellectual property from third party infringers. Costs of supporting such
litigation and disputes may be considerable, and there can be no assurances that a favorable outcome will be obtained. Patent infringement,
trademark infringement, trade secret misappropriation and other intellectual property claims and proceedings brought against or
by us or MoviePass, whether successful or not, could result in substantial costs, harm to our brand and the MoviePass brand, and
have an adverse effect on our business.
Risks Related to the Business of MoviePass
Films
MoviePass Films’ content production business requires
a substantial investment of capital, and failure to access sufficient capital while awaiting delayed revenues will have a material
adverse effect on our results of operation.
The production, acquisition and distribution
of film and other content requires significant capital. In addition, if a distributor does not provide the funds for the distribution
and marketing of our film, MoviePass Films will require additional capital to distribute and market the film. A significant amount
of time may elapse between MoviePass Films’ expenditure of funds and the receipt of revenues from MoviePass Films’
productions. MoviePass Films does not have a traditional credit facility with a financial institution on which to depend for its
liquidity needs, and a time lapse may require us to fund a significant portion of MoviePass Films’ capital requirements through
loans and additional issuances of our common stock, securities convertible into our common stock, debt securities or a combination
of such financing alternatives. There can be no assurance that any additional financing will be available to MoviePass Films as
and when required, or on terms that will be acceptable to MoviePass Films. MoviePass Films’ inability to raise capital necessary
to sustain its operations while awaiting delayed revenues would have a material adverse effect on our liquidity and results of
operations.
MoviePass Films’ success is highly dependent on
audience acceptance of its films and acquired content, which is extremely difficult to predict and, therefore, inherently risky.
We cannot predict the economic success of
any of films or acquired content of MoviePass Films or because the revenue derived from the distribution of a film (which does
not necessarily directly correlate with the production or distribution costs incurred) or other acquired content depends primarily
upon its acceptance by the public, which cannot be accurately predicted. The economic success of a film or other acquired content
also depends upon the public’s acceptance of competing films and content, the availability of alternative forms of entertainment
and leisure-time activities, general economic conditions and other tangible and intangible factors, all of which can change and
cannot be predicted with certainty.
The economic success of a film is largely
determined by MoviePass Films’ ability to produce content and develop stories and characters that appeal to a broad audience
and by the effective marketing of the film. The theatrical performance of a film is a key factor in predicting revenue from post-theatrical
markets. If we are unable to accurately judge audience acceptance of MoviePass Films’ film content or to have the film effectively
marketed, the commercial success of the film will be in doubt, which could result in costs not being recouped or anticipated profits
not being realized. Moreover, we cannot assure you that any particular feature film will generate enough revenue to offset its
distribution, fulfillment services and marketing or acquisition costs, in which case MoviePass Films would not receive any revenues
for such film.
We may incur significant write-offs if MoviePass Films’
feature films and other projects do not perform well enough to recoup production, marketing, distribution, acquisition and other
costs.
We are required to amortize capitalized
production costs over the expected revenue streams as we recognize revenue from MoviePass Films’ films or other projects.
The amount of production costs that will be amortized each quarter depends on, among other things, how much future revenue we expect
to receive from each project. Unamortized production costs are evaluated for impairment each reporting period on a project-by-project
basis. If estimated remaining revenue is not sufficient to recover the unamortized production costs, the unamortized production
costs will be written down to fair value. In any given quarter, if we lower our previous forecast with respect to total anticipated
revenue from any individual feature film or other project, we may be required to accelerate amortization or record impairment charges
with respect to the unamortized costs, even if we have previously recorded impairment charges for such film or other project. Such
impairment charges could have a material adverse impact on our business, operating results and financial condition.
MoviePass Films is substantially dependent upon the success
of a limited number of film releases and other productions, if any, in any given year and its inability to release any film or
other productions or the unexpected delay or commercial failure of any one of them could have a material adverse effect on our
financial results and cash flows
.
The content production business of MoviePass
Films is currently substantially dependent upon the success of a limited number of film releases and other productions in any given
year. The unexpected delay in release or commercial failure of just one of these films or productions, or MoviePass Films’
inability to release any productions at all, could have a significant adverse impact on our results of operations and cash flows
in both the year of release and in the future. Historically, feature films that are successful in the domestic theatrical market
are generally also successful in the international theatrical and ancillary markets, although each film is different and there
is no way to guarantee such results. If MoviePass Films’ films fail to achieve domestic box office success, their success
in the international box office and ancillary markets and our business, results of operations and financial condition could be
adversely affected. Further, we can make no assurances that the historical correlation between results in the domestic box office
and results in the international box office and ancillary markets will continue in the future. If MoviePass Films is unable to
release any film or other productions in a given year, or if the feature films it releases do not perform well in the domestic
or international theatrical markets and ancillary markets, or its other productions do not perform as anticipated, the failure
to release any productions, or the failure of any one of the productions it releases, could a material adverse effect on our financial
results and cash flows.
Delays, cost overruns, cancellation or abandonment of
the completion or release of MoviePass Films’ films may have an adverse effect on our business.
There are substantial financial risks relating
to production, completion and release of films. Actual costs may exceed their budgets due to factors such as labor disputes, unavailability
of a star performer, equipment shortages, disputes with production teams or adverse weather conditions, any of which may cause
cost overruns and delay or hamper film completion. MoviePass Films is typically responsible for paying all production costs in
accordance with a budget and receive a fixed producer’s fee for its services plus a portion of any project income. However,
to the extent that delays or cost overruns result in MoviePass Films not completing the film within budget, there may not be enough
funds left to pay MoviePass Films’ producer’s fee, to generate any project income or complete the project at all. If
this were to occur, it would significantly and adversely affect our revenue and results of operations.
MoviePass Films will rely on third party distributors
to distribute its films and their failure to perform or promote its films could negatively impact our ability to generate revenues
and have a material adverse effect on our operating results.
MoviePass Films’ films will be primarily
distributed and marketed by third party distributors. If any of these third-party distributors fails to perform under their respective
arrangements, such failure could negatively impact the success of MoviePass Films’ films and have a material adverse effect
on our business, reputation and ability to generate revenues.
MoviePass Films generally will not control
the timing and manner in which its distributors distribute its films; the distributors decisions regarding the timing of release
and promotional support are important in determining success. Any decision by those distributors not to distribute or promote one
of MoviePass Films’ films or to promote a competitors’ films or related products to a greater extent than they promote
MoviePass Films’ could have a material adverse effect on our business, cash flows and operating results. Additionally, because
third parties are the principal distributors of MoviePass Films’ movies, the amount of revenue that is recognized from films
in any given period is dependent on the timing, accuracy and sufficiency of the information received from its distributors. As
is typical in the film industry, MoviePass Films’ distributors may make adjustments in future periods to information previously
provided to it that could have a material impact on our operating results in later periods.
The popularity and commercial success of MoviePass Films’
films and acquired content are subject to numerous factors, over which we may have limited or no control.
The popularity and commercial success of
MoviePass Films’ films and acquired content depends on many factors including, but not limited to, the key talent involved,
the timing of release, the promotion and marketing of the film, the quality and acceptance of other competing productions released
into the marketplace at or near the same time, the availability of alternative forms of entertainment, general economic conditions,
the genre and specific subject matter of the film, its critical acclaim and the breadth, timing and format of its initial release.
We cannot predict the impact of such factors on any film or other acquired content, and many are factors that are beyond our control.
As a result of these factors and many others, MoviePass Films’ films and acquired content may not be as successful as we
anticipate, and as a result, our results of operations may suffer.
MoviePass Films must successfully respond to rapid technological
changes and alternative forms of delivery or storage to remain competitive.
The entertainment industry continues to
undergo significant developments as advances in technologies and new methods of product delivery and storage, and certain changes
in consumer behavior driven by these developments emerge. New technologies affect the demand for MoviePass Films’ content,
the manner in which its content is distributed to consumers, the sources and nature of competing content offerings and the time
and manner in which consumers acquire and view its content. MoviePass Films and its distributors must adapt their businesses to
shifting patterns of content consumption and changing consumer behavior and preferences through the adoption and exploitation of
new technologies. If MoviePass Films cannot successfully exploit these and other emerging technologies, it could have a material
adverse effect on our business, financial condition, operating results, liquidity and prospects.
MoviePass Films’ business may be affected by changes
in consumer discretionary spending in the U.S. or internationally.
MoviePass Films’ success depends
on its ability to distribute or otherwise generate income from its current and future motion pictures and other acquired content.
MoviePass Films’ industry is subject to discretionary consumer spending, which is influenced by general economic conditions,
consumer confidence and the availability of discretionary income. Changes in economic conditions affecting potential distributors
or viewers of motion pictures could reduce MoviePass Films’ ability to generate income from motion pictures. Furthermore,
weak economic conditions and geopolitical and economic uncertainties in international regions and countries where MoviePass Films’
movie productions are distributed could lead to lower consumer spending for its content, which could have a material adverse effect
on our financial condition and results of operations.
If MoviePass Films is unable to compete
effectively, our business will be affected adversely.
The business in which MoviePass Films engages
is highly competitive. Its primary business operations are subject to competition from companies which, in many instances, have
greater development, production and distribution and capital resources than MoviePass Films. MoviePass Films competes for the services
of writers, producers, directors, actors and other artists to produce its motion picture content, as well as for advertisement
dollars. Larger companies have a broader and more diverse selection of scripts than MoviePass Films does, which translates to a
greater probability that they will be able to more closely fit the demands and interests of advertisers than MoviePass Films can.
As a small independent producer, MoviePass
Films competes with major U.S. and international studios. Most of the major U.S. studios are part of large diversified corporate
groups with a variety of other operations that can provide both the means of distributing their products and stable sources of
earnings that may allow them better to offset fluctuations in the financial performance of their film and other operations. In
addition, the major studios have more resources with which to compete for ideas, storylines and scripts created by third parties,
as well as for actors, directors and other personnel required for production. Such competition for the industry’s talent
and resources may negatively affect MoviePass Films’ ability to acquire, develop, produce, advertise and distribute motion
picture content.
As a new entrant into film
distribution, MoviePass Films will have competitors with longer operating histories in the distribution of independent films, deeper
ties with industry executives and film producers, and greater financial, marketing and other resources than MoviePass Films. MoviePass
Films will also face competition from larger film distributors which focus on higher budget film production and distribution.
MoviePass Films may be adversely affected by union activity.
MoviePass Films retains the services of
actors who are covered by collective bargaining agreements with Screen Actors Guild – American Federation of Television and
Radio Artists, and it may also become signatories to certain guilds such as Directors Guild of America and Writers Guild of America
in order to allow it to hire directors and talent for its productions. Collective bargaining agreements are industry-wide agreements,
and MoviePass Films lacks practical control over the negotiations and terms of these agreements.
In addition, if negotiations to renew expiring
collective bargaining agreements are not successful or become unproductive, the union could take actions such as strikes, work
slowdowns or work stoppages. Strikes, work slowdowns or work stoppages or the possibility of such actions could result in delays
in production of MoviePass Films’ films. MoviePass Films could also incur higher costs from such actions, new collective
bargaining agreements or the renewal of collective bargaining agreements on less favorable terms. Depending on their duration,
union activity or labor disputes could have an adverse effect on our results of operations.
MoviePass Films may be unable to recoup advances paid
to secure exclusive distribution rights
.
MoviePass Films’ most significant
costs and cash expenditures relate to acquiring content for exclusive distribution. Most agreements to acquire content require
upfront advances against royalties or net profits participations expected to be earned from future distribution. The amount MoviePass
Films is willing to advance is derived from its estimate of net revenues that will be realized from its distribution of the title.
Although these estimates are based on management’s knowledge of competitive title performance, current events and actions
management may undertake in the future, actual results will differ from those estimates. If sales do not meet our original estimates,
MoviePass Films may (i) not recognize the expected gross margin or net profit, (ii) not recoup its advances or (iii) record
accelerated amortization and/or fair value write-downs of advances paid.
MoviePass Films’ inability to maintain relationships
with its program suppliers and vendors may adversely affect its business
.
MoviePass Films receives a significant amount
of its revenues from the distribution of content for which it already has exclusive agreements with program suppliers. However,
titles which have been financed by MoviePass Films may not be timely delivered as agreed or may not be of the expected quality.
Delays or inadequacies in delivery of titles, including rights clearances, could negatively affect the performance of any given
quarter or year. In addition, results of operations and financial condition may be materially adversely affected if:
|
●
|
MoviePass Films is unable to renew existing agreements as they expire;
|
|
|
|
|
●
|
MoviePass Films current program suppliers do not continue to support digital, DVD or other applicable format in accordance with its exclusive agreements;
|
|
|
|
|
●
|
MoviePass Films’ current content suppliers do not continue to license titles to it on terms acceptable to it; or
|
|
|
|
|
●
|
MoviePass Films is unable to establish new beneficial supplier relationships to ensure acquisition of exclusive or high-profile titles in a timely and efficient manner.
|
Others may assert intellectual property infringement claims
or liability claims for film content against MoviePass Films which may force us to incur substantial legal expenses.
There is a possibility that others may
claim that MoviePass Films’ productions and production techniques misappropriate or infringe the intellectual property rights
of third parties with respect to its previously developed web series, films, stories, characters, other entertainment or intellectual
property. In addition, as distributors of film content, MoviePass Films may face potential liability for such claims as defamation,
invasion of privacy, negligence, copyright or trademark infringement or other claims based on the nature and content of the materials
distributed. If successfully asserted, our insurance may not be adequate to cover any of the foregoing claims. Irrespective of
the validity or the successful assertion of such claims, we could incur significant costs and diversion of resources in defending
against them, which could have a material adverse effect on our operating results.
If MoviePass Films fails to protect its intellectual property
and proprietary rights adequately, our business could be adversely affected.
MoviePass Films’ ability to compete
depends, in part, upon successful protection of its respective intellectual property. MoviePass Films attempt to protect proprietary
and intellectual property rights to its productions and acquired content through available copyright and trademark laws and distribution
arrangements with companies for limited durations. Unauthorized parties may attempt to copy aspects of its intellectual property
or to obtain and use property that MoviePass Films regards as proprietary. We cannot assure you that MoviePass Films’ means
of protecting its proprietary rights will be adequate. In addition, the laws of some foreign countries do not protect these proprietary
rights to as great an extent as the laws of the United States. Intellectual property protections may also be unavailable, limited
or difficult to enforce in some countries, which could make it easier for competitors to steal MoviePass Films’ intellectual
property. The failure to protect adequately MoviePass Films’ intellectual property and proprietary rights could adversely
affect our business and results of operations.
Risks Related to the Moviefone Assets
Our focus on our online advertising-supported business
model involves significant risks.
Growth in Moviefone’s advertising
revenues depends on its ability to maintain and expand its existing relationships with advertisers and publishers and its ability
to develop new relationships with other advertisers and publishers. Growth in its advertising revenues also depends on its ability
to continue offering effective products and services for advertisers and publishers. As the advertising market generates and develops
new concepts and technology, Moviefone may incur additional costs to implement more effective products and services. As programmatic
advertising gains traction with more advertisers and publishers, we continue to invest in and focus on Moviefone’s end-to-end
open technology and programmatic platforms. Continuing to develop and improve these products and services may require significant
time and additional investment. If Moviefone cannot continue to develop and improve its advertising products, services and technologies
in a timely and cost-effective fashion, its competitive position and results of operations could be adversely affected.
The commercial attractiveness of the programmatic
advertising solutions that Moviefone offers to publishers and advertisers depends on a variety of complex and evolving factors,
among them the continued effective functioning and improvement of Moviefone’s proprietary learning algorithms, the continued
ability to access and utilize relevant data about consumers and their consumption habits across multiple devices and, with respect
to programmatic advertising exchange-related activities, continued automated access to the advertising inventory and application
programming interfaces of publishers as well as continued robust relationships with brand advertisers and agencies.
Moviefone’s programmatic advertising
solutions may become less attractive, and our results of operations may suffer, as a result of changes in laws and regulations
and changes in industry standards generally. In addition, the following factors may further diminish the appeal of Moviefone’s
programmatic advertising solutions and thereby negatively affect our results of operations: with respect to the availability of
consumer data, changes in consumer choices; with respect to the functioning of Moviefone’s algorithms, the failure or inability
to access, collect or analyze relevant data (for technological reasons or otherwise); and with respect to programmatic exchange
activities, access to publisher inventory and relationships with advertisers and agencies, technological limitations or restrictions
imposed by advertisers and publishers themselves.
Additionally, advertising revenues are unpredictable
and variable, and are more likely to be adversely affected during economic downturns, as spending by advertisers tends to be cyclical
in line with general economic conditions.
The Moviefone service faces intense competition in all
aspects of its business.
The internet industry, with its low barriers
to entry and rapidly shifting consumer tastes, is dynamic and rapidly evolving. Competition among internet companies offering online
content, products and services, as well as with traditional offline content and advertising companies which are increasingly offering
their own online content, products and services, is intense both domestically and globally and new competitors can quickly emerge.
Additionally, as the use of programmatic advertising continues to increase, we compete with companies that have also invested in
programmatic platform offerings. As companies integrate into larger, more comprehensive programmatic platforms, new competitors
may arise and our business could be adversely affected if Moviefone does not continue to invest in, develop and improve our programmatic
products and services.
As consumers increasingly use mobile devices
and as the demand for video content and advertising increases, Moviefone competes with other companies in developing and offering
mobile and video content and advertising products and services. If consumers, advertisers and publishers do not widely adopt Moviefone’s
mobile and video offerings or if it does not generate sufficient revenue from its mobile or video offerings, Moviefone’s
competitive position could be adversely affected.
In addition, companies offering services
to advertisers are increasingly seeking to track individual consumer usage across devices through the use of tracking and data
correlation technologies. To the extent companies with a larger audience reach than Moviefone’s are able to track individual
consumer usage in this way and gather data about consumers that is valuable to advertisers, those companies will have a competitive
advantage. If Moviefone cannot develop and offer effective tracking and data correlation technologies or it does not have access
to a sufficient consumer audience, its advertising products and services may not be as valuable to advertisers and publishers and
its competitive position and our results of operations may be harmed.
Additionally, Moviefone could be at a competitive
disadvantage in the long term if it is not able to capitalize on international opportunities, especially as compared to a number
of its competitors who maintain an expansive global presence. If Moviefone’s competitors are more successful than it in developing
compelling content, products and services or in attracting and retaining consumers, advertisers, publishers and subscribers domestically
and internationally, our business could be adversely affected.
If Moviefone does not continue to develop and offer compelling
content, products and services and attract new users or maintain the engagement of its existing users, its advertising revenues
could be adversely affected.
In order to attract users and maintain or
increase engagement on Moviefone, we believe Moviefone must offer compelling content, products and services across all devices,
including mobile. Acquiring, developing and offering new content, products and services, as well as new functionality, features
and enhanced performance of Moviefone’s existing content, products and services, may require significant investment and time
to develop. In addition, consumer tastes are difficult to predict and subject to rapid change.
If Moviefone cannot effectively distribute its content,
products and services, its ability to attract new users and maintain the engagement of existing users could be adversely affected.
As the behavior of internet consumers continues
to change, distribution of Moviefone’s content, products and services via traditional methods may become less effective,
and new distribution strategies may need to be developed. Consumers are increasingly using social networking sites to communicate
and to acquire and disseminate information rather than through instant messaging, electronic mail and portals. As consumers migrate
towards social networks, Moviefone continues to build social elements into its content, products and services in order to make
them available on social networks and to attract and engage consumers on Moviefone’s properties, for example by allowing
consumers to contribute comments or their own original content. There is no guarantee that we will be able to successfully integrate
Moviefone’s content with such social networking or other new consumer trends. Even if Moviefone is able to distribute its
content, products and services effectively through social networking or other new or developing distribution channels, this does
not assure that it will be able to attract new consumers.
If Moviefone is unable to grow organically
by attracting new consumers directly to its content, products and services or if traffic to Moviefone’s portals declines,
Moviefone may need to rely on distribution channels that require Moviefone to pay significant fees to third parties such as operators
of third-party websites, online networks, software companies, device manufacturers, and others to promote or supply Moviefone’s
services to their users.
To
the extent that we cannot generate consumer and advertiser awareness and adoption of our mobile applications, content, products
and services, including new forms of internet advertising for mobile and other internet enabled devices, our business could be
adversely impacted.
Global
consumers are increasingly accessing and using the internet through devices other than personal computers, such as smartphones,
tablets and televisions. As consumer usage shifts away from personal computers and laptops, we expect that Moviefone’s ability
to grow advertising revenue will become increasingly dependent on its ability to generate revenue from ads on mobile and other
internet enabled devices such as set-top boxes (e.g., Roku, Amazon Fire TV). In order for consumers to access and use Moviefone’s
content, products and services via these devices, it must continue to ensure that its content, products and services are compatible
with such devices. Moviefone needs to continue to secure arrangements with device manufacturers and carriers to promote prominent
and effective distribution of its content, products and services. In addition to placement agreements with wireless carriers and
device manufacturers, currently Moviefone offer applications directly to consumers for download from the Apple App Store, the
Google Play Store, or through other distribution channels. Moviefone is dependent on the interoperability of its products with
popular mobile operating systems that we do not control, such as Android and iOS. To the extent a manufacturer or access provider
makes any changes in these systems or terms of service that decreases Moviefone’s products’ functionality, gives preferential
treatment to competitive products, or prevents Moviefone’s ability to show ads, this could adversely affect Moviefone’s
usage and revenue on mobile devices.
The
amount of revenues earned in connection with mobile and other internet enabled devices is currently small relative to total advertising
revenues. Also, business models in the marketplace seem to be undergoing experimentation and rapid change.
A
disruption or failure of our networks and information systems, the internet or other technology may disrupt the Moviefone service.
The
Moviefone service is heavily dependent on the availability of network and information systems and services, other technologies,
including those owned or licensed by third parties, and the internet. Shutdowns or service disruptions caused by events such as
criminal activity, sabotage or espionage, computer viruses, hacking and other cyber-security attacks, router disruption, automated
attacks such as denial of service attacks, power outages, natural disasters, accidents, terrorism, equipment failure or other
events within or outside our control could adversely affect Moviefone and its consumers, including loss or compromise of data,
service disruption, damage to equipment and data and excessive call volume to call centers. Furthermore, such attacks are not
always able to be immediately detected, which means that we may not be in a position to promptly address the attacks or to implement
adequate preventative measures. Such events could result in large expenditures necessary to recover data, or repair or replace
such networks or information systems or to protect them from similar events in the future. As not all of our systems are fully
redundant, some data or systems might not be recoverable after such events. In addition, not all of our systems operate in the
same data centers. Significant incidents could result in a disruption of parts of our business, consumer dissatisfaction, damage
to Moviefone’s brands, legal costs or liability, and a loss of consumers or revenues.
If
our network and data security measures are breached, Moviefone’s products and services may be perceived as not being secure,
consumers and customers may curtail or stop using Moviefone’s products and services and we may incur significant legal and
financial costs.
Moviefone’s
products and services involve the storage and transmission of Moviefone’s consumers’ and customers’ personal
and proprietary information in our facilities and on our equipment, networks and corporate systems. Network and data security
breaches expose us to a risk of loss of this information, government enforcement actions and private litigation, remediation costs,
increased costs for security measures, loss of revenue, damage to Moviefone’s reputation and potential liability. Network
and data security breaches or unauthorized access have resulted in, and may in the future result in, a combination of significant
legal and financial costs, increased remediation and other costs, damage to Moviefone’s reputation and a loss of confidence
in the security of Moviefone’s products, services and networks that could have an adverse effect on our business. We take
steps to prevent unauthorized access to our network and consumer and customer data and corporate systems, however, because the
techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently or may be designed
to remain dormant until a triggering event, we may be unable to anticipate these techniques or implement adequate preventative
measures. In addition, hardware, software or applications we develop or procure from third parties may contain defects in design
or manufacture or other problems that could unexpectedly compromise network and data security. Unauthorized parties may also attempt
to gain access to our systems or facilities through fraud, trickery or other forms of deceiving our team members and contractors.
We can give no assurance that a future incident could not be caused by events such as criminal activity, sabotage or espionage,
computer viruses, hacking and other cyber-security attacks, router disruption, automated attacks such as denial of service attacks,
power outages, natural disasters, accidents, terrorism, equipment failure, malware in advertisements, or other events within or
outside our control which could adversely affect us and Moviefone’s consumers.
If
we cannot continue to enforce and protect Moviefone’s intellectual property rights, our business could be adversely affected.
We
rely on patent, copyright, trademark, domain name and trade secret laws in the United States and similar laws in other countries,
as well as licenses and other agreements with our employees, consumers, content providers, suppliers and other parties, to establish
and maintain our intellectual property rights in the technology, content, products and services related to the Moviefone brand.
These laws and agreements may not guarantee that our intellectual property rights will be protected and our intellectual property
rights could be challenged or invalidated. Amendments to or interpretations of U.S. patent laws or new rulings around U.S. patent
laws may adversely impact our ability to protect our new technologies, content, products and services and to defend against claims
of patent infringement. In addition, such intellectual property rights may not be sufficient to permit us to take advantage of
current industry trends or otherwise to provide competitive advantages, which could result in costly redesign efforts, discontinuance
of offerings, decreased traffic and associated revenue or otherwise adversely affect our business. As Moviefone publishes more
original content, our intellectual property may be increasingly subject to misappropriation by others, and the costs to protect
and enforce our intellectual property rights may increase.
We
have been, and may in the future be, subject to claims of intellectual property infringement or tort law violations that could
adversely affect our business.
Many
companies (including patent holding companies) and individuals own patents, copyrights, trademarks, and trade secrets and frequently
enter into litigation based on allegations of infringement or other violations of intellectual property rights. As Moviefone develops
and offers new products, services, and technologies through various distribution channels we may experience an increase in the
number of intellectual property claims against us. These claims, whether meritorious or not, may result in litigation, may be
time-consuming and costly to resolve, and may require expensive changes in our methods of doing business and/or our content, products
and services. These intellectual property infringement claims may require us to enter into royalty or licensing agreements on
unfavorable terms or to incur substantial monetary liability. Additionally, these claims may result in our being enjoined preliminarily
or permanently from further use of certain intellectual property and/or Moviefone content, products and services, or may require
us to cease or significantly alter certain of operations related to the Moviefone brand. The occurrence of any of these events
as a result of these claims could result in substantially increased costs, could limit or reduce the number of Moviefone’s
offerings to consumers, advertisers and publishers, could stifle innovation or otherwise adversely affect our business.
Some
of our commercial agreements may require us to indemnify third parties against intellectual property infringement claims, which
may require us to use substantial resources to defend against or settle such claims or, potentially, to pay damages. These third
parties may also discontinue the use of Moviefone’s products, services, and technologies, as a result of injunctions or
otherwise, which could result in loss of revenues and adversely impact our business. Additionally, we may be exposed to liability
or substantially increased costs if a commercial partner does not honor its contractual obligation to indemnify us for intellectual
property infringement claims made by third parties or if any amounts received are not adequate to cover our liabilities or the
costs associated with defense of such claims. The occurrence of any of these events could adversely affect our business.
As
a publisher of original content and aggregator of third party content, we also face risks of periodic tort claims such as defamation
or improper use of publicity rights, as well as infringement claims such as plagiarism. Whether or not they have merit, these
claims may be time-consuming or costly to resolve.
The
misappropriation, release, loss or misuse of consumer or other data could adversely affect our business.
Moviefone
utilizes significant amounts of data about our business and consumers and Moviefone’s advertising and publishing partners
in order to deliver Moviefone’s content, products and services and advertising solutions. Although we take measures to protect
against unauthorized intrusion into such data, the misappropriation, release, loss or misuse of this data, whether by accident,
omission or as the result of criminal activity, sabotage or espionage, hacking, computer viruses, natural disasters, terrorism,
equipment failure or other events, could lead to negative publicity, harm to Moviefone’s reputation, customer dissatisfaction,
regulatory enforcement actions or individual or class-action lawsuits or significant expenditures to recover the data or protect
data from similar releases in the future, and may otherwise adversely affect our business.
Failure
to comply with federal, state or international privacy laws or regulations, or the expansion of current or the enactment of new
privacy laws or regulations, could adversely affect our business.
A
variety of federal, state and international laws and regulations govern the collection, use, retention, sharing and security of
consumer data. In addition to the potentially differing interpretations of existing law, the present landscape of public policy
and privacy creates uncertainty for business planning. In such an uncertain environment, it is difficult to make informed long-term
business planning decisions about data use, notice, storage, access, retention or choice. The existing privacy-related laws and
regulations as well as industry self-regulatory principles are evolving and subject to potentially differing interpretations.
There is a possibility that these laws may be interpreted in a way that is inconsistent with our practices. In addition, various
federal, state and foreign legislative and regulatory bodies may expand current or enact new laws regarding data protection and
privacy matters. We have posted privacy policies and practices concerning the collection, use and disclosure of user data on our
Moviefone website. Any failure, or perceived failure, by us to comply with Moviefone’s posted privacy policies or with any
data-related consent orders, Federal Trade Commission requirements or orders or other federal, state or international privacy
or consumer protection-related laws, regulations or industry self-regulatory principles could result in claims, proceedings or
actions against us by governmental entities or others or other liabilities, or could result in us having to change Moviefone’s
data collection practices, which could adversely affect our business. In addition, a failure or perceived failure to comply with
industry standards or with Moviefone’s own privacy policies and procedures could result in a loss of consumers or advertisers
and adversely affect our business.
Federal,
state and international governmental authorities continue to evaluate the privacy implications inherent in the use of cookies
and a variety of other data correlation technologies for advertising and measurement. Our data management platform is designed
to be a comprehensive suite of advertising technologies that will deploy tracking and data correlation technologies, the regulation
of which could adversely affect our business.
Risks
Related to this Offering and our Series B Preferred Stock, Common Stock and Warrants
The
proceeds from this offering, along with our cash and cash equivalents, may not be sufficient to fund our operations for the near
future and we may not be able to obtain additional financing.
As of March 21, 2019, we had approximately
$2.8 million in available cash and approximately $13.1 million on deposit with our merchant and fulfillment processors related
to subscription revenues. The funds held by these processors represent a portion of the payments received for annual and other
extended term MoviePass subscription plans and future ticket fulfillment, which we classify as current assets on our balance sheet
and which we expect to be disbursed to us or utilized during 2019. Historically, our monthly cash deficit has been significant,
and our monthly cash deficit will continue to increase in the coming months.
The
anticipated proceeds from this offering, along with our cash and cash equivalents, may not be sufficient to fund our operations
for the near future and we may not be able to obtain additional financing. We will continue to require significant proceeds from
sales of our debt or equity securities, among other sources of capital. However, we no longer have access to funds from the sale
of shares of common stock in an at-the-market offering, and we will need to seek other sources of capital, of which there can
be no assurance. Furthermore, to the extent we use any net proceeds from sales of our securities for acquisitions of other businesses
or financial interests in additional movies (through MoviePass Films), we will need additional capital to offset our monthly cash
deficit to the extent resulting from those further investments.
We will continue to require significant
proceeds from sales of our debt or equity securities, each of which may have a significant dilutive effect on our stockholders.
If we are unable to obtain sufficient amounts of additional capital, we may be required to reduce the scope of our planned growth
or otherwise further alter our business model, objectives and operations, which could harm our business, financial condition and
operating results.
Our
common stock was delisted from the Nasdaq Capital Market, which could make trading in our common stock more difficult for investors,
potentially leading to declines in our share price and liquidity and could limit our ability to raise additional capital.
Effective
at the open of business on February 13, 2019, our common stock was suspended and delisted from the Nasdaq Capital Market and began
trading on the OTC Pink Market operated by OTC Markets Group Inc. The delisting was the result of our non-compliance with Nasdaq
Listing Rule 5550(a)(2), which requires that we maintain a minimum closing bid price of $1.00 per share for continued listing
on the Nasdaq Capital Market.
Our
delisting from the Nasdaq Capital Market could make trading in our common stock more difficult for investors, potentially leading
to declines in our share price and liquidity. Without the Nasdaq Capital Market listing, stockholders may have a difficult time
getting a quote for the sale or purchase of our stock, the sale or purchase of our stock will likely be made more difficult and
the trading volume and liquidity of our stock could decline. Our delisting from the Nasdaq Capital Market could also result in
additional negative publicity and could also make it more difficult for us to raise additional capital. The absence of such a
listing may adversely impact the acceptance of our common stock as currency or the value accorded by other parties. Further, following
our delisting, we will also incur additional costs under state blue sky laws in connection with any sales of our securities. These
requirements could severely limit the market liquidity of our common stock and the ability of our stockholders to sell our common
stock in the secondary market.
Now
that our common stock is traded on an over-the-counter quotation system, an investor may find it more difficult to sell our stock
or obtain accurate quotations as to the market value of our common stock.
We
have identified material weaknesses in our internal control over financial reporting, which resulted in the need to restate our
consolidated financial statements. If we do not remediate the material weaknesses in our internal control over financial reporting,
we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may cause
investors to lose confidence in our reported financial information and may lead to a decline in the market price of our common
stock.
Effective
internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. Section
404 of the Sarbanes-Oxley Act of 2002 requires us to include in our annual reports on Form 10-K an assessment by management of
the effectiveness of our internal control over financial reporting. Our management assessed our internal control over financial
reporting as of December 31, 2017. Based on such assessment, we concluded that our internal control over financial reporting was
not effective as of December 31, 2017 to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.
A material weakness is a significant deficiency, or a combination of significant deficiencies, in internal control over financial
reporting such that it is reasonably possible that a material misstatement of the annual or interim financial statements will
not be prevented or detected on a timely basis. The material weakness we have identified is as follows:
|
●
|
Due
to the significant number of transactions that occurred during the fourth quarter of 2017 including, but not limited to, the
acquisition of MoviePass and the related financing arrangements, it was determined that we had inadequate monitoring controls
in place related to our financial reporting, debt and equity related transactions and other management oversight procedures
due to the lack of sufficient accounting resources to complete an effective review of the various complex and significant
transactions.
|
On
March 11, 2019, our board of directors and the audit committee of our board of directors, following discussions with management,
determined that our previously issued quarterly and year-to-date unaudited consolidated financial statements for September 30,
2018 should no longer be relied upon. In addition, we determined that related press releases, earnings releases, and investor
communications describing our financial statements for these periods should no longer be relied upon. The errors primarily relate
to the overstatement of subscription revenues in the third quarter of 2018 due to (1) the erroneous recognition of approximately
$0.7 million of revenue from MoviePass subscriptions that had been terminated through refunds of subscriptions by Costco Wholesale
Corporation; and (2) the erroneous recognition of approximately $5.9 million of revenue from certain MoviePass subscriptions that
were in a suspended state due to changes made to the MoviePass subscription service that had not yet been consented to by the
applicable subscribers. In addition, we identified a non-cash error related to the accounting for derivative liabilities, which
resulted in an additional understatement of net loss of approximately $2.9 million. We also identified the erroneous omission
of a $1.6 million investment in the film
Axis Sally
, offset by a $1.6 million note payable, as well as the related party
disclosures associated with the production of the film
Axis Sally
. Accordingly, we restated the quarterly and year-to-date
unaudited consolidated financial statements for September 30, 2018. We completed the restatement by filing an amendment to the
Quarterly Report on Form 10-Q for the period ended September 30, 2018 with the SEC on March 29, 2019.
We
determined that the aggregate impact of these errors on consolidated total revenues, loss from operations, net loss and loss per
share, calculated in accordance with accounting principles generally accepted in the U.S., to be as follows:
|
●
|
A
decrease in revenues for the three-month period and nine-month period ended September
30, 2018, of $6,637,226;
|
|
●
|
An
increase in loss from operations for the three-month period and nine-month period ended
September 30, 2018, of $6,637,226;
|
|
●
|
An
increase in net loss for the three-month period and nine-month period ended September
30, 2018, of $9,464,036; and
|
|
●
|
An
increase in the basic and diluted loss per share for the three-month period and nine-month
period ended September 30, 2018, of $0.02 per share and $0.04 per share, respectively.
|
In
connection with the restatement, management also determined that a material weakness relating to subscription management existed
in our internal control over financial reporting as of September 30, 2018 and through December 31, 2018. Our chief executive officer
and chief financial officer have concluded that our disclosure controls and procedures were not effective at the reasonable assurance
level as of September 30, 2018 and December 31, 2018, and our management has concluded that our internal control over financial
reporting was not effective as of December 31, 2018. Effective January 1, 2019, we have implemented a new software solution to
automate and provide real-time information for managing and accounting for subscriptions.
Although
we plan to complete the remediation processes for these material weaknesses and associated evaluations and testing as quickly
as possible, we may not be able to do so and our initiatives may prove not to be successful. Our remediation efforts may not remediate
our material weaknesses in a timely manner, or at all, or prevent restatements of our financial statements in the future. If we
are unable to successfully remediate our material weaknesses, or identify any future significant deficiencies or material weaknesses,
the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities
law requirements regarding timely filing of periodic reports, and the market price of our common stock may decline as a result.
We also could become subject to investigations by the SEC or other regulatory authorities.
Our
disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Our internal control over financial
reporting may not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can
provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of the inherent
limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or
fraud will not occur or that all control issues and instances of fraud will be detected. If we are not able to comply with the
requirements of Section 404 in a timely manner, if we do not remedy the current material weaknesses identified above or if we
identify additional material weaknesses in our internal controls, investors could lose confidence in the reliability of our financial
statements, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC or other
regulatory authorities.
The
restatement of certain of our financial statements may subject us to additional risks and uncertainties, including the increased
possibility of legal proceedings.
As a result of the restatement of our
previously issued quarterly and year-to-date unaudited consolidated financial statements for September 30, 2018, we may become
subject to additional risks and uncertainties, including, among others, the increased possibility of legal proceedings or a review
by the SEC and other regulatory bodies, which could cause investors to lose confidence in our reported financial information and
could subject us to civil or criminal penalties, shareholder class actions or derivative actions. We could face monetary judgments,
penalties or other sanctions that could have a material adverse effect on our business, financial condition and results of operations
and could cause our stock price to decline.
We
do not believe that we will be able to file our Form 10-K for the year ended December 31, 2018 with the SEC when it is due, and
as a result, at such time we will be delinquent in our SEC reports, which could limit the liquidity of our common stock.
Because the market value of our common
stock held by non-affiliates exceeded $75 million, as of the last trading day of our fiscal quarter ended June 30, 2018, we are
subject to the requirement to include in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, the auditor’s
attestation report on its assessment of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley
Act. Because the market value of our common stock held by non-affiliates was less than $250 million, we will continue to be a
“smaller reporting company” as defined by the SEC’s revised rules.
We
do not believe that we will be able to file our Form 10-K for the year ended December 31, 2018 with the SEC when it is due because
we require additional time to provide our auditor with the information and documentation regarding our assessment of our internal
control over financial reporting to enable our auditor to provide the required attestation report. If we are unable to obtain
the auditor attestation by the due date of our Form 10-K for the year ended December 31, 2018, our Form 10-K will be considered
delinquent and not timely filed, which could limit the liquidity of our common stock. The inability of our auditor to timely provide
its attestation could result in lost investor confidence in the accuracy, reliability, and completeness of our financial reports.
We
expect that our compliance with this increased reporting requirement will require management to expend additional time while also
condensing the time frame available to comply with certain requirements, which may further increase our legal and financial compliance
costs.
The sale of a substantial amount of our common stock
in the market and the issuance of shares reserved for issuance to consultants and upon conversion of convertible instruments,
including the shares issuable upon conversion of the Series B Preferred Stock (including the Warrant Preferred Shares), could
adversely affect the prevailing market price of our common stock.
As of March 20, 2019, we had 2,001,541,260
shares of common stock issued and outstanding and the closing sale price of our common stock on March 22, 2019 was $0.012.
We
may engage in transactions to issue convertible debt and warrants to purchase common stock, as we have in the past, which transactions
may include registration rights. The registration of such additional securities and the potential for high volume trades of our
common stock in connection with these financings may have a downward effect on our market price. Future issuance of our common
stock upon exercise of these warrants may have a further negative impact on our stock price.
Further, as of March 20, 2019, we have
reserved for issuance, but not yet issued, a substantial amount of additional shares that are included in “Summary––The
Offering––Common stock outstanding after the offering.” In connection with this offering, we will enter into
amendments with holders of certain of our outstanding warrants to purchase an aggregate of 666,666,668 shares of common stock,
to reduce the exercise price of each such warrants from $0.0163 to $0.01 per share of common stock. The issuance of shares we
are obligated to issue, which may increase dilution of existing investors and further depress the market price of our common stock,
which may negatively affect our stockholders’ equity and our ability to raise capital on terms acceptable to us in the future.
The
price of our common stock has been volatile, and the market price of our common stock may decrease.
The
per share price of our common stock has been volatile. Since July 25, 2018, the day after we effected the Reverse Stock Split,
the per share closing price of our common stock has been as low as $0.0069 on February 20, 2019, and as high as $10.60 on July
25, 2018. The factors that may cause the market price of our common stock to fluctuate include, but are not limited to:
|
●
|
our
ability to derive financial benefits from our ownership stake in MoviePass, MoviePass Films, and our ownership of the Moviefone
assets;
|
|
●
|
the
ability of MoviePass to become cash flow positive or profitable;
|
|
●
|
the
ability of MoviePass Films to enter into economic arrangements with film distributors and derive economic benefits from such
arrangements;
|
|
●
|
fluctuations
in our quarterly or annual earnings results or those of other companies in our industry;
|
|
●
|
actual
or anticipated fluctuations in our operating results due to factors related to our business;
|
|
●
|
success
or failure of our business strategy;
|
|
●
|
failures
of our operating results to meet the estimates of securities analysts or the expectations of our stockholders, or changes
by securities analysts in their estimates of our future earnings;
|
|
●
|
announcements
by us or our suppliers or competitors;
|
|
●
|
changes
in laws or regulations which adversely affect our industry or us;
|
|
●
|
changes
in accounting standards, policies, guidance, interpretations or principles;
|
|
●
|
our
ability to obtain financing as needed;
|
|
●
|
the
operating and stock price performance of other comparable companies;
|
|
●
|
our
ability to recruit and retain qualified personnel;
|
|
●
|
changes
in the perception of investors and securities analysts regarding the risks to our business or the condition of our business;
|
|
●
|
changes
in our relationships with key clients;
|
|
●
|
changes
in the market valuation or earnings of our competitors or companies viewed as similar to us;
|
|
●
|
changes
in key personnel;
|
|
●
|
changes
in our capital structure, such as future issuances of securities or the incurrence of debt;
|
|
●
|
the
granting or exercise of employee stock options or other equity awards;
|
|
●
|
general
market and economic conditions; and
|
|
●
|
the
other factors described in these “Risk Factors” and other parts of this prospectus.
|
In
addition, the equity markets have experienced significant price and volume fluctuations that have affected the market prices for
the securities of technology companies for a number of reasons, including reasons that may be unrelated to our business or operating
performance. These broad market fluctuations may result in a material decline in the market price of our common stock and you
may not be able to sell your shares at prices you deem acceptable. In the past, following periods of volatility in the equity
markets, securities class action lawsuits have been instituted against public companies. Such litigation, if instituted against
us, could result in substantial cost and the diversion of management attention. In addition, our common stock is quoted on the
OTC Pink Market operated by OTC Markets Group Inc., which may increase price quotation volatility and could limit liquidity, all
of which may adversely affect the market price of our shares.
There
is not now, and there may not ever be, an active market for shares of our common stock, which trades in the over-the-counter market.
We
do not now meet the initial listing standards of the Nasdaq Capital Market or any other national securities exchange. We presently
anticipate that our common stock will continue to be quoted on the OTC Pink Market operated by OTC Markets Group Inc. or another
over-the-counter quotation system. In those venues, our stockholders may find it difficult to obtain accurate quotations as to
the market value of their shares of our common stock, and may find few buyers to purchase their stock and few market makers to
support its price. As a result, investors must bear the economic risk of holding their shares of our common stock for an indefinite
period of time.
“Penny
stock” rules may make buying or selling our common stock difficult.
Following
the delisting of our common stock, our common stock now falls within the definition of a “penny stock” as defined
in the Exchange Act. The SEC has adopted regulations that generally define a penny stock to be any equity security that has a
market price of less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. These
rules require that any broker-dealer who recommends our securities to persons other than prior customers and accredited investors,
must, prior to the sale, make a special written suitability determination for the purchaser and receive the purchaser’s
written agreement to execute the transaction. Unless an exception is available, the regulations require the delivery, prior to
any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the risks associated with
trading in the penny stock market. In addition, broker-dealers must disclose commissions payable to both the broker-dealer and
the registered representative and current quotations for the securities they offer. The additional burdens imposed upon broker-dealers
by such requirements may discourage broker-dealers from effecting transactions in our securities, which could severely limit the
market price and liquidity of our securities.
Financial
Industry Regulatory Authority (“FINRA”) sales practice requirements may limit a stockholder’s ability to buy
and sell our stock.
In
addition to the “penny stock” rules described above, FINRA has adopted rules that require that, in recommending an
investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that
customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make
reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other
information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative
low-priced securities will not be suitable for at least some customers. These FINRA requirements make it more difficult for broker-dealers
to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy
and sell our common stock and could have an adverse effect on the market for our shares.
If
you purchase securities in this offering, assuming conversion of the Series B Preferred Stock into shares of our common stock,
you will incur immediate and substantial dilution in your investment.
Because
the effective price per share of our Series B Preferred Stock being offered will be higher than the book value per share of our
common stock, you will suffer substantial dilution in the net tangible book value between the offering price per share of the
Series B Preferred Stock you purchase in this offering and the net tangible book value per share of our common stock after this
offering, assuming conversion of the Series B Preferred Stock into shares of our common stock. In the event Series F Warrants
are exercised by holders into Warrant Preferred Shares, which are subsequently converted into shares of our common stock, you
will experience additional dilution to the extent that the conversion price of such Warrant Preferred Shares is higher than the
book value per share of our common stock. See the section titled “Dilution” below for a more detailed discussion of
the dilution you will incur if you purchase Series B Preferred Stock in this offering.
The
Series F Warrants may never have any value.
The Series F-1 Warrants in this
offering have an exercise price of $100.00 per share of Series B Preferred Stock and will be exercisable at any time on or
after the issuance date until the five-year anniversary of such initial exercise date. The Series F-2 Warrants in this
offering have an exercise price of $100.00 per share of Series B Preferred Stock and will be exercisable at any time on or
after the date on which we obtain stockholder approval for a reverse stock split or to increase our authorized common stock
to allow for the reservation in full of all shares of common stock issuable upon conversion of the Warrant Preferred Shares
issuable upon exercise of the Series F-2 Warrants until the five-year anniversary of such initial exercise date.
In the event the price per share of our common
stock does not exceed the per share conversion price of the Warrant Preferred Shares during the period when the Series F Warrants
are exercisable, the Series F Warrants will not have any value. Additionally, a holder of Series F Warrants who exercises Series
F Warrants into Warrant Preferred Shares will be prohibited from converting such Warrant Preferred Shares into shares of our common
stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of
the total number of shares of our common stock then issued and outstanding after giving effect to such conversion. Upon at least
61 days’ prior notice, a holder of Warrant Preferred Shares may increase or decrease the holder’s amount of ownership
of outstanding shares of common stock after converting the holder’s Warrant Preferred Shares to up to 9.99% of the number
of shares of our common stock outstanding immediately after giving effect to such conversion, as such percentage ownership is
determined in accordance with the terms of the Certificate of Designation of Series B Preferred Stock (the “Certificate
of Designation”). Further, if we do not obtain stockholder approval of a reverse stock split or an increase in our authorized
common stock, the Series F-2 Warrants will not be exercisable. There is no assurance that we will be able to obtain such stockholder
approval.
There
is no public market for the Series B Preferred Stock or the Series F Warrants being offered in this offering.
There
is no public trading market for the Series B Preferred Stock or the Series F Warrants being offered in this offering, and we do
not expect a market to develop. In addition, we do not intend to apply to list the Series B Preferred Stock or the Series F Warrants
or the underlying shares of our common stock on any national securities exchange or other nationally recognized trading system.
Without an active market, the liquidity of the Series B Preferred Stock or the Series F Warrants will be limited, and you may
not be able to resell your shares of Series B Preferred Stock or the Series F Warrants. If your shares of Series B Preferred Stock
or the Series F Warrants cannot be resold, you will have to depend upon any appreciation in the value of our common stock over
the conversion price of the Series B Preferred Stock in order to realize a return on your investment in the shares of Series B
Preferred Stock or the Series F Warrants.
We
do not plan to pay cash dividends in the foreseeable future.
We
currently intend to retain all future earnings for use in the operation and expansion of our business and do not intend to pay
any cash dividends in the foreseeable future. Unless we pay dividends, our stockholders will not be able to receive a return on
their shares unless they sell them. There is no assurance that stockholders will be able to sell shares when desired.
Except
as otherwise provided in the Series F Warrants, holders of our Series F Warrants will not have the rights or privileges of a holder
of our common stock or holder of Series B Preferred Stock, including any voting rights, until such holders exercise their Series
F Warrants for Warrant Preferred Shares or convert such Warrant Preferred Shares and acquire our common stock, as applicable.
Except as otherwise provided in the
Series F Warrants, holders of shares of our Series F Warrants will not have the rights or privileges of a holder of our common
stock or holder of Series B Preferred Stock, including any voting rights, until such holders exercise their Series F Warrants
for Warrant Preferred Shares or convert such Warrant Preferred Shares and acquire our common stock, as applicable. As a result,
absent exercise of the Series F Warrants for Warrant Preferred Shares or a conversion of such Warrant Preferred Shares into shares
of our common stock, holders of shares of our Series F Warrants will not have the ability to vote their shares underlying their
Series F Warrants, which may limit the influence that investors in our offering may have over the outcome of matters submitted
to our stockholders for a vote.
Because
our management will have broad discretion and flexibility in how the net proceeds from this offering are used, we may use the
net proceeds in ways in which you disagree.
We
currently intend to use the net proceeds from this offering for general corporate purposes of the Company and its subsidiaries;
to satisfy $870,000 of the amounts payable in connection with the senior non-convertible notes issued by the Company on October
4, 2018 and December 18, 2018; and for transaction expenses including placement agent fees. We have not allocated specific amounts
of the net proceeds from this offering for any of the foregoing purposes other than the payment of a portion of the senior non-convertible
notes and transaction expenses. Accordingly, our management will have significant discretion and flexibility in applying the net
proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds,
and you will not have the opportunity, as part of your investment decision, to assess whether the net proceeds are being used
appropriately. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return
for us. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial
condition, operating results and cash flow.
This
offering is being conducted on a “best efforts” basis.
We
have retained H.C. Wainwright & Co., LLC as our exclusive placement agent in connection with the securities offered by this
prospectus supplement and the accompanying prospectus. The placement agent has agreed to use its reasonable best efforts to solicit
offers to purchase the securities offered by this prospectus supplement and the accompanying prospectus. The placement agent has
no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount
of the securities. As a “best efforts” offering, there can be no assurance that the offering contemplated hereby will
ultimately be consummated.
The
conditions to the completion of the creation of MoviePass Entertainment Holdings Inc. , or “MoviePass Entertainment,”
and the distribution of shares of MoviePass Entertainment to our security holders may not be satisfied, and we may not have the
required surplus or cash flow solvency under Delaware law to effect a distribution of shares of MoviePass Entertainment to our
security holders.
On
October 23, 2018, we issued a press release announcing that our board of directors preliminarily approved a plan to create a new
subsidiary named MoviePass Entertainment Holdings Inc. that would take ownership of the shares of MoviePass and other film related
assets held by the Company, including our equity interests in MoviePass Films and MoviePass Ventures and the Moviefone brand and
related assets. If permitted under Delaware law and subject to other conditions, we plan to distribute a minority of the outstanding
shares of MoviePass Entertainment common stock as a dividend to holders of common stock and certain warrants of the Company as
of a record date that is yet to be determined, with the Company retaining control of MoviePass Entertainment upon any such distribution,
which we refer to as the “Spin-Off Transaction.” Following the Spin-Off Transaction, MoviePass Entertainment would
become a separate publicly traded company.
The
Spin-Off Transaction is subject to numerous conditions, including MoviePass Entertainment completing the necessary audited financial
statements and having a registration statement on Form S-1 declared effective by the Securities and Exchange Commission, and the
approved listing of MoviePass Entertainment’s common stock on Nasdaq or an alternative trading market.
Additionally,
we may not have the required surplus or cash flow solvency under Delaware law to effect the Spin-Off Transaction. No assurance
can be given that the Spin-Off Transaction will occur, or if it occurs that it will occur on the terms described in this prospectus
supplement. In addition to the conditions to the Spin-Off Transaction described herein (certain of which may be waived by our
board of directors in its sole discretion), our board of directors may abandon the Spin-Off Transaction at any time prior to the
distribution date for any reason or for no reason.
We
may not realize the potential benefits from the Spin-Off Transaction in the near term or at all.
We
believe that the Spin-Off Transaction will better position MoviePass Entertainment and us to take advantage of certain business
opportunities and financing strategies that more closely align to MoviePass Entertainment’s and our business goals. However,
no assurance can be given that any investment or other strategic opportunities will become available to us or MoviePass Entertainment
following the Spin-Off Transaction on terms that we or MoviePass Entertainment find favorable or at all. Given the added costs
associated with the completion of the Spin-Off Transaction, including the separate accounting, legal and other compliance costs
of MoviePass Entertainment being a separate public company, we and MoviePass Entertainment may fail to realize the anticipated
benefits of the Spin-Off Transaction in the near term or at all, which could have a material adverse effect on our business, financial
condition, operating results and cash flow, and our results of operations.
USE
OF PROCEEDS
We
estimate the net proceeds we will receive from this offering, after deducting the placement agent fees and estimated offering
expenses payable by us, will be approximately $4.135 million. This amount does not include the proceeds that we may receive in
connection with any exercise of the Series F Warrants or the Placement Agent Warrants issued in this offering.
We will use approximately $0.87 million
of the net proceeds from the sale of the Series B Preferred Stock and the Series F Warrants offered by us under this prospectus
supplement to redeem a portion of our outstanding non-convertible senior notes that we issued on October 4, 2018 and December
18, 2018, or the “Senior Notes,” and the remaining proceeds for general corporate purposes of the Company and our
subsidiaries and transaction expenses. As of March 21, 2019, the Senior Notes have an aggregate principal amount of $30.2 million
(including capitalized interest of $0.16 million), subject to 50% reduction for a total of approximately $14.4 million if repaid
within nine months, and bear interest at 3% per annum, capitalized quarterly. Unless earlier redeemed, the Senior Notes will mature
on May 29, 2020.
In
order to fund our operations for the foreseeable future, we will require additional capital exceeding our cash on hand even after
giving effect to the net proceeds from this offering. In addition, actual costs and expenditures may exceed management’s
current expectations. It is unlikely that we will generate sufficient operating cash flow to meet our business objectives. Accordingly,
we will need to raise additional capital in the future over and above the net proceeds from this offering.
The
amounts and timing of our actual expenditures will depend on numerous factors, including the factors described under “Risk
Factors” in this prospectus supplement, the accompanying prospectus and in the documents incorporated by reference herein,
as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for other
purposes, and our management will have significant flexibility in applying the net proceeds of this offering. Until the funds
are used as described above, we intend to invest the net proceeds from this offering in short-term, interest-bearing instruments
or other investment-grade securities.
CAPITALIZATION
The
following table sets forth our capitalization as of September 30, 2018:
|
●
|
on an actual basis; and
|
|
●
|
on a pro forma basis to give effect to our receipt of net proceeds of approximately $3.4 million from the sale of Common Units in the January 2019 Offering after deducting the placement agent fees and offering expenses payable by us and the mandatory redemption of $1.2 million of Senior Notes; and
|
|
●
|
on a pro forma as adjusted basis to give
effect to our receipt of net proceeds of approximately $4.135 million from the sale of our Series B Preferred Stock and
Series F Warrants that we are offering after deducting the placement agent fees and estimated offering expenses payable by
us and the mandatory redemption of $870,000 of Senior Notes.
|
This
capitalization table should be read in conjunction with management’s discussion and analysis of results of operations and
our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December
31, 2017 and Amendment No. 1 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018.
|
|
As of September 30, 2018
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
Actual
(as restated)
|
|
|
Pro
forma (1)
|
|
|
Pro forma as adjusted
for this
offering(1)(2)
|
|
Cash
and cash equivalents
|
|
$
|
4,851,972
|
|
|
$
|
8,223,889
|
|
|
$
|
12,358,889
|
|
Preferred stock, $0.01 par value;
2,000,000 shares authorized; 20,500 shares issued and outstanding actual, and 80,500 shares
issued and outstanding, as adjusted, as of September 30, 2018
|
|
|
205
|
|
|
|
205
|
|
|
|
6,000,205
|
|
Common stock,
$0.01 par value; 5,000,000,000 shares authorized; 1,357,590,536 issued and outstanding actual, and 1,690,923,870 issued and
outstanding, as adjusted, as of September 30, 2018
|
|
$
|
13,575,906
|
|
|
$
|
16,909,239
|
|
|
$
|
16,909,239
|
|
Additional
paid-in-capital
|
|
|
464,197,744
|
|
|
|
465,418,077
|
|
|
|
464,423,077
|
|
Accumulated
deficit
|
|
|
(386,186,649
|
)
|
|
|
(389,186,649
|
)
|
|
|
(386,186,649
|
)
|
Accumulated
other comprehensive loss – foreign currency translation
|
|
|
(156,399
|
)
|
|
|
(156,399
|
)
|
|
|
(156,339
|
)
|
Non-controlling
interest
|
|
|
(25,984,783
|
)
|
|
|
(25,984,783
|
)
|
|
|
(25,984,783
|
)
|
Total
stockholders’ equity
|
|
$
|
65,446,024
|
|
|
$
|
69,999,690
|
|
|
$
|
75,004,690
|
|
|
(1)
|
Cash
does not include the effects of results of operations from October 1, 2018 through the
date of this offering.
|
(2)
|
Cash reflects the
net proceeds from this offering, after deducting the mandatory redemption of $870,000 of Senior Notes,
but does not include any proceeds from the exercise of the Series F Warrants or the Placement Agent Warrants.
|
The
total number of shares of common stock and shares of preferred stock to be outstanding immediately after this offering assumes
no conversion of the shares of Series B Preferred Stock (or any Warrant Preferred Shares) and no exercise of the Series F Warrants
or the Placement Agent Warrants issued in this offering, and is based on 1,357,590,536 shares of common stock issued and outstanding
as of September 30, 2018, but does not include the following:
|
●
|
10,440
shares of common stock available and reserved for issuance pursuant to the Helios and Matheson Analytics Inc. 2014 Equity
Incentive Plan;
|
|
●
|
29,364
shares of common stock that may be issued upon the exercise of warrants by Palladium Capital Advisors LLC;
|
|
●
|
18,545
shares of common stock reserved for issuance to various officers, directors, employees and consultants;
|
|
●
|
16,000
shares of common stock issuable to MoviePass upon receipt of stockholder approval and unrestricted conversion of the convertible
promissory note in the principal amount of $12 million that we issued to MoviePass upon the closing of the Securities Purchase
Agreement, dated August 15, 2017, between the Company and MoviePass;
|
|
●
|
50,886
shares of common stock issuable upon the exercise of warrants issued in public offerings in December 2017, February 2018 and
April 2018;
|
|
●
|
10,201
shares of common stock issuable upon the exercise of warrants, issued to Oath Inc. upon the closing of the acquisition of
the Moviefone assets;
|
|
●
|
2,000 shares of common
stock reserved for issuance to Helios and Matheson Information Technology Ltd. in exchange
for entering into prior lockup agreements and a new 12-month lockup agreement; and
|
|
●
|
1,026,666,669
shares of common stock issuable upon the exercise of the warrants and placement agent
warrants issued in the January 2019 Offering. In connection with this offering, the exercise
price of warrants to purchase 666,666,668 shares of common stock issued to institutional
investors in the January 2019 Offering will be reduced from $0.0163 to $0.01 per share
of common stock.
|
DILUTION
If
you invest in our securities in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the offering price per share of our Series B Preferred Stock and accompanying Series F Warrants and the pro forma net
tangible book value per share of our common stock after this offering. For the purpose of this calculation, the entire purchase
price for the shares of Series B Preferred Stock and accompanying Series F Warrants is being allocated to the shares of Series
B Preferred Stock, and no Warrant Preferred Shares have been included. We calculate net tangible book value per share by dividing
our net tangible book value, which is tangible assets less total liabilities, by the number of outstanding shares of our common
stock.
Our net tangible book value (deficit)
as of September 30, 2018 was approximately $(13.8) million, or $(0.0102) per share. After giving effect to the sale by us of 333,333,334
Common Units in the January 2019 Offering at the offering price of $0.0163 per Common Unit, and after deducting the placement
agent fees and offering expenses payable by us and the mandatory redemption of $1.2 million of Senior Notes, our pro forma net
tangible book value (deficit) as of September 30, 2018, would have been approximately $(9.2) million, or $(0.0055) per share.
After giving effect to the sale by us of 60,000 shares of Series B Preferred Stock at the offering price
of $100.00 per share of Series B Preferred Stock, and attributing no value to the accompanying Series F Warrants (or any Warrant Preferred Shares), assuming
the conversion of 60,000 shares of our Series B Preferred Stock into 1,000,020,000 shares of our common stock, and after deducting
the placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of
the Series F Warrants and the Placement Agent Warrants issued pursuant to this offering, our pro forma as adjusted net tangible
book value (deficit) as of September 30, 2018 would have been approximately $(4.2) million,
or $(0.0016) per share. This represents an immediate increase in as adjusted net
tangible book value of $0.0039 per share to existing stockholders and an immediate dilution
of $0.0076 per share to new investors purchasing securities in this offering. The following
table illustrates the per share dilution to new investors purchasing securities in this offering:
Conversion
rate per share of common stock into which the shares of Series B Preferred Stock being offered in this offering are convertible
($100/16,667)
|
|
|
|
|
|
|
0.006
|
|
Historical
net tangible book value (deficit) per share as of September 30, 2018
|
|
$
|
(0.0102
|
)
|
|
|
|
|
Increase
in pro forma net tangible book value per share after the January 2019 Offering
|
|
|
0.0047
|
|
|
|
|
|
Pro
forma net tangible book value (deficit) per share as of September 30, 2018 after the January 2019 Offering
|
|
|
(0.0055
|
)
|
|
|
|
|
Increase
in pro forma as adjusted net tangible book value per share after this offering
|
|
$
|
0.0039
|
|
|
|
|
|
As
adjusted pro forma net tangible book value (deficit) per share as of September 30, 2018, after giving effect to this offering
|
|
|
|
|
|
$
|
(0.0016
|
)
|
Dilution
per share to new investors
|
|
|
|
|
|
$
|
0.0076
|
|
The
foregoing table does not take into account further dilution to new investors that could occur upon the exercise of outstanding
options, restricted stock units and warrants having a per share exercise price less than the per share offering price in this
offering.
For purposes of calculating pro forma net tangible book value, the above table is based on 1,357,590,536
shares of our common stock issued and outstanding as of September 30, 2018, and does not include the shares issued or issuable
as disclosed above under “Capitalization”, except for those shares of our common stock issuable upon conversion of
the Series B Preferred Stock purchased in this offering (but, for avoidance of doubt, excluding any Warrant Preferred Shares).
DESCRIPTION
OF THE SECURITIES WE ARE OFFERING
We are offering on a “best-efforts”
basis 60,000 shares of our Series B Preferred Stock, together with Series F-1 Warrants to purchase an aggregate of 59,760
shares of our Series B Preferred Stock and Series F-2 Warrants to purchase an aggregate of 60,240 shares of our Series B
Preferred Stock, at a combined offering purchase price of $100.00 per fixed combination of (i) one share of Series B Preferred
Stock, (ii) one Series F-1 Warrant to purchase 0.996 shares of our Series B Preferred Stock, (iii) one Series F-2 Warrant to purchase
1.004 shares of our Series B Preferred Stock. Each share of Series B Preferred Stock and accompanying Series F-1 Warrant and Series
F-2 Warrant will be issued separately and will be immediately separable upon issuance. Pursuant to this prospectus supplement
and the accompanying prospectus, we will also issue the Placement Agent Warrants described below, as part of the compensation
payable to the placement agent in connection with this offering. This prospectus supplement also includes the offering of the
shares of common stock issuable upon conversion of the Series B Preferred Stock (including upon conversion of the Warrant Preferred
Shares).
Common Stock and Series A Preferred Stock
The material terms and provisions of
our common stock are described under the caption “Description of the Securities that may be Offered––Description
of Common Stock” beginning on page 2 of the accompanying prospectus, subject to the following modification. We have 5,002,000,000
shares of capital stock authorized under our certificate of incorporation, consisting of 5,000,000,000 shares of common stock,
$0.01 par value, and 2,000,000 shares of preferred stock, $0.01 par value. We have 20,500 shares of Series A Preferred Stock outstanding.
Each share of Series A Preferred Stock is entitled to 3,205 votes per share on all matters on which holders of common stock are
entitled to vote. However, the number of votes with respect to the Series A Preferred Stock held by any holder, when aggregated
with any other voting securities of our company held by such holder, cannot exceed 19.9% of our outstanding voting power calculated
as of June 21, 2018 (or such greater percentage allowed by Nasdaq without any stockholder approval requirements).
Series B Preferred Stock
The following is a brief summary of certain
terms and conditions of the Series B Preferred Stock (including the Warrant Preferred Shares) we are offering and is qualified
in its entirety by reference to the provisions of the Certificate of Designation and a securities purchase agreement to be entered
into between us and purchasers of shares our Series B Preferred Stock and Series F Warrants in this offering, the forms of which
are filed as exhibits to the registration statement of which this prospectus forms a part.
General
. Our certificate of incorporation
authorizes our board of directors to issue up to 2,000,000 shares of our preferred stock, par value $0.01 per share. Subject to
the limitations prescribed by our certificate of incorporation, our board of directors is authorized to establish the number of
shares constituting each series of preferred stock and to fix the designations, powers, preferences and rights of the shares of
each of those series and the qualifications, limitations and restrictions of each of those series, all without any further vote
or action by our stockholders. Our board of directors has designated 200,000 of the 2,000,000 authorized shares of preferred stock
as Series B Preferred Stock. When issued, the shares of Series B Preferred Stock will be validly issued, fully paid and non-assessable.
Rank and Liquidation Preference
.
Subject to the applicable law and the rights of the holders of any outstanding series of our preferred stock, our Series B Preferred
Stock will rank pari passu on an as-converted to common stock basis with all of our common stock as to distributions of assets
upon our liquidation, dissolution or winding up.
Conversion
. Each share
of our Series B Preferred Stock is convertible into such number of shares of our common stock equal to the Conversion Rate; provided,
that the holder will be prohibited from converting Series B Preferred Stock into shares of our common stock if, as a result of
such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares
of our common stock then issued and outstanding after giving effect to such conversion. However, upon at least 61 days’
prior notice from the holder to us, the holder may increase or decrease the holder’s amount of ownership of outstanding
shares of common stock after converting the holder’s Series B Preferred Stock to up to 9.99% of the number of shares of
our common stock outstanding immediately after giving effect to such conversion, as such percentage ownership is determined in
accordance with the terms of the Certificate of Designation.
Conversion Rate
. The Conversion
Rate for the Series B Preferred Stock is 16,667. The Conversion Rate is subject to appropriate adjustment in the event of stock
dividends, stock splits, reorganizations or similar events affecting our common stock and the Conversion Rate.
Voting Rights
. Shares of our Series
B Preferred Stock will be entitled to vote on an as-converted to common stock basis on all matters on which stockholders are generally
entitled to vote (provided that no holder of Series B Preferred Stock will be entitled to such number of votes in excess of such
holder’s beneficial ownership limitation as set forth in the Certificate of Designation). Additionally, the vote or written
consent of holders of a majority of the outstanding shares of our Series B Preferred Stock, voting separately as a single class,
will be required to:
|
●
|
amend, alter or repeal any provision of our certificate of incorporation
if such amendment, alteration or repeal would increase or decrease the aggregate number of authorized shares of the Series B Preferred
Stock;
|
|
●
|
amend, alter or repeal any provision of our certificate of incorporation
if such amendment, alteration or repeal would increase or decrease the par value of the shares of the Series B Preferred Stock;
or
|
|
●
|
amend, alter or repeal any provision of our certificate of incorporation,
whether by merger, consolidation or otherwise, if such amendment, alteration or repeal would alter or change the powers, preferences
or special rights of the holders of shares of Series B Preferred Stock so as to affect them adversely.
|
Dividends
. Subject to the applicable
law and the rights of the holders of any outstanding series of our preferred stock, shares of Series B Preferred Stock will be
entitled to receive dividends equal, on an as-converted to common stock basis, to and in the same form as dividends actually paid
on shares of common stock when, as and if such dividends are paid on shares of common stock.
Rights in Connection with Certain
Fundamental Transactions
. In the event of any merger or consolidation which results in 50% or more of the surviving entity
being held by persons other than persons that, immediately prior to such merger or consolidation, owned 50% or more of our capital
stock, subject to the rights of the holders of any outstanding series of our preferred stock, shares of Series B Preferred Stock
will be entitled to receive consideration from such merger or consolidation equal, on an as-converted to common stock basis, to
and in the same form as consideration actually paid on shares of common stock.
In the event of any sale, lease or exchange
of all or substantially all of our property and assets, subject to the rights of the holders of any outstanding series of our
preferred stock, shares of Series B Preferred Stock will be entitled to receive cash consideration from such sale, lease or exchange
equal, on an as-converted to common stock basis, to the consideration actually paid on shares of common stock.
Repurchase
. Following payment of
the amounts payable to the Series B Preferred Stock in connection with a sale, lease or exchange described above, we may, at our
election, repurchase each outstanding shares of Series B Preferred Stock for a repurchase price of $0.0001 per share.
Exchange Listing
. We do not plan
on making an application to list the Series B Preferred Stock on the Nasdaq Capital Market, any national securities exchange or
other nationally recognized trading system. We expect the common stock issuable upon conversion of the Series B Preferred Stock
will be quoted on the OTC Pink Market operated by OTC Markets Group Inc.
Subsequent Rights Offerings.
Pursuant
to the terms of the securities purchase agreement to be entered into between us and purchasers of shares our Series B Preferred
Stock and Series F Warrants in this offering, if we grant, issue or sell any shares of our common stock, or any securities that
would entitle the holder thereof to acquire shares of our common stock, or rights to purchase stock, warrants, securities or other
property pro rata to the record holders of any class of shares of our common stock (collectively, “Purchase Rights”),
then each holder of Series B Preferred Stock will be entitled to acquire the aggregate number of Purchase Rights that the holder
could have acquired if the holder had held the number of shares of common stock issuable upon conversion of the holder’s
shares of Series B Preferred Stock (without regard to any limitations on conversion thereof, including without limitation, any
beneficial ownership limitations set forth in the Certificate of Designation). However, if the holder’s ownership of the
Purchase Rights would result in the holder exceeding the beneficial ownership limitations set forth in the Certificate of Designation,
then the holder will not be entitled to the Purchase Rights, and the Purchase Rights will be held in abeyance until the Purchase
Right would not result in the holder exceeding the beneficial ownership limitation.
Distributions
. Pursuant to the terms
of the securities purchase agreement to be entered into between us and purchasers of shares our Series B Preferred Stock and Series
F Warrants in this offering, if we declare or make a dividend or other distribution of our assets to holders of shares of our common
stock, then the holders of shares of Series B Preferred Stock will be entitled to participate in the distribution to the same extent
that a holder would have participated therein if the holder had held the number of shares of our common stock that the holder could
have acquired if the holder had held the number of shares of common stock issuable upon conversion of the holder’s shares
of Series B Preferred Stock (without regard to any limitations on conversion thereof, including without limitation, any beneficial
ownership limitations set forth in the Certificate of Designation). However, if the holder’s right to participate in any
distribution would result in the holder exceeding the beneficial ownership limitations set forth in the Certificate of Designation,
then the holder will not be entitled to participate in that portion of the distribution, and that portion of the distribution will
be held in abeyance for the benefit of the holder until its right to the distribution would not result in the holder exceeding
the beneficial ownership limitation.
Rights as a Stockholder.
Except as
otherwise provided in the Certificate of Designation, or by virtue of such holder’s ownership of shares of our common stock,
the holders of shares of Series B Preferred Stock do not have the rights or privileges of holders of shares of our common stock,
until they convert their shares of Series B Preferred Stock.
Amendments
. Certain terms of the
Series B Preferred Stock may be amended or modified with the vote or written consent of the holders of a majority of the then-outstanding
shares of Series B Preferred Stock; see “Description of the Securities We are Offering–– Series B Preferred Stock––Voting.”
Fractional Shares.
No fractional
shares of our common stock will be issued in connection with the conversion of shares of Series B Preferred Stock. In lieu of
fractional shares of our common stock, we will either pay the holder an amount in cash equal to the fractional amount multiplied
by the Conversion Rate or round up to the next whole share.
Warrants
The following is a brief summary of certain
terms and conditions of the Series F Warrants we are offering and the Placement Agent Warrants and is qualified in its in its
entirety by reference to the provisions of the Series F Warrants and the Placement Agent Warrants, as applicable, the forms of
which are filed as exhibits to the registration statement of which this prospectus forms a part.
Series F-1 Warrants
Form.
The Series F-1 Warrants
will be issued as individual warrant agreements issued to purchasers.
Amount.
The purchasers of shares
of Series B Preferred Stock will receive Series F-1 Warrants exercisable into 59,760 shares of Series B Preferred Stock in
the aggregate, or “Warrant Preferred Shares”.
Exercisability.
The Series F-1
Warrants will be exercisable at any time on or after the issuance date until the five-year anniversary of such initial exercise
date. The Series F-1 Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly
executed exercise notice accompanied by payment in full for the number of shares of our Series B Preferred Stock purchased upon
such exercise (except in the case of a cashless exercise as discussed below). As described above, if a holder exercises its Series
F-1 Warrants into Warrant Preferred Shares, each holder will be prohibited from converting such Warrant Preferred Shares into
shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own
more than 9.99% of the total number of shares of our common stock then issued and outstanding after giving effect to such conversion.
However, upon at least 61 days’ prior notice from a holder of Warrant Preferred Shares to us, the holder may increase or
decrease the holder’s amount of ownership of outstanding shares of common stock after converting the holder’s Warrant
Preferred Shares to up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to such
conversion, as such percentage ownership is determined in accordance with the terms of the Certificate of Designation.
Exercise Price.
The exercise price
per whole share of Series B Preferred Stock purchasable upon exercise of the Series F-1 Warrants is $100.00
per share of Series B Preferred Stock. The exercise price and number of Warrant Preferred Shares issuable upon exercise is subject
to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common
stock and the exercise price. In addition, the exercise price of the Series F-1 Warrants will be adjusted as follows:
|
●
|
until the date that we consummate more than $4 million of Dilutive Issuances (as described below), if we issue any shares of common stock, or securities convertible into, or exercisable or exchangeable for shares of common stock, at a price less than the then exercise price divided by the then Conversion Rate (the “Threshold Price”), which issuances we refer to as Dilutive Issuances, then the exercise price of the Series F-1 Warrant will automatically be reduced to an amount equal to the then exercise price multiplied by the quotient obtained by dividing the lower issuance price by the then Threshold Price, provided that the exercise price will not be lower than $0.01 in any event; and
|
|
●
|
if we complete a reverse or forward stock split or reclassification of our common stock, and during the five trading days following such reverse or forward stock split or reclassification, the market price (as calculated pursuant to the terms of the Series F-1 Warrants) is less than the exercise price in effect immediately before the reverse or forward stock split or reclassification divided by the Conversion Rate, the exercise price will automatically be reduced to an amount equal to the then exercise price multiplied by the quotient obtained by dividing the market price (as calculated pursuant to the terms of the Series F-1 Warrants) by the then Threshold Price, provided that the exercise price will not be lower than $0.01 in any event.
|
Cashless Exercise
. If, at the
time a holder exercises its Series F-1 Warrants, a registration statement registering the issuance of Warrant Preferred Shares
under the Securities Act, or a prospectus contained therein, is not then effective or available, then in lieu of making the cash
payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may
elect instead to receive upon such exercise (either in whole or in part) the net number of Warrant Preferred Shares determined
according to a formula set forth in the Series F-1 Warrants.
Transferability.
Subject to applicable
laws, a Series F-1 Warrant may be transferred at the option of the holder upon surrender of the Series F-1 Warrant to us together
with the appropriate instruments of transfer.
Exchange Listing.
We do not plan
on applying to list the Series F-1 Warrants or Warrant Preferred Shares on the Nasdaq Capital Market, any other national securities
exchange or any other nationally recognized trading system.
Subsequent Rights Offerings.
If
we grant, issue or sell any Purchase Rights, then each holder of a Series F-1 Warrant will be entitled to acquire the aggregate
number of Purchase Rights that the holder could have acquired if the holder had held the number of shares of common stock issuable
upon conversion of the Warrant Preferred Shares issuable upon exercise of the holder’s Series F-1 Warrant (without regard
to any limitations on conversion thereof, including without limitation, any beneficial ownership limitations set forth in the
Certificate of Designation). However, if the holder’s ownership of the Purchase Rights would result in the holder exceeding
the beneficial ownership limitations set forth in the Certificate of Designation, then the holder will not be entitled to the
Purchase Rights, and the Purchase Rights will be held in abeyance until the Purchase Right would not result in the holder exceeding
the beneficial ownership limitation.
Distributions
. If we declare or
make a dividend or other distribution of our assets to holders of shares of our common stock, then the holders of Series F-1 Warrants
will be entitled to participate in the distribution to the same extent that a holder would have participated therein if the holder
had held the number of shares of our common stock that the holder could have acquired if the holder had held the number of shares
of common stock issuable upon conversion of the Warrant Preferred Shares issuable upon exercise of the holder’s Series F-1
Warrant (without regard to any limitations on conversion thereof, including without limitation, any beneficial ownership limitations
set forth in the Certificate of Designation). However, if the holder’s right to participate in any distribution would result
in the holder exceeding the beneficial ownership limitations set forth in the Certificate of Designation, then the holder will
not be entitled to participate in that portion of the distribution, and that portion of the distribution will be held in abeyance
for the benefit of the holder until its right to the distribution would not result in the holder exceeding the beneficial ownership
limitation.
Fundamental Transactions.
In the
event of a fundamental transaction, as described in the Series F-1 Warrants and generally including any reorganization, recapitalization
or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties
or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of the outstanding shares
of our common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by the outstanding
shares of our common stock, the holders of the Series F-1 Warrants will be entitled to receive upon any subsequent exercise of
the Series F-1 Warrants and conversion of the Warrant Preferred Shares issuable upon such exercise the kind and amount of securities,
cash or other property that the holders would have received had they exercised the Series F-1 Warrants and converted the Warrant
Preferred Shares issuable upon such exercise immediately prior to such fundamental transaction.
Rights as a Stockholder.
Except
as otherwise provided in the Series F-1 Warrants or by virtue of such holder’s ownership of shares of our common stock or
Warrant Preferred Shares, the holders of the Series F-1 Warrants do not have the rights or privileges of holders of shares of
our common stock or Warrant Preferred Shares, including any voting rights, until they exercise their Series F-1 Warrants or convert
the Warrant Preferred Shares issuable upon exercise of their Series F-1 Warrants, as applicable.
Amendments
. The terms of a Series
F-1 Warrant may be amended or modified with the written consent of the Company and the holder of the Series F-1 Warrant.
Series F-2 Warrants
Form.
The Series F-2 Warrants
will be issued as individual warrant agreements issued to purchasers.
Amount.
The purchasers of shares
of Series B Preferred Stock will receive Series F-2 Warrants exercisable into 62,240 shares of Series B Preferred Stock in
the aggregate, or “Warrant Preferred Shares”.
Exercisability.
The Series F-2
Warrants will be exercisable at any time on or after the date on which we obtain stockholder approval for a reverse stock split
or to increase our authorized common stock to allow for the reservation in full of all shares of common stock issuable upon conversion
of the Warrant Preferred Shares issuable upon exercise of the Series F-2 Warrants until the five-year anniversary of such initial
exercise date. The Series F-2 Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to
us a duly executed exercise notice accompanied by payment in full for the number of shares of our Series B Preferred Stock purchased
upon such exercise (except in the case of a cashless exercise as discussed below). As described above, if a holder exercises its
Series F-2 Warrants into Warrant Preferred Shares, each holder will be prohibited from converting such Warrant Preferred Shares
into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially
own more than 9.99% of the total number of shares of our common stock then issued and outstanding after giving effect to such
conversion. However, upon at least 61 days’ prior notice from a holder of Warrant Preferred Shares to us, the holder may
increase or decrease the holder’s amount of ownership of outstanding shares of common stock after converting the holder’s
Warrant Preferred Shares to up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect
to such conversion, as such percentage ownership is determined in accordance with the terms of the Certificate of Designation.
Exercise Price.
The exercise price
per whole share of Series B Preferred Stock purchasable upon exercise of the Series F-2 Warrants is $100.00 per share of Series
B Preferred Stock. The exercise price and number of Warrant Preferred Shares issuable upon exercise is subject to appropriate
adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the
exercise price. In addition, the exercise price of the Series F-2 Warrants will be adjusted as follows:
|
●
|
until the date that we consummate more than $4 million of Dilutive Issuances (as described below), if we issue any shares of common stock, or securities convertible into, or exercisable or exchangeable for shares of common stock in a Dilutive Issuance, then the exercise price of the Series F-2 Warrant will automatically be reduced to an amount equal to the then exercise price multiplied by the quotient obtained by dividing the lower issuance price by the then Threshold Price, provided that the exercise price will not be lower than $0.01 in any event; and
|
|
|
|
|
●
|
if we complete a reverse or forward stock split or reclassification of our common stock, and during the five trading days following such reverse or forward stock split or reclassification, the market price (as calculated pursuant to the terms of the Series F-2 Warrants) is less than the exercise price in effect immediately before the reverse or forward stock split or reclassification divided by the Conversion Rate, the exercise price will automatically be reduced to an amount equal to the then exercise price multiplied by the quotient obtained by dividing the market price (as calculated pursuant to the terms of the Series F-2 Warrants) multiplied by the then Threshold Price, provided that the exercise price will not be lower than $0.01 in any event.
|
Cashless Exercise
. If, at the
time a holder exercises its Series F-2 Warrants, a registration statement registering the issuance of Warrant Preferred Shares
under the Securities Act, or a prospectus contained therein, is not then effective or available, then in lieu of making the cash
payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may
elect instead to receive upon such exercise (either in whole or in part) the net number of Warrant Preferred Shares determined
according to a formula set forth in the Series F-2 Warrants.
Transferability.
Subject to applicable
laws, a Series F-2 Warrant may be transferred at the option of the holder upon surrender of the Series F-2 Warrant to us together
with the appropriate instruments of transfer.
Exchange Listing.
We do not plan
on applying to list the Series F-2 Warrants or Warrant Preferred Shares on the Nasdaq Capital Market, any other national securities
exchange or any other nationally recognized trading system.
Subsequent Rights Offerings.
If
we grant, issue or sell any Purchase Rights, then each holder of a Series F-2 Warrant will be entitled to acquire the aggregate
number of Purchase Rights that the holder could have acquired if the holder had held the number of shares of common stock issuable
upon conversion of the Warrant Preferred Shares issuable upon exercise of the holder’s Series F-2 Warrant (without regard
to any limitations on conversion thereof, including without limitation, any beneficial ownership limitations set forth in the
Certificate of Designation). However, if the holder’s ownership of the Purchase Rights would result in the holder exceeding
the beneficial ownership limitations set forth in the Certificate of Designation, then the holder will not be entitled to the
Purchase Rights, and the Purchase Rights will be held in abeyance until the Purchase Right would not result in the holder exceeding
the beneficial ownership limitation.
Distributions
. If we declare or
make a dividend or other distribution of our assets to holders of shares of our common stock, then the holders of Series F-2 Warrants
will be entitled to participate in the distribution to the same extent that a holder would have participated therein if the holder
had held the number of shares of our common stock that the holder could have acquired if the holder had held the number of shares
of common stock issuable upon conversion of the Warrant Preferred Shares issuable upon exercise of the holder’s Series F-2
Warrant (without regard to any limitations on conversion thereof, including without limitation, any beneficial ownership limitations
set forth in the Certificate of Designation). However, if the holder’s right to participate in any distribution would result
in the holder exceeding the beneficial ownership limitations set forth in the Certificate of Designation, then the holder will
not be entitled to participate in that portion of the distribution, and that portion of the distribution will be held in abeyance
for the benefit of the holder until its right to the distribution would not result in the holder exceeding the beneficial ownership
limitation.
Fundamental Transactions.
In the
event of a fundamental transaction, as described in the Series F-2 Warrants and generally including any reorganization, recapitalization
or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties
or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of the outstanding shares
of our common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by the outstanding
shares of our common stock, the holders of the Series F-2 Warrants will be entitled to receive upon any subsequent exercise of
the Series F-2 Warrants and conversion of the Warrant Preferred Shares issuable upon such exercise the kind and amount of securities,
cash or other property that the holders would have received had they exercised the Series F-2 Warrants and converted the Warrant
Preferred Shares issuable upon such exercise immediately prior to such fundamental transaction.
Rights as a Stockholder.
Except
as otherwise provided in the Series F-2 Warrants or by virtue of such holder’s ownership of shares of our common stock or
Warrant Preferred Shares, the holders of the Series F-2 Warrants do not have the rights or privileges of holders of shares of
our common stock or Warrant Preferred Shares, including any voting rights, until they exercise their Series F-2 Warrants or convert
the Warrant Preferred Shares issuable upon exercise of their Series F-2 Warrants, as applicable.
Amendments
. The terms of a Series
F-2 Warrant may be amended or modified with the written consent of the Company and the holder of the Series F-2 Warrant.
Placement Agent Warrants
In addition, we have agreed to issue
to the placement agent the Placement Agent Warrants to purchase our Series B Preferred Stock in an amount equal to 8.0% of the
quotient obtained by dividing the gross proceeds raised in this offering by the combined offering purchase price of $100.00 per
fixed combination of one share of Series B Preferred Stock, one Series F-1 Warrant and one Series F-2 Warrant. The Placement Agent
Warrants will have an exercise price equal to $125.00 per share of our Series B Preferred Stock, or 125% of the combined offering
purchase price of $100.00 per fixed combination of one share of Series B Preferred Stock, one Series F-1 Warrant and one Series
F-2 Warrant. The Placement Agent Warrants will be exercisable at any time on or after the date on which we obtain stockholder
approval for a reverse stock split or to increase our authorized common stock to allow for the reservation in full of all shares
of common stock issuable upon conversion of the Warrant Preferred Shares issuable upon exercise of the Placement Agent Warrants
until the five-year anniversary of such initial exercise date.
PLAN
OF DISTRIBUTION
Pursuant
to an engagement letter dated March 8, 2019, we have engaged H.C. Wainwright & Co., LLC (“Wainwright” or the “placement
agent”) to act as our exclusive placement agent in connection with this offering of our securities pursuant to this prospectus
supplement and accompanying prospectus. Under the terms of the engagement letter, the placement agent has agreed to act as our
exclusive placement agent, on a reasonable best efforts basis, in connection with the issuance and sale by us of our securities
in this takedown from our shelf registration statement. The terms of this offering were subject to market conditions and negotiations
between us, the placement agent and prospective investors. The engagement letter does not give rise to any commitment by the placement
agent to purchase any of our securities, and the placement agent will have no authority to bind us by virtue of the engagement
letter. Further, the placement agent does not guarantee that it will be able to raise new capital in any prospective offering.
The placement agent may engage sub-agents or selected dealers to assist with this offering.
The placement agent proposes to arrange
for the sale of the securities we are offering pursuant to this prospectus supplement and accompanying prospectus to one or more
investors through a securities purchase agreement directly between the purchasers and us. The securities purchase agreement will
provide the purchasers with certain representations, warranties and covenants from us. Additionally, pursuant to the securities
purchase agreement, we will enter into amendments with holders of our outstanding Series C Common Stock Purchase Warrants and
Series D Common Stock Purchase Warrants to purchase an aggregate of 666,666,668 shares of common stock, to reduce the exercise
price of each such warrant from $0.0163 to $0.01 per share of common stock.
We expect to deliver the securities being
offered pursuant to this prospectus supplement on or about March 25, 2019.
We have agreed to pay the placement agent a
total cash fee equal to 8.0% of the gross proceeds of this offering (except in the case of one of the purchasers, if such purchaser
participates on the offering, the fee will be equal to 6.0% of the gross proceeds received from such purchaser). We will also
pay the placement agent a management fee equal to 1.0% of the gross proceeds raised in this offering, $85,000 for non-accountable
expenses and $10,000 for clearing expenses. Palladium Capital Advisors, LLC is an independent financial advisor to us in connection
with the offering and will receive an advisory fee of $150,000. Palladium Capital Advisors, LLC will not sell or offer to sell
any securities offered hereby. We estimate the total expenses payable by us for this offering will be approximately $0.2 million,
which amount excludes the placement agent fees. In addition, we have agreed to issue to the Placement Agent Warrants to purchase
shares of our Series B Preferred Stock in an amount equal to 8.0% of the quotient obtained by dividing the gross proceeds raised
in this offering by the combined offering purchase price of $100.00 per fixed combination of one share of Series B Preferred Stock,
one Series F-1 Warrant and one Series F-2 Warrant, or up to 4,800 shares of Series B Preferred Stock. The Placement Agent Warrants
will have substantially the same terms as the Series F-2 Warrants issued to the investors in this offering, except that each Placement
Agent Warrant will be exercisable for one share of our Series B Preferred Stock, will have an exercise price equal to $125.00
per share of our Series B Preferred Stock, or 125% of the combined offering purchase price of $100.00 per fixed combination of
one share of Series B Preferred Stock, one Series F-1 Warrant and one Series F-2 Warrant, and will not contain any provisions
to adjust the exercise price of the Placement Agent Warrant in the event of a Dilutive Issuance or if the market price is less
than the exercise price after a reverse or forward stock split or reclassification of our common stock. Pursuant to FINRA Rule
5110(g), the Placement Agent Warrants and any shares issued upon exercise of the Placement Agent Warrants shall not be sold, transferred,
assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would
result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the
date of effectiveness or commencement of sales of this offering, except the transfer of any security: (i) by operation of law
or by reason of our reorganization; (ii) to any FINRA member firm participating in this offering and the officers or partners
thereof, if all securities so transferred remain subject to the lock-up restriction set forth above for the remainder of the time
period; (iii) if the aggregate amount of our securities held by the placement agent or related persons do not exceed 1% of
the securities being offered; (iv) that is beneficially owned on a pro-rata basis by all equity owners of an investment fund,
provided that no participating member manages or otherwise directs investments by the fund and the participating members in the
aggregate do not own more than 10% of the equity in the fund; or (v) the exercise or conversion of any security, if all securities
remain subject to the lock-up restriction set forth above for the remainder of the time period.
We
have agreed to indemnify the placement agent and specified other persons against certain liabilities relating to or arising out
of the placement agent’s activities under the engagement letter and to contribute to payments that the placement agent may
be required to make in respect of such liabilities.
We
have also granted the placement agent certain rights of first refusal following the closing of the offering to act as sole book-runner,
sole manager, sole underwriter or sole placement agent for each and every future public or private equity offering by us or any
of our successors or subsidiaries, under certain circumstances. In addition, we have also agreed to pay the placement agent a
tail fee equal to the cash and warrants compensation in this offering, in case certain investors provide us with capital in any
public or private offering or other financing or capital raising transaction, subject to certain conditions and exceptions, during
the twelve-month period after the expiration of termination of the engagement letter.
Pursuant to the securities purchase agreement
between us and the purchasers, subject to certain exceptions, we have agreed not to issue, enter into any agreement to issue or
announce the issuance or proposed issuance of any shares of common stock or common stock equivalents for a period of 30 days following
the consummation of this offering.
The
placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions
received by it and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to
be underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required to
comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the
Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases
and sales of shares of common stock and warrants by the placement agent acting as principal. Under these rules and regulations,
the placement agent:
|
●
|
may
not engage in any stabilization activity in connection with our securities; and
|
|
●
|
may
not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than
as permitted under the Exchange Act, until it has completed its participation in the distribution.
|
From
time to time, the placement agent may provide in the future various advisory, investment and commercial banking and other services
to us in the ordinary course of business, for which they have received and may continue to receive customary fees and commissions.
The placement agent acted as our placement agent in connection with our January 2019 Offering, for which it received compensation.
However, except as disclosed in this prospectus supplement, we have no present arrangements with the placement agent for any further
services.
Listing;
Transfer Agent and Registrar
Our common stock is quoted on the OTC Pink Market operated by OTC Markets Group Inc. under the symbol
“HMNY”. We do not intend to list the Series B Preferred Stock, Series F Warrants or the Placement Agent Warrants to
be sold in this offering on any national securities exchange or any nationally recognized trading system.
The
transfer agent for our common stock is Computershare. Our transfer agent’s address is 350 Indiana Street, Suite 750, Golden,
Colorado 80401.
LEGAL
MATTERS
The
validity of the issuance of the securities offered hereby will be passed upon for us by Greenberg Traurig, LLP, Los Angeles, California.
EXPERTS
Rosenberg
Rich Baker Berman, P.A., independent registered public accounting firm, has audited our consolidated financial statements included
in our Annual Report on Form 10-K for the years ended December 31, 2017 and 2016, as set forth in their report, which is incorporated
by reference in this prospectus supplement and elsewhere in the registration statement in which this prospectus supplement is
included, which report includes an explanatory paragraph about the existence of substantial doubt concerning our ability to continue
as a going concern. Our consolidated financial statements for the years ended December 31, 2017 and 2016 are incorporated by reference
in reliance on Rosenberg Rich Baker Berman, P.A.’s report, given on their authority as experts in accounting and auditing.
The
balance sheets of MoviePass as of December 31, 2016 and 2015, and the related statements of operations, stockholders’ equity,
and cash flows for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting
firm, as stated in their report which is incorporated by reference from the Company’s Form 8-K filed with the Securities
and Exchange Commission on November 30, 2017 which report includes an explanatory paragraph about the existence of substantial
doubt concerning MoviePass’ ability to continue as a going concern. Such financial statements have been incorporated herein
by reference in reliance on the report of such firm given upon their authority as experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
We
have filed with the SEC a registration statement on Form S-3 under the Securities Act, with respect to the securities covered
by this prospectus supplement. This prospectus supplement, which is a part of the registration statement, does not contain all
of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further information
with respect to us and the securities covered by this prospectus supplement, please see the registration statement and the exhibits
filed with the registration statement. The SEC maintains an Internet website that contains reports, proxy and information statements
and other information regarding registrants that file electronically with the SEC. The address of the website is
http://www.sec.gov
.
We
are subject to the information and periodic reporting requirements of the Exchange Act and, in accordance therewith, we file periodic
reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information are
available for inspection and copying at the Public Reference Room and website of the SEC referred to above. We maintain a website
at
http://www.hmny.com
. You may access our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports
on Form 8-K and amendments to those reports filed pursuant to Sections 13(a) or 15(d) of the Exchange Act with the SEC free of
charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the
SEC. Our website and the information contained on that site, or connected to that site, are not incorporated into and are not
a part of this prospectus supplement.
INFORMATION
INCORPORATED BY REFERENCE
The
SEC and applicable law permits us to “incorporate by reference” into this prospectus supplement information that we
have or may in the future file with or furnish to the SEC. This means that we can disclose important information by referring
you to those documents. You should read carefully the information incorporated herein by reference because it is an important
part of this prospectus supplement. We hereby incorporate by reference the following documents into this prospectus supplement:
|
●
|
our
Annual Report on Form 10-K for the fiscal year ended December 31, 2017, as filed with the Securities and Exchange Commission
on April 17, 2018;
|
|
|
|
|
●
|
our
Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2018, June 30, 2018 and September 30, 2018, as filed with
the Securities and Exchange Commission on May 15, 2018, August 14, 2018 and November 15, 2018, respectively; and Amendment No.
1 to our Quarterly Report on Form 10-Q/A for the fiscal quarter ended September 30, 2018, as filed with the Securities and Exchange
Commission on March 19, 2019;
|
|
|
|
|
●
|
our Current Reports on Form 8-K filed with the Securities and Exchange Commission on January 9, 2018,
January 11, 2018, January 19, 2018, January 26, 2018, February 8, 2018, February 13, 2018, March 14, 2018, March 15, 2018, April
5, 2018, April 18, 2018, April 19, 2018, April 20, 2018, May 8, 2018, June 4, 2018, June 21, 2018, June 26, 2018, June 29, 2018,
July 11, 2018, July 13, 2018, July 24, 2018, July 25, 2018, July 27, 2018, July 31, 2018, August 1, 2018, August 30, 2018, September
12, 2018, October 4, 2018, October 15, 2018, December 18, 2018, December 21, 2018, December 31, 2018, January 16, 2019, January
25, 2019, February 7, 2019, February 12, 2019, March 12, 2019, March 15, 2019, March 21, 2019, and March 26, 2019; and our Current
Report on Form 8-K/A filed with the Securities and Exchange Commission on February 9, 2018, and July 25, 2018; and
|
|
|
|
|
●
|
the
financial statements of MoviePass for the year ended December 31, 2016 and the interim period ended September 30, 2017 included
in our Current Report on Form 8-K filed with the Securities and Exchange Commission on November 30, 2017.
|
Additionally,
all documents filed by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than any portions of
filings that are furnished rather than filed pursuant to Items 2.02 and 7.01 of a Current Report on Form 8-K), after the date
of this prospectus supplement and before the termination or completion of this offering shall be deemed to be incorporated by
reference into this prospectus supplement from the respective dates of filing of such documents. Any information that we subsequently
file with the SEC that is incorporated by reference as described above will automatically update and supersede any previous information
that is part of this prospectus supplement.
Upon
written or oral request, we will provide you without charge, a copy of any or all of the documents incorporated by reference,
other than exhibits to those documents unless the exhibits are specifically incorporated by reference in the documents. Please
send requests to Helios and Matheson Analytics Inc., Attn: Chief Executive Officer, The Empire State Building, 350 Fifth Avenue,
New York, New York 10118, telephone number is (212) 979-8228.
PROSPECTUS
$1,200,000,000
Common
Stock
Preferred
Stock
Debt
Securities
Warrants
Units
Subscription
Rights
We
may from time to time offer and sell, in one or more offerings, up to $1,200,000,000 in any combination of common stock, preferred
stock, debt securities, which may be senior, senior subordinated, or subordinated, warrants, units and subscription rights. This
prospectus provides you with a general description of the securities we may offer and certain other information about our company.
We may offer these securities in amounts, at prices and on terms determined at the time of offering.
We
will provide you the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also
authorize one or more free-writing prospectuses to be provided to you in connection with these offerings. Any prospectus supplement
and any related free-writing prospectus may also add, update or change information contained in this prospectus. You should carefully
read this prospectus, any applicable prospectus supplement and any related free-writing prospectus, as well as any documents incorporated
by reference, before you invest.
We
may offer these securities from time to time in amounts, at prices and on other terms to be determined at the time of the offering.
We may offer and sell these securities to or through underwriters, dealers or agents, or directly to investors, on a continuous
or delayed basis. The supplements to this prospectus will provide the specific terms of the plan of distribution. The price to
the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus
supplement.
Our common stock is listed on the Nasdaq Capital
Market under the symbol “HMNY.” On June 29, 2018, the closing price of our common stock as reported by the Nasdaq
Capital Market was $0.31 per share.
An
investment in our securities involves a high degree of risk. See “Risk Factors” on page 2 of this prospectus for
more information on these risks. We may include additional risk factors in an applicable prospectus supplement under the
heading “Risk Factors.” You should review that section of the prospectus supplement for a discussion of matters
that investors in our securities should consider.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The
date of this prospectus is July
5,
2018
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement filed with the Securities and Exchange Commission (the “SEC”) using
a “shelf” registration process. Under this shelf registration process, we may offer to sell any combination of the
securities described in this prospectus in one or more offerings for an aggregate offering price of up to $1,200,000,000. This
prospectus provides you with a general description of the securities which may be offered. Each time we offer securities for sale,
we will provide a prospectus supplement that contains specific information about the terms of that offering. Any prospectus supplement
may also add or update information contained in this prospectus. You should read both this prospectus and any prospectus supplement,
including all documents incorporated herein or therein by reference, together with additional information described below under
“Where You Can Find More Information” and “Information Incorporated by Reference.”
The
registration statement that contains this prospectus (including the exhibits thereto) contains additional important information
about us and the securities we may offer under this prospectus. Specifically, we have filed certain legal documents that establish
the terms of the securities offered by this prospectus as exhibits to the registration statement. We will file certain other legal
documents that establish the terms of the securities offered by this prospectus as exhibits to reports we file with the SEC. You
may obtain copies of that registration statement and the other reports and documents referenced herein as described below under
the heading “Where You Can Find More Information.”
You
should rely only on the information contained or incorporated by reference in this prospectus and in any prospectus supplement.
We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. We are not making offers to sell or solicitations to buy the securities in any jurisdiction
in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified
to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should not assume that the information in this
prospectus or any prospectus supplement, as well as the information we file or previously filed with the SEC that we incorporate
by reference in this prospectus or any prospectus supplement, is accurate as of any date other than its respective date. Our business,
financial condition, results of operations and prospects may have changed since those dates.
In
this prospectus, unless the context otherwise requires, references to “we,” “us,” “our,” “our
company,” “the Company,” or “Helios” refer to Helios and Matheson Analytics Inc. and its subsidiaries.
MARKET,
INDUSTRY AND OTHER DATA
This
prospectus, including the information incorporated by reference, contains estimates, projections and other information concerning
our industry, our business, and the markets for certain products and services, including data regarding the estimated size of
those markets and their projected growth rates. Information that is based on estimates, forecasts, projections or similar methodologies
is based on a number of assumptions and is inherently subject to uncertainties, including those described in “Risk Factors”
and elsewhere in this prospectus and documents incorporated by reference in this prospectus, and actual events or circumstances
may differ materially from events and circumstances reflected in this information. You are cautioned not to give undue weight
to such estimates, projections and other information.
Unless
otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies
and similar data prepared by third parties and general publications. In some cases, we do not expressly refer to the sources from
which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should
assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly
stated or the context otherwise requires.
CAUTIONARY
NOTE CONCERNING FORWARD-LOOKING STATEMENTS
This
prospectus and any accompanying prospectus supplement, including the documents that we incorporate by reference, may contain forward-looking
statements within the meaning of the federal securities laws. Any such statements that do not relate to historical or current
facts or matters are forward-looking statements. You can identify some of the forward-looking statements by the use of forward-looking
terms, such as “may,” “will,” “should,” “expect,” “could,” “intend,”
“plan,” “anticipate,” “estimate,” “believe,” “continue,” “project,”
“potential,” “forecast” or the negative of such terms and other comparable terminology. Forward-looking
statements in this prospectus include, without limitation, statements related to our financial and operating performance, our
plans, strategies, objectives, expectations, intentions and adequacy of resources. Certain important risks, including those discussed
in the risk factors are described in the section entitled “Risk Factors” in this prospectus and other risks and uncertainties
detailed in our other reports and filings with the Securities and Exchange Commission, could cause results to differ materially
from those anticipated by some of the forward-looking statements. Some, but not all, of these risks include, among other things:
|
●
|
our
ability to successfully develop the business model of MoviePass, Inc., our majority-owned subsidiary;
|
|
●
|
our
ability to integrate the operations of MoviePass into our operations;
|
|
●
|
our
capital requirements and whether or not we will be able to raise capital when we need it;
|
|
●
|
changes
in local, state or federal regulations that will adversely affect our business;
|
|
●
|
our
ability to retain our existing clients and market and sell our services to new clients;
|
|
●
|
whether
we will continue to receive the services of certain officers and directors;
|
|
●
|
our
ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights
of others;
|
|
●
|
our
ability to effectively react to other risks and uncertainties described from time to time in our filings with the Securities and
Exchange Commission, such as fluctuation of quarterly financial results, reliance on third party consultants, litigation or other
proceedings and stock price volatility; and
|
|
●
|
other
uncertainties, all of which are difficult to predict and many of which are beyond our control.
|
The
forward-looking statements are based on our beliefs, assumptions and expectations of future events, taking into account all information
currently available to us. Forward-looking statements are not guarantees of future events or of our performance. These beliefs,
assumptions and expectations can change as a result of many possible events or factors, not all of which are known to us. You
are urged to carefully review the disclosures we make concerning risks and other factors that may affect our business and operating
results, including those made in the section entitled “Risk Factors” in this prospectus, and any of those made in
our other reports filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Except as required by law, we are not obligated to, and do not intend to,
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should
refer to and carefully review the information in future documents we file with the Securities and Exchange Commission.
PROSPECTUS
SUMMARY
OUR
BUSINESS
This
is only a summary and may not contain all the information that is important to you. You should carefully read both this prospectus
and any accompanying prospectus supplement and any other offering materials, together with the additional information described
under the heading “Where You Can Find More Information.”
About
Helios and Matheson Analytics Inc.
Overview
We provide high quality
information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business
intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, we have sought to
expand our business primarily through acquisitions that leverage our capabilities and expertise.
As of the date of this
prospectus, we own 91.8%, of the outstanding shares of MoviePass, Inc., or MoviePass, (excluding outstanding MoviePass options
and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides our subscribers
the ability to view up to one new movie title per day for one monthly subscription price.
MoviePass Ventures, LLC (“MoviePass
Ventures”) was formed as a Delaware limited liability company in January 2018 and is a wholly-owned subsidiary of the Company.
MoviePass Ventures aims to collaborate with film distributors to share in film revenues while using the data analytics MoviePass
offers for marketing and targeting services for MoviePass’ paying subscribers using the platform.
On April 4, 2018, we
acquired Moviefone assets from Oath Inc. (formerly, AOL Inc.), a wholly-owned subsidiary of Verizon Communications Inc. Moviefone,
a multimedia media information and advertising service, provides over 6 million monthly unique visitors full access to the entertainment
ecosystem, from movie theaters to streaming content.
On May 30, 2018 we formed
MoviePass Films LLC (“MoviePass Films”) with Emmett Furla Oasis Films (“EFO Films”). Helios owns 51% and
EFO Films owns 49% of MoviePass Films. MoviePass Films focuses on studio-driven content and new film production for theatrical
release and other distribution channels. We plan to capitalize on the capabilities of MoviePass to market future MoviePass
Films productions to MoviePass subscribers.
Corporate Information
Our executive offices are located at The Empire
State Building, 350 Fifth Avenue, New York, New York 10118, and our telephone number is (212) 979-8228. Additional information
about us is available on our website at www.hmny.com. The information contained on or that may be obtained from our website is
not, and shall not be deemed to be, a part of this prospectus. Our common stock, par value $0.01 per share, is currently traded
on the Nasdaq Capital Market under the ticker symbol “HMNY.”
For a description of our business, financial
condition, results of operations and other important information regarding us, we refer you to our filings with the SEC incorporated
by reference in this prospectus. For instructions on how to find copies of these documents, see “
Where You Can Find More
Information.
”
RISK
FACTORS
Investing
in our securities involves a high degree of risk. Please see the risk factors set forth in Part I, Item 1A of our most recent
Annual Report on Form 10-K and Part II, and other filings we make with the SEC, which are incorporated by reference in this prospectus.
Additional risk factors may be included in a prospectus supplement relating to a particular offering of securities. Before making
an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference
in this prospectus. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties
not presently known to us or that we currently deem immaterial may also affect our business operations. These risks could materially
affect our business, results of operations or financial condition and cause the value of our securities to decline.
USE
OF PROCEEDS
Unless
we state otherwise in an accompanying prospectus supplement, we intend to use the net proceeds from the sale of the securities
offered by us under this prospectus and any related prospectus supplement for general corporate purposes of Helios and its subsidiaries
and/or to support MoviePass and MoviePass Ventures operations. These purposes may include capital expenditures and additions to
working capital. When a particular series of securities is offered, the prospectus supplement relating to that series will set
forth our intended use for the net proceeds we receive from the sale of the securities. Pending the application of the net proceeds,
we may invest the proceeds in short-term, interest-bearing instruments or other investment-grade securities.
DILUTION
We
will set forth in a prospectus supplement the following information regarding any material dilution of the equity interests of
investors purchasing securities sold by the Company in an offering under this prospectus:
|
●
|
the
net tangible book value per share of our equity securities before and after the offering;
|
|
|
|
|
●
|
the
amount of the increase in such net tangible book value per share attributable to the
cash payments made by purchases in the offering; and
|
|
|
|
|
●
|
the
amount of the immediate dilution from the public offering price which will be absorbed
by such purchasers.
|
DESCRIPTION
OF THE SECURITIES THAT MAY BE OFFERED
Description
of Common Stock
The
following summary of the rights of our common stock is not complete and is subject to and qualified in its entirety by reference
to our certificate of incorporation and bylaws, copies of which are included as exhibits to our registration statement on Form
S-3, of which this prospectus forms a part. See “Where You Can Find More Information.”
We
have 502,000,000,000 shares of capital stock authorized under our certificate of incorporation, consisting of 500,000,000 shares of
common stock, $0.01 par value, and 2,000,000 shares of preferred stock, $0.01 par value.
As of June 29, 2018 we had 249,870,588 shares
of common stock outstanding and 20,500 shares of Series A Preferred Stock outstanding. Our authorized but unissued shares of common
stock are available for issuance without further action by our stockholders, unless such action is required by applicable law
or the rules of any stock exchange or automated quotation system on which our securities may be listed or traded.
Holders of our
common stock are entitled to such dividends as may be declared by our board of directors out of funds legally available for such
purpose, subject to any preferential dividend rights of any then outstanding preferred stock. The shares of common stock are neither
redeemable or convertible. Holders of common stock have no preemptive or subscription rights to purchase any of our securities.
Each
holder of our common stock is entitled to one vote for each such share outstanding in the holder’s name. No holder of common
stock is entitled to cumulate votes in voting for directors.
In
the event of our liquidation, dissolution or winding up, the holders of our common stock are entitled to receive pro rata our
assets which are legally available for distribution, after payments of all debts and other liabilities and subject to the prior
rights of any holders of preferred stock then outstanding. All of the outstanding shares of our common stock are fully paid and
non-assessable. The shares of common stock offered by this prospectus will also be fully paid and non-assessable.
Our common stock is listed on the Nasdaq Capital
Market under the symbol “HMNY.” On June 29, 2018, the last sale price of our common stock was $0.31 per share. The
transfer agent and registrar for our common stock is Computershare. Its address is 250 Royall Street, Canton, Massachusetts 02021.
Description
of Preferred Stock
Our certificate of incorporation permits us
to issue up to 2,000,000 shares of preferred stock in one or more series and with rights and preferences that may be fixed or designated
by our board of directors without any further action by our stockholders. We currently have 20,500 shares of Series A Preferred
Stock outstanding. The following is a description of the Series A Preferred Stock:
Dividends
The Series A Preferred
Stock does not accrue dividends.
Conversion
The Series A Preferred
Stock is not convertible into common stock.
Voting Rights
Each share of Series A Preferred Stock is entitled
to 3,205 votes per share on all matters on which holders of common stock are entitled to vote. However, the amount of votes with
respect to the Series A Preferred Stock held by any holder, when aggregated with any other voting securities of our company held
by such holder, cannot exceed 19.9% of our outstanding voting power calculated as of June 21, 2018 (or such greater percentage
allowed by Nasdaq without any stockholder approval requirements).
Redemption
From and after the time when the first 15% of
the aggregate principal amount of any Series B-2 Senior Secured Convertible Notes issued on June 26, 2018 (the “Convertible
Notes”) is paid or converted in accordance with the terms of the Convertible Notes, we will have the right to redeem all
or a portion of the Series A Preferred Stock at a price per share equal to $0.01, payable, at our option with cash or shares of
our common stock or, if required by, certain beneficial ownership limitations, rights to receive common stock.
Transfer
The shares of Series A
Preferred Stock are transferable, subject to limitations in the voting agreements between us and each of the buyers of the Convertible
Notes and applicable securities laws.
Liquidation Preference
Upon any liquidation,
dissolution or winding up of our company, the holders of the shares of Series A Preferred Stock will be entitled to receive in
cash out of the assets of our company, before any amount is paid to the holders of any junior stock, including our common stock,
an amount per share of Series A Preferred Stock equal to 100% of the stated value per share (which is equal to $1,000) plus $0.01.
The Certificate of
Designations also includes covenants restricting the Company’s ability to take certain actions without the approval of at
least a majority of the outstanding shares of the Preferred Stock.
Subject to the limitations prescribed in
our certificate of incorporation and under Delaware law, our certificate of incorporation authorizes the board of directors, from
time to time by resolution and without further stockholder action, to provide for the issuance of shares of preferred stock, in
one or more series, and to fix the designation, powers, preferences and other rights of the shares and to fix the qualifications,
limitations and restrictions thereof.
Description
of Debt Securities
The
following description, together with the additional information we include in any applicable prospectus supplement, summarizes
certain general terms and provisions of the debt securities that we may offer offered under this prospectus. When we offer to
sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this prospectus.
The supplement will also indicate to what extent the general terms and provisions described in this prospectus apply to a particular
series of debt securities.
We
may issue debt securities, either separately, or together with, or upon the conversion or exercise of or in exchange for, other
securities described in this prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations, issued
in one or more series, and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct,
unsecured obligations.
The
debt securities will be issued under an indenture between us and a trustee to be identified in the applicable prospectus supplement.
We have summarized select portions of the indenture below. Please note, however, that the summary below is not complete. The form
of the indenture has been filed as an exhibit to the registration statement of which this prospectus forms a part and you should
read the indenture for provisions that may be important to you. Capitalized terms used in the summary below and not defined herein
have the meanings specified in the form of the indenture.
General
The
terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth
or determined in the manner provided in a resolution of our board of directors, in an officer’s certificate, or by a supplemental
indenture. The particular terms of each series of debt securities will be described in a prospectus supplement relating to such
series (including any pricing supplement or term sheet).
We
can issue an unlimited amount of debt securities under the indenture that may be in one or more series with the same or various
maturities, at par, at a premium, or at a discount. The prospectus supplement (including any pricing supplement or term sheet)
relating to any series of debt securities being offered will set forth the aggregate principal amount and the other terms of the
debt securities, including, if applicable:
|
●
|
the
title and ranking of the debt securities (including the terms of any subordination provisions);
|
|
|
|
|
●
|
the
price or prices (expressed as a percentage of the principal amount) at which the debt
securities will be sold;
|
|
|
|
|
●
|
any
limit on the aggregate principal amount of the debt securities;
|
|
|
|
|
●
|
the
date or dates on which the principal of and premium, if any, on the debt securities is
payable and/or the method of determination thereof;
|
|
|
|
|
●
|
the
rate or rates (which may be fixed or variable) per annum or the method used to determine
the rate or rates (including any commodity, commodity index, stock exchange index or
financial index) at which the debt securities will bear interest, the date or dates from
which interest will accrue, the date or dates on which interest will commence and be
payable and any regular record date for the interest payable on any interest payment
date;
|
|
●
|
the
place or places where principal of, and interest, if any, on the debt securities will
be payable (and the method of such payment), where the securities of such series may
be surrendered for registration of transfer or exchange, and where notices and demands
to us in respect of the debt securities may be delivered;
|
|
|
|
|
●
|
the
right, if any, to extend the interest payment periods and the duration of such extension;
|
|
|
|
|
●
|
the
period or periods within which, the price or prices at which, and the terms and conditions
upon which, we may redeem the debt securities;
|
|
●
|
any
obligation we will have to redeem or purchase the debt securities pursuant to any sinking
fund or analogous provisions (including payments made in cash in participation of future
sinking fund obligations) or at the option of a holder of debt securities, and the period
or periods within which (or manner of determining the same), the price or prices at which
(or manner of determining the same), and in the terms and conditions upon which, debt
securities of the series shall be redeemed or purchased, in whole or in part, pursuant
to such obligation;
|
|
|
|
|
●
|
the
dates on which and the price or prices at which we will repurchase debt securities at
the option of the holders of debt securities and other detailed terms and provisions
of these repurchase obligations;
|
|
|
|
|
●
|
the
form of the debt securities of the series, including the form of the trustee’s
certificate of authentication for such series and any legends or endorsements to be placed
thereon;
|
|
|
|
|
●
|
the
denominations in which the debt securities will be issued, if other than denominations
of $1,000 and any integral multiple thereof;
|
|
|
|
|
●
|
whether
the debt securities will be issued in the form of certificated debt securities or global
debt securities;
|
|
|
|
|
●
|
the
portion of principal amount of the debt securities payable upon declaration of acceleration
of the maturity date, if other than the principal amount;
|
|
|
|
|
●
|
the
currency of denomination of the debt securities, which may be United States Dollars or
any foreign currency, and if such currency of denomination is a composite currency, the
agency or organization, if any, responsible for overseeing such composite currency;
|
|
|
|
|
●
|
the
designation of the currency, currencies or currency units in which payment of principal
of, premium, and interest on the debt securities will be made;
|
|
|
|
|
●
|
if
payments of principal of, or premium, if any, or interest on the debt securities will
be made in one or more currencies or currency units other than that or those in which
the debt securities are denominated, the manner in which the exchange rate with respect
to these payments will be determined;
|
|
|
|
|
●
|
the
manner in which the amounts of payment of principal of, premium, if any, or interest
on the debt securities will be determined, if these amounts may be determined by reference
to an index based on a currency or currencies other than that in which the debt securities
are denominated or designated to be payable or by reference to a commodity, commodity
index, stock exchange index or financial index;
|
|
|
|
|
●
|
any
provisions relating to any security provided for the debt securities;
|
|
|
|
|
●
|
any
addition to, deletion of or change in the Events of Default described in this prospectus
or in the indenture with respect to the debt securities and any change in the acceleration
provisions described in this prospectus or in the indenture with respect to the debt
securities;
|
|
|
|
|
●
|
any
addition to, deletion of or change in the covenants described in this prospectus or set
forth in the indenture with respect to the debt securities;
|
|
●
|
the
provisions, if any, relating to conversion or exchange of any debt securities of such
series, including if applicable, the conversion or exchange price and period, provisions
as to whether conversion or exchange will be mandatory, the events requiring an adjustment
of the conversion or exchange price and provisions affecting conversion or exchange;
|
|
|
|
|
●
|
if
other than the trustee, the identity of the trustee, the registrar, paying agent and
custodian for the depositary;
|
|
|
|
|
●
|
if
other than The Depository Trust Company, the identity of the depositary; and
|
|
|
|
|
●
|
any
other terms of the debt securities, which may supplement, modify or delete any provision
of the indenture as it applies to that series, including any terms that may be required
under applicable law or regulations or advisable in connection with the marketing of
the securities.
|
We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration
of acceleration of their maturity pursuant to the terms of the indenture. Information on the federal income tax considerations
and other special considerations applicable to any of these debt securities will be provided in the applicable prospectus supplement.
If
the purchase price of any of the debt securities is denominated in a foreign currency or currencies or a foreign currency unit
or units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency
or currencies or a foreign currency unit or units, then information on the restrictions, elections, general tax considerations,
specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or
foreign currency unit or units will be provided in the applicable prospectus supplement.
Transfer
and Exchange
Each
debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company
(which we refer to as “DTC”) or a nominee of DTC (which we refer to as a “book-entry debt security”),
or a certificate issued in definitive registered form (which is referred to as a “certificated debt security”), as
set forth in the applicable prospectus supplement. Except as set forth under the heading “Global Debt Securities and Book-Entry
System” below, book-entry debt securities will not be issuable in certificated form.
Certificated
Debt Securities
. Holders may transfer or exchange certificated debt securities at any office we maintain for this purpose
in accordance with the terms of the indenture. No service charge will be made for any transfer or exchange of certificated debt
securities, but payment of a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer
or exchange may be required.
Holders
may effect the transfer of certificated debt securities and the right to receive the principal of, or any premium or interest
on, certificated debt securities only by surrendering the certificate representing those certificated debt securities and either
reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of a new certificate
to the new holder.
Global
Debt Securities and Book-Entry System
. Each global debt security representing book-entry debt securities will be deposited
with, or on behalf of, DTC, and registered in the name of DTC or a nominee of DTC. Please see the section entitled “Global
Securities” in this prospectus for more information.
Covenants
Any
restrictive covenants applicable to any issue of debt securities will be set forth in the applicable prospectus supplement.
No
Protection in the Event of a Change of Control
Unless
stated otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions that may afford
holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction
(whether or not such transaction results in a change in control) that could adversely affect holders of debt securities.
Consolidation,
Merger and Sale of Assets
We
may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets
to any person (a “successor person”) unless:
|
●
|
we
are the surviving corporation or the successor person (if other than us) is a corporation
that is organized and validly existing under the laws of any U.S. domestic jurisdiction
and expressly assumes our obligations on the debt securities and under the indenture;
and
|
|
|
|
|
●
|
immediately
after giving effect to the transaction, no Default or Event of Default shall have
occurred and be continuing.
|
Notwithstanding
the above, any of our subsidiaries may consolidate with, merge into, or transfer all or part of its properties to us.
Events
of Default
“Event
of Default” means with respect to any series of debt securities, any of the following:
|
●
|
default
in the payment of any interest upon any debt security of that series when it becomes
due and payable, and continuance of such default for a period of 30 days (unless the
entire amount of the payment is deposited by us with the trustee or with a paying agent
prior to the expiration of the 30-day period);
|
|
|
|
|
●
|
default
in the payment of principal of any security of that series when it becomes due and payable,
whether at stated maturity, upon redemption, upon purchase, upon acceleration or otherwise;
|
|
●
|
default
in the performance or breach of any other covenant or warranty by us in the indenture
(other than a covenant or warranty that has been included in the indenture solely for
the benefit of a series of debt securities other than that series), which default continues
uncured for a period of 60 days after we receive written notice from the trustee, or
we and the trustee receive written notice from the holders of not less than 25% in principal
amount of the outstanding debt securities of that series as provided in the indenture;
|
|
|
|
|
●
|
certain
voluntary or involuntary events of bankruptcy, insolvency or reorganization of the Company;
and
|
|
|
|
|
●
|
any
other Event of Default provided with respect to debt securities of that series that is
described in the applicable prospectus supplement.
|
No
Event of Default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency
or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. The occurrence
of certain Events of Default or an acceleration under the indenture may constitute an event of default under certain other of
our indebtedness or indebtedness of our subsidiaries outstanding from time to time.
So
long as any of the securities are outstanding, we will provide the trustee written notice of any Default or Event of Default within
30 days of becoming aware of the occurrence of such Default or Event of Default.
If
an Event of Default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee
or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in
writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal of (or, if
the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms
of that series) and accrued and unpaid interest, if any, on all debt securities of that series. Such acceleration will not be
effective until the earlier of (1) the acceleration of indebtedness under our senior secured credit facilities or (2) five business
days after receipt by us of written notice of such acceleration, at which time the principal premium, if any, interest and any
other monetary obligations on all the then outstanding series of debt securities will become due and payable immediately. In the
case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such
specified amount) of accrued and unpaid interest, if any, on all outstanding debt securities or the applicable series will
become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding
debt securities. At any time after a declaration of acceleration with respect to debt securities of any series has been made,
but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal
amount of the outstanding debt securities of that series may rescind and annul the acceleration if all Events of Default, other
than the non-payment of accelerated principal and interest, if any, with respect to debt securities of that series, have been
cured or waived as provided in the indenture. Please refer to the prospectus supplement relating to any series of debt securities
that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such
discount securities upon the occurrence of an Event of Default.
The
indenture will provide that the trustee will be under no obligation to exercise any of its rights or powers under the indenture
unless the trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it
in exercising such right of power. Subject to certain rights of the trustee, the holders of a majority in principal amount of
the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding
for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities
of that series.
No
holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect
to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless:
|
●
|
that
holder has previously given to the trustee written notice of a continuing Event of Default
with respect to debt securities of that series; and
|
|
|
|
|
●
|
the
holders of not less than 25% in principal amount of the outstanding debt securities of
that series have made written request, and offered indemnity or security satisfactory
to the trustee, to the trustee to institute the proceeding as trustee, and the trustee
has not received from the holders of not less than a majority in principal amount of
the outstanding debt securities of that series a direction inconsistent with that request
and has failed to institute the proceeding within 60 days.
|
Notwithstanding
any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive
payment of the principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security
and to institute suit for the enforcement of payment.
The
indenture require us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance
with the indenture. If a Default or Event of Default occurs and is continuing with respect to the debt securities of any series
and if it is known to a responsible officer of the trustee, the trustee shall mail to each holder of the debt securities of that
series notice of a Default or Event of Default within 90 days after it occurs. The indenture provides that the trustee may withhold
notice to the holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities
of that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice
is in the interest of the holders of those debt securities.
Modification
and Waiver
We
and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any
holder of any debt security:
|
●
|
to
cure any ambiguity, defect or inconsistency;
|
|
|
|
|
●
|
to
comply with covenants in the indenture described above under the heading “Consolidation,
Merger and Sale of Assets”;
|
|
|
|
|
●
|
to
provide for uncertificated securities in addition to or in place of certificated securities;
|
|
|
|
|
●
|
to
make any change that does not adversely affect the rights of any holder of debt securities;
|
|
|
|
|
●
|
to
provide for the issuance of and establish the form and terms and conditions of debt securities
of any series as permitted by the indenture;
|
|
|
|
|
●
|
to
add covenants for the benefit of the holders of debt securities of any series or to surrender
any right or power conferred upon the Company;
|
|
|
|
|
●
|
to
effect the appointment of a successor trustee with respect to the debt securities of
any series and to add to or change any of the provisions of the indenture to provide
for or facilitate administration by more than one trustee; or
|
|
|
|
|
●
|
to
comply with requirements of the SEC in order to effect or maintain the qualification
of the indenture under the Trust Indenture Act of 1939, as amended.
|
We
may also modify and amend the indenture with the consent of the holders of at least a majority in principal amount of the outstanding
debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without
the consent of the holders of each affected debt security then outstanding if that amendment will:
|
●
|
reduce
the amount of debt securities whose holders must consent to an amendment, supplement
or waiver;
|
|
|
|
|
●
|
reduce
the rate of or extend the time for payment of interest (including default interest) on
any debt security;
|
|
|
|
|
●
|
reduce
the principal of or premium on or change the fixed maturity of any debt security or reduce
the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous
obligation with respect to any series of debt securities;
|
|
|
|
|
●
|
reduce
the principal amount of discount securities payable upon acceleration of maturity;
|
|
●
|
waive
a default in the payment of the principal of, premium or interest on any debt security
(except a rescission of acceleration of the debt securities of any series by the holders
of at least a majority in aggregate principal amount of the then outstanding debt securities
of that series and a waiver of the payment default that resulted from such acceleration);
|
|
|
|
|
●
|
make
the principal of or premium or interest on any debt security payable in currency other
than that stated in the debt security;
|
|
|
|
|
●
|
make
any change to certain provisions of the indenture relating to, among other things, the
right of holders of debt securities to receive payment of the principal of, premium and
interest on those debt securities and to institute suit for the enforcement of any such
payment and to waivers or amendments; or
|
|
|
|
|
●
|
waive
a redemption payment with respect to any debt security.
|
Except
for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of
any series may on behalf of the holders of all debt securities of that series waive compliance by us with provisions of the indenture.
The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of
all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences,
except a default in the payment of the principal of, premium or any interest on any debt security of that series; provided, however,
that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration
and its consequences, including any related payment default that resulted from the acceleration.
Defeasance
of Debt Securities and Certain Covenants in Certain Circumstances
Legal
Defeasance
. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities,
we may be discharged from any and all obligations in respect of the debt securities of any series (subject to certain exceptions).
We will be so discharged upon the deposit with the trustee, in trust, of money and/or U.S. government obligations or, in the case
of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued
or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will
provide money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment
bank to pay and discharge each installment of principal, premium and interest on and any mandatory sinking fund payments in respect
of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and
those debt securities.
This
discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received
from, or there has been published by, the United States Internal Revenue Service a ruling or, since the date of execution of the
indenture, there has been a change in the applicable United States federal income tax law, in either case to the effect that,
and based thereon such opinion shall confirm that, the holders of the debt securities of that series will not recognize income,
gain or loss for United States federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject
to United States federal income tax on the same amounts and in the same manner and at the same times as would have been the case
if the deposit, defeasance and discharge had not occurred.
Defeasance
of Certain Covenants
. The indenture provides that, unless otherwise provided by the terms of the applicable series of
debt securities, upon compliance with certain conditions:
|
●
|
we
may omit to comply with the covenant described under the heading “Consolidation,
Merger and Sale of Assets” and certain other covenants set forth in the indenture,
as well as any additional covenants that may be set forth in the applicable prospectus
supplement; and
|
|
|
|
|
●
|
any
omission to comply with those covenants will not constitute a Default or an Event of
Default with respect to the debt securities of that series (“covenant defeasance”).
|
The
conditions include:
|
●
|
depositing
with the trustee money and/or U.S. government obligations or, in the case of debt securities
denominated in a single currency other than U.S. Dollars, government obligations of the
government that issued or caused to be issued such currency, that, through the payment
of interest and principal in accordance with their terms, will provide money in an amount
sufficient in the opinion of a nationally recognized firm of independent public accountants
or investment bank to pay and discharge each installment of principal of, premium and
interest on and any mandatory sinking fund payments in respect of the debt securities
of that series on the stated maturity of those payments in accordance with the terms
of the indenture and those debt securities; and
|
|
|
|
|
●
|
delivering
to the trustee an opinion of counsel to the effect that the holders of the debt securities
of that series will not recognize income, gain or loss for United States federal income
tax purposes as a result of the deposit and related covenant defeasance and will be subject
to United States federal income tax on the same amounts and in the same manner and at
the same times as would have been the case if the deposit and related covenant defeasance
had not occurred.
|
Covenant
Defeasance and Events of Default.
In the event we exercise our option to
effect covenant defeasance with respect to any series of debt securities and the debt securities of that series are declared due
and payable because of the occurrence of any Event of Default, the amount of money and/or U.S. government obligations or foreign
government obligations on deposit with the trustee will be sufficient to pay amounts due on the debt securities of that series
at the time of their stated maturity but may not be sufficient to pay amounts due on the debt securities of that series at the
time of the acceleration resulting from the Event of Default. However, we shall remain liable for those payments.
No
Personal Liability of Directors, Officers, Employees or Stockholders
None
of our past, present or future directors, officers, employees or stockholders, as such, will have any liability for any of our
obligations under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations
or their creation. By accepting a debt security, each holder waives and releases all such liability. This waiver and release is
part of the consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive
liabilities under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy.
Governing
Law
The
indenture and the debt securities will be governed by, and construed in accordance with, the laws of the State of New York without
regard to conflict of law principles that would result in the application of any law other than the law of the State of New York.
Description
of Warrants
We
may issue warrants for the purchase of our common stock or preferred stock or of debt securities. As explained below, each warrant
will entitle its holder to purchase our securities at an exercise price set forth in, or to be determined as set forth in, the
related prospectus supplement. Warrants may be issued separately or together with other securities. The warrants are to be issued
under warrant agreements to be entered into between us and the investors or a warrant agent.
The
particular terms of each issue of warrants and the warrant agreement relating to the warrants will be described in the applicable
prospectus supplement, including, as applicable:
|
●
|
the
title of the warrants;
|
|
|
|
|
●
|
the
initial offering price;
|
|
|
|
|
●
|
the
aggregate number of warrants and the aggregate number of shares of common stock or preferred
stock purchasable upon exercise of the warrants;
|
|
|
|
|
●
|
the
principal amount of debt securities that may be purchased upon exercise of a debt warrant
and the exercise price for the warrants, which may be payable in cash, securities or
other property;
|
|
|
|
|
●
|
if
applicable, the designation and terms of the equity securities with which the warrants
are issued, and the number of warrants issued with each equity security;
|
|
|
|
|
●
|
the
date on which the right to exercise the warrants will commence and the date on which
the right will expire;
|
|
|
|
|
●
|
if
applicable, the minimum or maximum number of the warrants that may be exercised at any
one time;
|
|
|
|
|
●
|
anti-dilution
provisions of the warrants, if any;
|
|
|
|
|
●
|
redemption
or call provisions, if any, applicable to the warrants;
|
|
|
|
|
●
|
any
additional terms of the warrants, including terms, procedures and limitations relating
to the exchange and exercise of the warrants; and
|
|
|
|
Holders
of warrants will not be entitled, solely by virtue of being holders, to vote, to receive dividends, to receive notice as stockholders
with respect to any meeting or written consent of stockholders for the election of directors or any other matter, or to exercise
any rights whatsoever as a holder of the equity securities purchasable upon exercise of the warrants. Until any warrants to purchase
debt securities are exercised, the holder of the warrants will not have any rights of holders of the debt securities that can
be purchased upon exercise, including any rights to receive payments of principal, premium or interest on the underlying debt
securities or to enforce covenants in the indenture.
Description
of Units
We
may, from time to time, issue units comprised of one or more of the other securities described in this prospectus in any combination.
A prospectus supplement will describe the specific terms of the units offered under that prospectus supplement, and any special
considerations applicable to investing in those units. You must look at the applicable prospectus supplement and any applicable
unit agreement for a full understanding of the specific terms of any units. We will incorporate by reference into the registration
statement of which this prospectus is a part the form of unit agreement, including a form of unit certificate, if any, that describes
the terms of the series of units we are offering before the issuance of the related series of units. While the terms we have summarized
below will generally apply to any units that we may offer in the future under this prospectus, we will describe the particular
terms of any series of units that we may offer in more detail in the applicable prospectus supplement and incorporated documents.
The terms of any units offered under a prospectus supplement may differ from the terms described below.
General
We
may issue units consisting of common stock, preferred stock, warrants, subscription rights or any combination thereof. Each unit
will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a
unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued
may provide that the securities included in the unit may not be held or transferred separately, at any time, or at any time before
a specified date.
We
will describe in the applicable prospectus supplement and any incorporated documents the terms of the series of units, including
the following:
|
●
|
the
designation and terms of the units and of the securities comprising the units, including
whether and under what circumstances those securities may be held or transferred separately;
|
|
|
|
|
●
|
any
unit agreement under which the units will be issued; and
|
|
|
|
|
●
|
any
provisions for the issuance, payment, settlement, transfer, or exchange of the units
or of the securities comprising the units.
|
The
provisions described in this section, as well as those described under “Description of Common Stock,” “Description
of Preferred Stock,” “Description of Debt Securities,” “Description of Warrants,” and “Description
of Units” will apply to each unit and to any common stock, preferred stock, debt securities, or warrant included in each
unit, respectively.
Issuance
in Series
We
may issue units in such amounts and in such numerous distinct series as we determine.
Enforceability
of Rights by Holders of Units
Each
unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship
of agency or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series
of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or
unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any
holder of a unit, without the consent of the related unit agent or the holder of any other unit, may enforce by appropriate legal
action its rights as holder under any security included in the unit.
Title
We,
the unit agent, and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units
evidenced by that certificate for any purposes and as the person entitled to exercise the rights attaching to the units so requested,
despite any notice to the contrary.
Description
of Subscription Rights
We
may issue subscription rights to purchase common stock, preferred stock, debt securities or other securities. These subscription
rights may be issued independently or together with any other security offered hereby and may or may not be transferable by the
stockholder receiving the subscription rights in such offering. In connection with any offering of subscription rights, we may
enter into a standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other
purchasers may be required to purchase any securities remaining unsubscribed for after such offering.
The
applicable prospectus supplement will describe the specific terms of any offering of subscription rights for which this prospectus
is being delivered, including the following:
|
●
|
the
price, if any, for the subscription rights;
|
|
|
|
|
●
|
the
exercise price payable for each share of common stock, preferred stock, debt securities
or other securities upon the exercise of the subscription rights;
|
|
|
|
|
●
|
the
number of subscription rights issued to each stockholder;
|
|
|
|
|
●
|
the
number and terms of the shares of common stock, preferred stock, or other securities
which may be purchased per each subscription right;
|
|
|
|
|
●
|
the
principal amount of debt securities that may be purchased per each subscription right;
|
|
|
|
|
●
|
the
extent to which the subscription rights are transferable;
|
|
|
|
|
●
|
any
other terms of the subscription rights, including the terms, procedures and limitations
relating to the exchange and exercise of the subscription rights;
|
|
|
|
|
●
|
the
date on which the right to exercise the subscription rights shall commence, and the date
on which the subscription rights shall expire;
|
|
|
|
|
●
|
the
extent to which the subscription rights may include an over-subscription privilege with
respect to unsubscribed securities; and
|
|
|
|
|
●
|
if
applicable, the material terms of any standby underwriting or purchase arrangement entered
into by us in connection with the offering of subscription rights.
|
The
description in the applicable prospectus supplement of any subscription rights we offer will not necessarily be complete and will
be qualified in its entirety by reference to the applicable subscription rights certificate, which will be filed with the SEC
if we offer subscription rights. For more information on how you can obtain copies of any subscription rights certificate if we
offer subscription rights, see “Where You Can Find More Information”. We urge you to read the applicable subscription
rights certificate and any applicable prospectus supplement in their entirety.
Anti-Takeover
Effects of Certain Provisions of Delaware Law and Our Charter Documents
The
following is a summary of our certificate of incorporation and our bylaws. This summary does not purport to be complete and is
qualified in its entirety by reference to our certificate of incorporation and bylaws. Our certificate of incorporation states
that we expressly elect not to be governed by Section 203 of the General Corporation Law of the State of Delaware.
Our
charter documents include provisions that may have the effect of discouraging, delaying or preventing a change in control or an
unsolicited acquisition proposal that a stockholder might consider favorable, including a proposal that might result in the payment
of a premium over the market price for the shares held by our stockholders. These provisions are summarized in the following paragraphs.
Effects
of authorized but unissued common stock and blank check preferred stock
. One of the effects of the existence of authorized
but unissued common stock and undesignated preferred stock may be to enable our board of directors to make more difficult or to
discourage an attempt to obtain control of our company by means of a merger, tender offer, proxy contest or otherwise, and thereby
to protect the continuity of management. If, in the due exercise of its fiduciary obligations, the board of directors were to
determine that a takeover proposal was not in our best interest, such shares could be issued by the board of directors without
stockholder approval in one or more transactions that might prevent or render more difficult or costly the completion of the takeover
transaction by diluting the voting or other rights of the proposed acquirer or insurgent stockholder group, by putting a substantial
voting block in institutional or other hands that might undertake to support the position of the incumbent board of directors,
by effecting an acquisition that might complicate or preclude the takeover, or otherwise.
In
addition, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of
authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings
and assets available for distribution to holders of shares of common stock. The issuance also may adversely affect the rights
and powers, including voting rights, of those holders and may have the effect of delaying, deterring or preventing a change in
control of our company.
Cumulative
Voting
. Our certificate of incorporation does not provide for cumulative voting in the election of directors which would
allow holders of less than a majority of the stock to elect some directors.
Vacancies
.
Section 223 of the Delaware General Corporation Law and our bylaws provide that all vacancies, including newly created directorships,
may be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum.
Special
Meeting of Stockholders
. A special meeting of stockholders may be called by our board of directors or the Chairman of
our board of directors and at the request in writing of holders of record of a majority of our outstanding capital stock entitled
to vote. The requirement that a majority of our outstanding capital stock is required to call a special meeting means that small
stockholders will not have the power to call a special meeting to, for example, elect new directors.
GLOBAL
SECURITIES
Book-Entry,
Delivery and Form
Unless
we indicate differently in a prospectus supplement, the securities initially will be issued in book-entry form and represented
by one or more global notes or global securities (which we refer to collectively as “global securities”). The global
securities will be deposited with, or on behalf of, The Depository Trust Company, New York, New York, as depositary (which we
refer to as “DTC”), and registered in the name of Cede & Co., the nominee of DTC. Unless and until it is exchanged
for individual certificates evidencing securities under the limited circumstances described below, a global security may not be
transferred except as a whole by the depositary to its nominee or by the nominee to the depositary, or by the depositary or its
nominee to a successor depositary or to a nominee of the successor depositary.
DTC
has advised us that it is:
|
●
|
a
limited-purpose trust company organized under the New York Banking Law;
|
|
|
|
|
●
|
a
“banking organization” within the meaning of the New York Banking Law;
|
|
|
|
|
●
|
a
member of the Federal Reserve System;
|
|
|
|
|
●
|
a
“clearing corporation” within the meaning of the New York Uniform Commercial
Code; and
|
|
|
|
|
●
|
a
“clearing agency” registered pursuant to the provisions of Section 17A of
the Exchange Act.
|
DTC
holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants of securities
transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants’
accounts, thereby eliminating the need for physical movement of securities certificates. “Direct participants” in
DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations.
DTC is a wholly-owned subsidiary of The Depository Trust & Clearing Corporation, or DTCC. DTCC is the holding company for
DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies.
DTCC is owned by the users of its regulated subsidiaries. Access to the DTC system is also available to others, which we sometimes
refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly
or indirectly. The rules applicable to DTC and its participants are on file with the SEC.
Purchases
of securities under the DTC system must be made by or through direct participants, which will receive a credit for the securities
on DTC’s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial
owner, is in turn recorded on the direct and indirect participants’ records. Beneficial owners of securities will not receive
written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing
details of their transactions, as well as periodic statements of their holdings, from the direct or indirect participants through
which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made
on the books of participants acting on behalf of beneficial owners. Beneficial owners will not receive certificates representing
their ownership interests in the global securities, except under the limited circumstances described below.
To
facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name
of DTC’s partnership nominee, Cede & Co., or such other name as may be requested by an authorized representative of
DTC. The deposit of securities with DTC and their registration in the name of Cede & Co. or such other nominee will not change
the beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC’s
records reflect only the identity of the direct participants to whose accounts the securities are credited, which may or may not
be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers.
So
long as the securities are in book-entry form, you will receive payments and may transfer securities only through the facilities
of the depositary and its direct and indirect participants. We will maintain an office or agency in the location specified in
the prospectus supplement for the applicable securities, where notices and demands in respect of the securities and the indenture
may be delivered to us and where certificated securities may be surrendered for payment, registration of transfer or exchange.
Conveyance
of notices and other communications by DTC to direct participants, by direct participants to indirect participants and by direct
participants and indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal
requirements in effect from time to time.
Redemption
notices will be sent to DTC. If less than all of the securities of a particular series are being redeemed, DTC’s practice
is to determine by lot the amount of the interest of each direct participant in the securities of such series to be redeemed.
Neither
DTC nor Cede & Co. (or such other DTC nominee) will consent or vote with respect to the securities. Under its usual procedures,
DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the consenting or voting
rights of Cede & Co. to those direct participants to whose accounts the securities of such series are credited on the record
date, identified in a listing attached to the omnibus proxy.
So
long as securities are in book-entry form, we will make payments on those securities to the depositary or its nominee, as the
registered owner of such securities, by wire transfer of immediately available funds. If securities are issued in definitive certificated
form under the limited circumstances described below, we will have the option of making payments by check mailed to the addresses
of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in writing to the applicable
trustee or other designated party at least 15 days before the applicable payment date by the persons entitled to payment, unless
a shorter period is satisfactory to the applicable trustee or other designated party.
Redemption
proceeds, distributions and dividend payments on the securities will be made to Cede & Co., or such other nominee as may be
requested by an authorized representative of DTC. DTC’s practice is to credit direct participants’ accounts upon DTC’s
receipt of funds and corresponding detail information from us on the payment date in accordance with their respective holdings
shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices,
as is the case with securities held for the account of customers in bearer form or registered in “street name.” Those
payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements
in effect from time to time. Payment of redemption proceeds, distributions and dividend payments to Cede & Co., or such other
nominee as may be requested by an authorized representative of DTC, is our responsibility, disbursement of payments to direct
participants is the responsibility of DTC, and disbursement of payments to the beneficial owners is the responsibility of direct
and indirect participants.
Except
under the limited circumstances described below, purchasers of securities will not be entitled to have securities registered in
their names and will not receive physical delivery of securities. Accordingly, each beneficial owner must rely on the procedures
of DTC and its participants to exercise any rights under the securities and the indenture.
The
laws of some jurisdictions may require that some purchasers of securities take physical delivery of securities in definitive form.
Those laws may impair the ability to transfer or pledge beneficial interests in securities.
DTC
may discontinue providing its services as securities depositary with respect to the securities at any time by giving reasonable
notice to us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are
required to be printed and delivered.
As
noted above, beneficial owners of a particular series of securities generally will not receive certificates representing their
ownership interests in those securities. However, if:
|
●
|
DTC
notifies us that it is unwilling or unable to continue as a depositary for the global
security or securities representing such series of securities or if DTC ceases to be
a clearing agency registered under the Exchange Act at a time when it is required to
be registered and a successor depositary is not appointed within 90 days of the notification
to us or of our becoming aware of DTC’s ceasing to be so registered, as the case
may be;
|
|
|
|
|
●
|
we
determine, in our sole discretion, not to have such securities represented by one or
more global securities; or
|
|
|
|
|
●
|
an
Event of Default has occurred and is continuing with respect to such series of securities,
|
we
will prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities. Any beneficial
interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable
for securities in definitive certificated form registered in the names that the depositary directs. It is expected that these
directions will be based upon directions received by the depositary from its participants with respect to ownership of beneficial
interests in the global securities.
We
have obtained the information in this section and elsewhere in this prospectus concerning DTC and DTC’s book-entry system
from sources that are believed to be reliable, but we take no responsibility for the accuracy of this information.
PLAN
OF DISTRIBUTION
We
may offer and sell the securities in any one or more of the following ways:
|
●
|
to
or through underwriters, brokers or dealers;
|
|
|
|
|
●
|
directly
to one or more other purchasers;
|
|
|
|
|
●
|
through
a block trade in which the broker or dealer engaged to handle the block trade will attempt
to sell the securities as agent, but may position and resell a portion of the block as
principal to facilitate the transaction;
|
|
|
|
|
●
|
through
agents on a best-efforts basis;
|
|
|
|
|
●
|
in
“at the market” offerings, as defined in Rule 415 under the Securities Act,
at negotiated prices, at prices prevailing at the time of sale or at prices related to
such prevailing market prices, including sales made directly on the Nasdaq Capital Market
or sales made through a market maker other than on an exchange or other similar offerings
through sales agents; or
|
|
|
|
|
●
|
otherwise
through any other method permitted by applicable law or a combination of any of the above
methods of sale.
|
In
addition, we may enter into option, share lending or other types of transactions that require us to deliver shares of common stock
to an underwriter, broker or dealer, who will then resell or transfer the shares of common stock under this prospectus. We may
also enter into hedging transactions with respect to our securities. For example, we may:
|
●
|
enter
into transactions involving short sales of the shares of common stock by underwriters,
brokers or dealers;
|
|
|
|
|
●
|
sell
shares of common stock short and deliver the shares to close out short positions;
|
|
|
|
|
●
|
enter
into option or other types of transactions that require the delivery of shares of common
stock to an underwriter, broker or dealer, who will then resell or transfer the shares
of common stock under this prospectus; or
|
|
|
|
|
●
|
loan
or pledge the shares of common stock to an underwriter, broker or dealer, who may sell
the loaned shares or, in the event of default, sell the pledged shares.
|
We
may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties
in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives,
the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short
sale transactions. If so, the third party may use securities pledged by or borrowed from us or others to settle those sales or
to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives
to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not
identified in this prospectus, will be identified in the applicable prospectus supplement (or a post-effective amendment). In
addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the
securities short using this prospectus. Such financial institution or other third party may transfer its economic short position
to investors in our securities or in connection with a concurrent offering of other securities.
Each
time we sell securities, we will provide a prospectus supplement that will name any underwriter, dealer or agent involved in the
offer and sale of the securities. Any prospectus supplement will also set forth the terms of the offering, including:
|
●
|
the
purchase price of the securities and the proceeds we will receive from the sale of the
securities;
|
|
|
|
|
●
|
any
underwriting discounts and other items constituting underwriters’ compensation;
|
|
|
|
|
●
|
any
public offering or purchase price and any discounts or commissions allowed or re-allowed
or paid to dealers;
|
|
|
|
|
●
|
any
commissions allowed or paid to agents;
|
|
|
|
|
●
|
any
other offering expenses;
|
|
|
|
|
●
|
any
securities exchanges on which the securities may be listed;
|
|
|
|
|
●
|
the
method of distribution of the securities;
|
|
|
|
|
●
|
the
terms of any agreement, arrangement or understanding entered into with the underwriters,
brokers or dealers; and
|
|
|
|
|
●
|
any
other information we think is important.
|
|
|
|
|
●
|
If
underwriters or dealers are used in the sale, the securities will be acquired by the underwriters or dealers for their own account.
|
The securities
may be sold from time to time by us in one or more transactions:
|
●
|
at
a fixed price or prices, which may be changed;
|
|
|
|
|
●
|
at
market prices prevailing at the time of sale;
|
|
|
|
|
●
|
at
prices related to such prevailing market prices;
|
|
|
|
|
●
|
at
varying prices determined at the time of sale; or
|
|
|
|
Such
sales may be effected:
|
●
|
in
transactions on any national securities exchange or quotation service on which the securities
may be listed or quoted at the time of sale;
|
|
|
|
|
●
|
in
transactions in the over-the-counter market;
|
|
●
|
in
block transactions in which the broker or dealer so engaged will attempt to sell the
securities as agent but may position and resell a portion of the block as principal to
facilitate the transaction, or in crosses, in which the same broker acts as an agent
on both sides of the trade;
|
|
|
|
|
●
|
through
the writing of options; or
|
|
|
|
|
●
|
through
other types of transactions.
|
The
securities may be offered to the public either through underwriting syndicates represented by one or more managing underwriters
or directly by one or more of such firms. Unless otherwise set forth in the prospectus supplement, the obligations of underwriters
or dealers to purchase the securities offered will be subject to certain conditions precedent and the underwriters or dealers
will be obligated to purchase all the offered securities if any are purchased. Any public offering price and any discount or concession
allowed or reallowed or paid by underwriters or dealers to other dealers may be changed from time to time.
The
securities may be sold directly by us or through agents designated by us from time to time. Any agent involved in the offer or
sale of the securities in respect of which this prospectus is delivered will be named, and any commissions payable to such agent
will be set forth in, the prospectus supplement. Unless otherwise indicated in the prospectus supplement, any such agent will
be acting on a best efforts basis for the period of its appointment.
Offers
to purchase the securities offered by this prospectus may be solicited, and sales of the securities may be made by us directly
to institutional investors or others, who may be deemed to be underwriters within the meaning of the Securities Act with respect
to any resale of the securities. The terms of any offer made in this manner will be included in the prospectus supplement relating
to the offer.
Some
of the underwriters, dealers or agents used by us in any offering of securities under this prospectus may be customers of, engage
in transactions with, and perform services for us or affiliates of ours in the ordinary course of business. Underwriters, dealers,
agents and other persons may be entitled to indemnification against and contribution toward certain civil liabilities, including
liabilities under the Securities Act, and to be reimbursed for certain expenses.
Subject
to any restrictions relating to debt securities in bearer form, any securities initially sold outside the United States may be
resold in the United States through underwriters, dealers or otherwise.
Any
underwriters to which offered securities are sold by us for public offering and sale may engage in transactions that stabilize,
maintain or otherwise affect the price of the common stock during and after this offering, but those underwriters will not be
obligated to do so and may discontinue any market making at any time. Specifically, the underwriters may over-allot or otherwise
create a short position in the common stock for their own accounts by selling more common stock than have been sold to them by
us. The underwriters may elect to cover any such short position by purchasing common stock in the open market or by exercising
the over-allotment option granted to the underwriters. In addition, the underwriters may stabilize or maintain the price of the
common stock by bidding for or purchasing common stock in the open market and may impose penalty bids. If penalty bids are imposed,
selling concessions allowed to syndicate members or other broker-dealers participating in the offering are reclaimed if common
stock previously distributed in the offering are repurchased, whether in connection with stabilization transactions or otherwise.
The effect of these transactions may be to stabilize or maintain the market price of the common stock at a level above that which
might otherwise prevail in the open market. The imposition of a penalty bid may also affect the price of the common stock to the
extent that it discourages resales of the common stock. The magnitude or effect of any stabilization or other transactions is
uncertain. These transactions may be effected on the Nasdaq Capital Market or otherwise and, if commenced, may be discontinued
at any time.
In
connection with this offering, the underwriters and selling group members may also engage in passive market making transactions
in our common stock. Passive market making consists of displaying bids on the Nasdaq Capital Market limited by the prices of independent
market makers and effecting purchases limited by those prices in response to order flow. Rule 103 of Regulation M promulgated
by the SEC limits the amount of net purchases that each passive market maker may make and the displayed size of each bid. Passive
market making may stabilize the market price of the common stock at a level above that which might otherwise prevail in the open
market and, if commenced, may be discontinued at any time.
We
are subject to the applicable provisions of the Exchange Act and the rules and regulations under the Exchange Act, including Regulation
M. This regulation may limit the timing of purchases and sales of any of the shares of common stock offered in this prospectus
by any person. The anti-manipulation rules under the Exchange Act may apply to sales of shares in the market and to the activities
of us.
The
anticipated date of delivery of the securities offered by this prospectus will be described in the applicable prospectus supplement
relating to the offering.
Any
broker-dealer participating in the distribution of the shares of common stock may be deemed to be an “underwriter”
within the meaning of the Securities Act with respect to any securities such entity sells pursuant to this prospectus.
To
comply with the securities laws of some states, if applicable, the securities may be sold in these jurisdictions only through
registered or licensed brokers or dealers. In addition, in some states the securities may not be sold unless they have been registered
or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.
LEGAL
MATTERS
The
validity of the issuance of the securities offered hereby will be passed upon for us by Greenberg Traurig LLP, Los Angeles, California.
Any underwriters will also be advised about the validity of the securities and other legal matters by their own counsel, which
will be named in the prospectus supplement.
EXPERTS
Rosenberg
Rich Baker Berman P.A., independent registered public accounting firm, has audited our consolidated financial statements included
in our Annual Report on Form 10-K for the years ended December 31, 2017 and 2016, as set forth in their report, which is incorporated
by reference in this registration statement. Our consolidated financial statements for the years ended December 31, 2017 and 2016 are incorporated by reference in
reliance on Rosenberg Rich Baker Berman P.A.’s report, given on their authority as experts in accounting and auditing.
The
balance sheet of Zone Technologies, Inc. as of December 31, 2015, and the related statements of operations, stockholders’
deficit, and cash flows for the period then ended, have been audited by EisnerAmper LLP, independent registered public accounting
firm, as stated in their report which is incorporated by reference from the Company’s Form 8-K/A, Amendment No. 1, filed
with the Securities and Exchange Commission on September 20, 2016, which report includes an explanatory paragraph about the existence
of substantial doubt concerning Zone Technologies, Inc.’s ability to continue as a going concern. Such financial statements
have been incorporated herein by reference in reliance on the report of such firm given upon their authority as experts in accounting
and auditing.
The
balance sheets of MoviePass Inc. as of December 31, 2016 and 2015, and the related statements of operations, stockholders’
equity, and cash flows for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting
firm, as stated in their report which is incorporated by reference from the Company’s Form 8-K filed with the Securities
and Exchange Commission on November 30, 2017 which report includes an explanatory paragraph about the existence of substantial
doubt concerning MoviePass Inc.’s ability to continue as a going concern. Such financial statements have been incorporated
herein by reference in reliance on the report of such firm given upon their authority as experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
We
have filed with the SEC a registration statement on Form S-3 under the Securities Act, with respect to the securities covered
by this prospectus. This prospectus, which is a part of the registration statement, does not contain all of the information set
forth in the registration statement or the exhibits and schedules filed therewith. For further information with respect to us
and the securities covered by this prospectus, please see the registration statement and the exhibits filed with the registration
statement. A copy of the registration statement and the exhibits filed with the registration statement may be inspected without
charge at the Public Reference Room maintained by the SEC, located at 100 F Street, N.E., Washington, D.C. 20549. Please call
the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. The SEC also maintains an Internet
website that contains reports, proxy and information statements and other information regarding registrants that file electronically
with the SEC. The address of the website is http://www.sec.gov.
We
are subject to the information and periodic reporting requirements of the Exchange Act and, in accordance therewith, we file periodic
reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information are
available for inspection and copying at the Public Reference Room and website of the SEC referred to above. We maintain a website
at http://www.hmny.com. You may access our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form
8-K and amendments to those reports filed pursuant to Sections 13(a) or 15(d) of the Exchange Act with the SEC free of charge
at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. Our
website and the information contained on that site, or connected to that site, are not incorporated into and are not a part of
this prospectus.
INFORMATION
INCORPORATED BY REFERENCE
The
SEC and applicable law permits us to “incorporate by reference” into this prospectus information that we have or may
in the future file with or furnish to the SEC. This means that we can disclose important information by referring you to those
documents. You should read carefully the information incorporated herein by reference because it is an important part of this
prospectus. We hereby incorporate by reference the following documents into this prospectus:
|
●
|
our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC on April 17, 2018;
|
|
|
|
|
●
|
our Current Reports on Form 8-K filed with the SEC on April 18, 2018, April 19, 2018, April 20, 2018, May 8, 2018, June 4, 2018, June 21, 2018. June 26, 2018, and June 29, 2018;
|
|
|
|
|
●
|
our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the SEC on May 15, 2018;
|
|
|
|
|
●
|
the financial statements of Zone Technologies, Inc. for the period ended December 31, 2015 and the interim period ended June 30, 2016 included in our Current Report on Form 8-K/A filed with the SEC on September 20, 2016; and
|
|
|
|
|
●
|
the financial statements of MoviePass Inc. for the year ended December 31, 2016 and the interim period ended September 30, 2017 included in our Current Report on Form 8-K filed with the SEC on November 30, 2017.
|
Additionally,
all documents filed by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than any portions of
filings that are furnished rather than filed pursuant to Items 2.02 and 7.01 of a Current Report on Form 8-K), after the date
of this prospectus and before the termination or completion of this offering (including all such documents filed with the SEC
after the date of the initial registration statement and prior to the effectiveness of the registration statement) shall be deemed
to be incorporated by reference into this prospectus from the respective dates of filing of such documents. Any information that
we subsequently file with the SEC that is incorporated by reference as described above will automatically update and supersede
any previous information that is part of this prospectus.
Upon
written or oral request, we will provide you without charge, a copy of any or all of the documents incorporated by reference,
other than exhibits to those documents unless the exhibits are specifically incorporated by reference in the documents. Please
send requests to Helios and Matheson Analytics Inc., Attn: Chief Executive Officer, The Empire State Building, 350 Fifth Avenue,
New York, New York 10118, telephone number is (212) 979-8228.
UNAUDITED
PRO FORMA FINANCIAL INFORMATION
On
December 11, 2017, we completed the acquisition of a 62.41% majority interest in MoviePass, for the following consideration: (1)
a subordinated convertible promissory note in the principal amount of $12,000,000, which is convertible into shares of our common
stock, as further described below; (2) a $5,000,000 promissory note issued to MoviePass; (3) the exchange of a convertible promissory
note issued by MoviePass to us in an aggregate principal amount of $11,500,000 (plus accrued interest thereon); (4) $1,000,000
in cash to purchase outstanding convertible notes of MoviePass, which were converted into shares of MoviePass’ common stock
amounting to an additional 2% of the outstanding shares of MoviePass common stock; and (5) $20,000,000 in cash pursuant to the
Investment Option Agreement, dated October 11, 2017, between us and MoviePass.
On
March 8, 2018, we entered into a subscription agreement with MoviePass, pursuant to which, in lieu of repayment of advances totaling
$55,525,000 made by us, MoviePass agreed to sell to us an amount of MoviePass common stock equal to 18.79% of the total then outstanding
shares of MoviePass common stock (excluding shares underlying MoviePass options and warrants), which we refer to as the March
2018 MoviePass Purchased Shares. MoviePass also agreed to issue to us, in addition to the March 2018 MoviePass Purchased Shares,
without payment of additional consideration by us, for purposes of anti-dilution, an amount of shares of MoviePass common stock
that caused our total ownership of the outstanding shares of MoviePass common stock (excluding shares underlying MoviePass options
and warrants), together with the March 2018 MoviePass Purchased Shares, to equal 81.2% as of March 8, 2018.
From
February 27, 2018 through April 12, 2018, we advanced a total of $35,000,000 to MoviePass, which we refer to as the second advance.
On April 16, 2018, we entered into an additional subscription agreement with MoviePass, pursuant to which, in lieu of repayment
of the second advance, MoviePass agreed to sell to us an amount of shares of common stock of MoviePass equal to 10.6% of the total
then outstanding MoviePass common stock (excluding shares underlying MoviePass options and warrants), which we refer to as the
April 2018 MoviePass Purchased Shares, based on a pre-money valuation of MoviePass of $295,525,000 as of March 31, 2018. Pursuant
to the April 16, 2018 subscription agreement, MoviePass also agreed to issue to us, in addition to the April 2018 MoviePass Purchased
Shares, without payment of additional consideration by us, for purposes of anti-dilution, an amount of shares of common stock
of MoviePass that caused our total ownership of the outstanding shares of common stock of MoviePass (excluding shares underlying
MoviePass options and warrants), together with the April 2018 MoviePass Purchased Shares, to equal 91.8% as of April 12, 2018.
The acquisition of 91.8% of the MoviePass shares of common stock is referred to as the MoviePass Transaction.
The
following unaudited pro forma condensed combined financial information is based on our historical consolidated financial statements
and MoviePass’ historical consolidated financial statements as adjusted to give effect to the MoviePass Transaction. The
unaudited pro forma condensed combined statements of operations for the three months ended March 31, 2018 and the 12 months ended
December 31, 2017 give effect to the MoviePass Transaction as if it had occurred on January 1, 2017.
The
pro forma combined financial statements do not necessarily reflect what the combined company’s financial condition or results
of operations would have been had the MoviePass Transaction occurred on the dates indicated. They also may not be useful in predicting
the future financial condition and results of operations of the combined company. The actual financial position and results of
operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors.
Unaudited
Pro Forma Condensed Combined Statements of Operations
Year Ended December 31, 2017
|
|
Helios and Matheson Analytics Inc.
|
|
|
MoviePass, Inc. for the period from January 1, 2017 to December 10, 2017
|
|
|
Adjustments
|
|
|
Notes
|
|
Pro Forma Results Adjusted for Acquisition of MoviePass, Inc.
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consulting
|
|
$
|
4,512,300
|
|
|
$
|
-
|
|
|
$
|
|
|
|
|
|
$
|
4,512,300
|
|
Subscription
|
|
|
5,929,267
|
|
|
|
14,554,809
|
|
|
|
|
|
|
|
|
|
20,484,076
|
|
Total Revenues
|
|
|
10,441,567
|
|
|
|
14,554,809
|
|
|
|
|
|
|
|
|
|
24,996,376
|
|
Cost of revenue
|
|
|
20,538,709
|
|
|
|
46,187,587
|
|
|
|
|
|
|
1
|
|
|
66,726,296
|
|
Gross (loss)
|
|
|
(10,097,142
|
)
|
|
|
(31,632,778
|
)
|
|
|
|
|
|
|
|
|
(41,729,920
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general & administrative
|
|
|
35,698,134
|
|
|
|
12,881,485
|
|
|
|
(691,500
|
)
|
|
2
|
|
|
47,888,119
|
|
Research and development
|
|
|
2,012,548
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,012,548
|
|
Loss on impairment of Zone goodwill and intangible assets
|
|
|
6,256,983
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,256,983
|
|
Depreciation & amortization
|
|
|
1,951,977
|
|
|
|
104,379
|
|
|
|
3,384,868
|
|
|
3
|
|
|
5,441,224
|
|
Total operating expenses
|
|
|
45,919,642
|
|
|
|
12,985,864
|
|
|
|
2,693,368
|
|
|
|
|
|
61,598,874
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(56,016,784
|
)
|
|
|
(44,618,642
|
)
|
|
|
(2,693,368
|
)
|
|
|
|
|
(103,328,794
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income/(expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair market value – derivative liabilities
|
|
|
28,303,612
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28,303,612
|
|
Change in fair market value – warrant liabilities
|
|
|
(20,409,937
|
)
|
|
|
4,818
|
|
|
|
|
|
|
|
|
|
(20,405,119
|
)
|
Loss on extinguishment of debt
|
|
|
(4,346,885
|
)
|
|
|
(11,680,959
|
)
|
|
|
|
|
|
|
|
|
(16,027,844
|
)
|
Interest expense
|
|
|
(98,478,473
|
)
|
|
|
(661,626
|
)
|
|
|
|
|
|
|
|
|
(99,140,099
|
)
|
Interest income
|
|
|
177,157
|
|
|
|
|
|
|
|
|
|
|
|
|
|
177,157
|
|
Total other expense
|
|
|
(94,754,526
|
)
|
|
|
(12,337,767
|
)
|
|
|
-
|
|
|
4
|
|
|
(107,092,293
|
)
|
Loss before income taxes
|
|
|
(150,771,310
|
)
|
|
|
(56,956,409
|
)
|
|
|
(2,693,368
|
)
|
|
|
|
|
(210,421,087
|
)
|
Provision for income tax
|
|
|
53,532
|
|
|
|
|
|
|
|
|
|
|
|
|
|
53,532
|
|
Net loss
|
|
|
(150,824,842
|
)
|
|
|
(56,956,409
|
)
|
|
|
(2,693,368
|
)
|
|
|
|
|
(210,474,619
|
)
|
Net loss attributable to the non-controlling interest
|
|
|
4,850,308
|
|
|
|
|
|
|
|
1,987,461
|
|
|
5
|
|
|
6,837,769
|
|
Net loss attributable to Helios and Matheson Analytics, Inc.
|
|
$
|
(145,974,534
|
)
|
|
$
|
(56,956,409
|
)
|
|
$
|
(705,907
|
)
|
|
|
|
$
|
(203,636,850
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income – foreign currency adjustment
|
|
|
3,011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,011
|
|
Comprehensive loss
|
|
$
|
(145,971,523
|
)
|
|
$
|
(56,956,409
|
)
|
|
$
|
(705,907
|
)
|
|
|
|
$
|
(203,633,839
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share attributable to
common stockholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and Diluted
|
|
$
|
(17.46
|
)
|
|
$
|
|
|
|
$
|
|
|
|
|
|
$
|
(24.35
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares
|
|
|
8,361,094
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,361,094
|
|
Notes:
|
1.
|
In
connection with the allocation of purchase price to the acquired assets and liabilities, we determined that the acquired deferred
revenue at the acquisition date should be increased to include the estimated additional service obligations which will be incurred
in the future as the deferred revenue is recognized. These amounts will be recognized in future periods as a credit against service
costs. As these credits are non-recurring and relate to future periods, except to the extent included in the actual results for
the period December 11, 2017 through December 31, 2017 and for the Quarter ended March 31, 2018, the unaudited pro forma condensed
combined statements of operations for the year ended December 31, 2017 do not include any further adjustments related to these
deferred service cost credits.
|
|
2.
|
Adjustment
to remove non-recurring transaction costs associated with the acquisition.
|
|
3.
|
Adjustment
to reflect amortization of acquired identifiable intangible assets of MoviePass from January 1, 2017 to December 10, 2017. Amortization
expense is recognized on a straight line basis over the useful life of the intangible assets. The useful lives of the MoviePass
intangible assets are as follows:
|
Intangible Assets
|
|
Useful Life
|
Customer Relationships
|
|
7
|
Technology
|
|
3
|
Tradenames and Trademarks
|
|
10
|
|
4.
|
The
unaudited pro forma condensed combined statements of operations for the year ended December 31, 2017 do not include any adjustments
related to acquisition financing costs as we believe that the financing costs that would have been incurred had the MoviePass
Transaction taken place on January 1, 2017, would not vary materially from the costs included in the actual results for 2017 and
due to the complexity of the financing transactions recalculation was deemed to be impractical.
|
|
5.
|
Represents
the adjustment to recognize the non- controlling interest share of the MoviePass net loss for the period January 1, 2017 through
December 31, 2017 at 8.2%.
|
Unaudited
Pro Forma Condensed Combined Statements of Operations
Quarter Ended March 31, 2018
|
|
Helios and Matheson Analytics Inc.
|
|
|
Adjustments
|
|
|
Notes
|
|
Pro Forma Results Adjusted for Increase in Ownership of MoviePass, Inc.
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
Consulting
|
|
$
|
839,503
|
|
|
|
|
|
|
|
|
$
|
839,503
|
|
Subscription
|
|
|
47,162,447
|
|
|
|
|
|
|
|
|
|
47,162,447
|
|
Marketing and promotional services
|
|
|
1,440,910
|
|
|
|
|
|
|
|
|
|
1,440,910
|
|
Total Revenues
|
|
|
49,442,860
|
|
|
|
-
|
|
|
|
|
|
49,442,860
|
|
Cost of revenue
|
|
|
135,968,976
|
|
|
|
|
|
|
|
|
|
135,968,976
|
|
Gross (loss)
|
|
|
(86,526,116
|
)
|
|
|
-
|
|
|
|
|
|
(86,526,116
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general & administrative
|
|
|
19,709,831
|
|
|
|
|
|
|
|
|
|
19,709,831
|
|
Research and development
|
|
|
224,771
|
|
|
|
|
|
|
|
|
|
224,771
|
|
Depreciation & amortization
|
|
|
1,271,275
|
|
|
|
|
|
|
|
|
|
1,271,275
|
|
Total operating expenses
|
|
|
21,205,877
|
|
|
|
-
|
|
|
|
|
|
21,205,877
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(107,731,993
|
)
|
|
|
|
|
|
|
|
|
(107,731,993
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income/(expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair market value – derivative liabilities
|
|
|
8,597,378
|
|
|
|
|
|
|
|
|
|
8,597,378
|
|
Change in fair market value – warrant liabilities
|
|
|
93,608,200
|
|
|
|
|
|
|
|
|
|
93,608,200
|
|
Gain on extinguishment of debt
|
|
|
15,007,699
|
|
|
|
|
|
|
|
|
|
15,007,699
|
|
Interest expense
|
|
|
(35,534,899
|
)
|
|
|
|
|
|
1
|
|
|
(35,534,899
|
)
|
Interest income
|
|
|
15,341
|
|
|
|
|
|
|
|
|
|
15,341
|
|
Total other income
|
|
|
81,693,719
|
|
|
|
-
|
|
|
|
|
|
81,693,719
|
|
Loss before income taxes
|
|
|
(26,038,274
|
)
|
|
|
-
|
|
|
|
|
|
(26,038,274
|
)
|
Provision for income tax
|
|
|
7,951
|
|
|
|
|
|
|
|
|
|
7,951
|
|
Net loss
|
|
|
(26,046,225
|
)
|
|
|
-
|
|
|
|
|
|
(26,046,225
|
)
|
Net loss attributable to the non-controlling interest
|
|
|
31,222,100
|
|
|
|
23,177,198
|
|
|
2
|
|
|
8,044,902
|
|
Net income/(loss) attributable to Helios and Matheson Analytics, Inc.
|
|
$
|
5,175,875
|
|
|
$
|
23,177,198
|
|
|
|
|
$
|
(18,001,323
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive (loss) – foreign currency adjustment
|
|
|
(7,150
|
)
|
|
|
|
|
|
|
|
|
(7,150
|
)
|
Comprehensive income/(loss)
|
|
$
|
5,168,725
|
|
|
$
|
23,177,198
|
|
|
|
|
$
|
(18,008,473
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income/(loss) per share attributable to common stockholders –basic
|
|
$
|
0.15
|
|
|
|
|
|
|
|
|
$
|
(0.52
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares – basic
|
|
|
34,850,281
|
|
|
|
|
|
|
|
|
|
34,850,281
|
|
Diluted income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share attributable to common stockholders –diluted
|
|
$
|
0.09
|
|
|
|
|
|
|
|
|
|
n/a
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares – diluted
|
|
|
36,602,367
|
|
|
|
|
|
|
|
|
|
n/a
|
|
Notes:
|
1.
|
The
unaudited pro forma condensed combined statements of operations for the quarter ended March 31, 2018 do not include any adjustments
related to acquisition financing costs as we believe that the financing costs that would have been incurred had the MoviePass
transaction taken place on January 1, 2017, would not vary materially from the costs included in the actual results for the quarter
ended March 31, 2018 and due to the complexity of the financing transactions, recalculation was deemed to be impractical.
|
|
2.
|
Represents
the adjustment to reduce the non-controlling interest share of the MoviePass net loss for the period January 1, 2018 through March
7, 2018 to 8.2%.
|
HELIOS AND MATHESON ANALYTICS INC.
184,800 Shares
of Series B Preferred Stock (Including Shares of Series B Preferred Stock Underlying the Series F-1 Preferred Stock Purchase Warrants,
Series F-2 Preferred Stock Purchase Warrants and Placement Agent Warrants);
Series F-1
Preferred Stock Purchase Warrants to Purchase 59,760 Shares of Series B Preferred Stock;
Series F-2
Preferred Stock Purchase Warrants to Purchase 60,240 Shares of Series B Preferred Stock;
Placement Agent
Warrants to Purchase 4,800 Shares of Series B Preferred Stock;
3,080,061,600
Shares of Common Stock Underlying the Series B Preferred Stock (Including Shares of Series B Preferred
Stock Issuable Upon
Exercise of the Series F-1 Preferred Stock Purchase Warrants, Series F-2 Preferred Stock Purchase
Warrants and Placement Agent
Warrants)
PROSPECTUS SUPPLEMENT
H.C. Wainwright & Co.
March 25, 2019
Helios and Matheson Anal... (CE) (USOTC:HMNY)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Helios and Matheson Anal... (CE) (USOTC:HMNY)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025